WO2011094953A1 - Compounds for the treatment and prevention of influenza - Google Patents

Compounds for the treatment and prevention of influenza Download PDF

Info

Publication number
WO2011094953A1
WO2011094953A1 PCT/CN2010/070562 CN2010070562W WO2011094953A1 WO 2011094953 A1 WO2011094953 A1 WO 2011094953A1 CN 2010070562 W CN2010070562 W CN 2010070562W WO 2011094953 A1 WO2011094953 A1 WO 2011094953A1
Authority
WO
WIPO (PCT)
Prior art keywords
trimethyl
methyl
hydroxy
cyclohexanol
cis
Prior art date
Application number
PCT/CN2010/070562
Other languages
French (fr)
Inventor
Lisha Wang
Li Chen
Zongxing Qiu
Guozhi Tang
Xianfeng Lin
Jim Zhen Wu
Wengang Yang
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to PCT/CN2010/070562 priority Critical patent/WO2011094953A1/en
Priority to PCT/EP2011/051626 priority patent/WO2011095576A1/en
Priority to US13/021,793 priority patent/US20110195979A1/en
Publication of WO2011094953A1 publication Critical patent/WO2011094953A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the invention relates to compounds which are inhibitors of hemagglutinin (HA) and which are useful in the treatment or prophylaxis of influenza.
  • HA hemagglutinin
  • the invention relates in particular to (i) a compound of formula (I)
  • R is hydrogen, Ci- 6 alkyl, or trifluoromethyl
  • R 2 /R 3 are hydrogen, halogen, OR 10 , or R 1 R 12 ;
  • R is hydrogen, Ci- 6 alkyl, or trifluoromethyl
  • X is -CH 2 -, or carbonyl
  • Ar is selected from
  • R 5 /R 9 is hydrogen, halogen, trifluoromethyl, or Ci- 6 alkyl
  • R 6 /R 8 is hydrogen, halogen, trifluoromethyl, trifluoromethoxy, Ci_ 6 alkoxy, cyano, Ci_ salkyl, -C(0)- H 2 , -S(0) 2 - H 2 , or -S(0) 2 - Ci -6 alkyl;
  • R 7 is hydrogen, halogen, Ci-6alkyl, cyano, Ci-6alkoxy, or -S(0)2- H 2 ;
  • R 10 is hydrogen, Ci- 6 alkyl, carbonyl-Ci- 6 alkyl, or trifluoromethyl
  • R 11 or R 12 is hydrogen, Ci- 6 alkyl, carbonyl-Ci- 6 alkyl, or sulfonyl; provided that R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are not hydrogen simultaneously; and pharmaceutically acceptable salt and stereoisomers thereof.
  • the invention also relates to a process for the manufacture of these novel compounds and medicaments containing them.
  • These compounds are inhibitors of hemagglutinin (HA) and useful in the treatment or prophylaxis of influenza.
  • HA hemagglutinin
  • Influenza viruses belong to the Orthomyxoviridae family of RNA viruses. Based on antigenic differences of viral nucleocapsid and matrix proteins, influenza viruses are further divided into three types named influenza A, B, and C viruses. All influenza viruses have an envelope, and their genomes are composed of eight or seven single-stranded, negative-sensed RNA segments. These viruses cause respiratory diseases in human and animals with a significant morbidity and mortality. Influenza pandemic of 1918, Spanish flu, is thought to have killed up to 100 million human beings. The reassortment of avian flu RNA fragments with circulating human viruses caused the other two pandemic, 1957 H2N2 "Asian influenza" and 1968 H3N2 "Hong Kong influenza".
  • neuraminidase inhibitors such as oseltamivir phosphate (Tamilflu) and zanamivir (Relenza); and M2 ion channel blockers such as amantadine and rimantadine.
  • Amilflu oseltamivir phosphate
  • Relenza zanamivir
  • M2 ion channel blockers such as amantadine and rimantadine.
  • HA is a viral glycoprotein, located on the surface of virus particles.
  • HA is synthesized as a precursor molecule, HAo, and is cleaved by a cellular protease to yield two subunits, HAi and HA 2 . This cleavage is indispensible for the function of HA.
  • Individual HAi and HA 2 that are linked by one disulfide bond, assemble to form homotrimers on mature virus envelope.
  • the life cycle of influenza virus infection begins with binding between the receptor binding pocket located in the membrane distal region of HA and sialic acid sugars on the surface of host epithelial cells.
  • N-acetylneuraminic acid a - (2,3)-Gal and N- acetylneuraminic acid a - (2,6)-Gal is preferably recognized, dependent on host species involved.
  • virus enters into cell by a process of endocytosis, resulting in the formation of virus-containing endosome.
  • fusion between viral envelope and endosome membrane occurs in an acidic environment within endosome that triggers an irreversibly conformational change of HA protein in which the hydrophobic fusion peptide at the N-terminus of HA2 is released from a buried position to a position that is 100 A away from its original location.
  • the exposed fusogenic domain interacts with endosomal membrane and leads a series of structural rearrangements of HA2, which finally leads to fusion and release of viral RNP complexes into cytoplasm.
  • Viral genomes then are translocated into nucleus where they act as the templates for virus RNA replication.
  • HA-mediated fusion is essential for influenza virus replication
  • HA has been used as a feasible target in the development of anti-influenza drugs.
  • fusion inhibitors that block influenza infection by means of two different mechanisms:
  • the examples of the first mechanism include chloroquine (Ooi et al, 2006), triperiden (Oka et al, 2001), and maybe arbidol, a compound with a broad spectrum of anti-viral activities (Boriskin et al, 2006; Leneva et al, 2008).
  • chloroquine Ooi et al, 2006
  • triperiden Oka et al, 2001
  • arbidol a compound with a broad spectrum of anti-viral activities
  • BMY 27709 was discovered by a group of researchers at BMS Pharmaceutical Research Institute (Luo et al, 1997). This compound had a moderate anti-flu activity with an EC 50 of 6-8 ⁇ for HI and H2 viruses, but not H3 viruses. Resistant selection showed that resistant mutations were located around a position where HA 2 fusion peptide is hidden. Other mutations were scattered in both HA 2 and HAi regions. Studies of hemolysis and trypsin sensitivity assays suggested that HA itself was the target of the compound. Photoaffinity labeling indicated the presence of a binding pocket close to HA 2 N-terminal fusion peptide, but this site was not confirmed yet.
  • HA destabilizer this type of compounds was named as HA destabilizer. Recently, a group of Chinese scientists also reported a series of thiazolidinone compounds and their analogs that showed fusion inhibition activities through destabilizing HA homotrimers (Yang and Luo, 2009).
  • TBHQ tert-butyl hydroquinone
  • TBHQ inhibits fusion of H3 influenza viruses.
  • the compounds of the present invention belong to a new class of influenza inhibitors.
  • these compounds acted at an early step of influenza virus replication.
  • Results from HA-mediated hemolysis of chicken red blood cells and trypsin sensitivity of isolated HA in the presence of the compounds clearly showed that they targeted at HA.
  • the compounds inhibited an established influenza infection by dramatically reducing the production of progeny viruses by an order of more than 8-log when compared with a negative control.
  • Ci -6 alkyl alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, preferably 1 to 4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, 1 -butyl, 2-butyl, tert-butyl and the like.
  • Preferred “Ci-6alkyl” groups are methyl, ethyl, isopropyl, tert-butyl.
  • Ci-6 alkoxy alone or in combination signifies a group Ci-6alkyl-0-, wherein the "Ci-6alkyl” is as defined above; for example methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, i- butoxy, 2-butoxy, t-butoxy and the like.
  • Preferred Ci_6alkoxy groups are methoxy and ethoxy and more preferably methoxy.
  • halogen means fluorine, chlorine, bromine or iodine. Halogen is preferably fluorine or chlorine.
  • carbonyl alone or in combination refers to the group -C(O)-.
  • the compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula (I) and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases.
  • Acid-addition salts include for example those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like.
  • Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide.
  • the chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. It is for example described in Bastin R.J., et. al, Organic Process Research & Development 2000, 4, 427-435; or in Ansel, H., et. al, In: Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed. (1995), pp. 196 and 1456-1457. Preferred are the sodium salts of the compounds of formula (I).
  • “Pharmaceutically acceptable esters” means that compounds of general formula (I) may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compounds in vivo. Examples of such compounds include physiologically acceptable and metabolically labile ester derivatives, such as methoxymethyl esters, methylthiomethyl esters and pivaloyloxymethyl esters. Additionally, any physiologically acceptable equivalents of the compounds of general formula (I), similar to the metabolically labile esters, which are capable of producing the parent compounds of general formula (I) in vivo, are within the scope of this invention. Preferred are the methyl and ethyl esters of the compounds of formula (I).
  • Racemates can be separated according to known methods into the enantiomers.
  • diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid.
  • Another embodiment of present invention is (ii) a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein
  • R is hydrogen or C 1-6 alkyl
  • R 2 /R 3 are hydrogen, halogen, OR 10 , or R 1 l R is hydrogen or C 1-6 alkyl;
  • X is -CH 2 -, or carbonyl
  • Ar is selected from
  • R 5 /R 9 is hydrogen, halogen, trifluoromethyl, or C 1-6 alkyl
  • R 6 /R 8 is hydrogen, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkoxy, cyano, C 1-6 alkyl, -C(0)- H 2 , -S(0) 2 - H 2 , or -S(0) 2 - d-e alkyl;
  • R 7 is hydrogen, halogen, C 1-6 alkyl, cyano, C 1-6 alkoxy, or -S(0) 2 - H 2
  • R 10 is hydrogen, C 1-6 alkyl, carbonyl-Ci-6 alkyl, or trifluoromethyl;
  • R 11 or R 12 is hydrogen, C 1-6 alkyl, carbonyl- C 1-6 alkyl, or sulfonyl; provided that R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are not hydrogen simultaneously, and compound with two chiral center is in cis configuration.
  • R 1 is C 1-6 alkyl; preferably R 1 is methyl;
  • R 2 /R 3 , R 4 , X, Ar, R 5 /R 9 , R 6 /R 8 , R 7 , R 10 , R 11 or R 12 is as defined above in embodiment (i) or (ii).
  • Another embodiment of present invention is (iv) a compound of formula (I) or a
  • R 4 is hydrogen; R 1 , R 2 /R 3 , X, Ar, R 5 /R 9 , R 6 /R 8 , R 7 , R 10 , R 11 or R 12 is as defined above in embodiment (i) or (ii).
  • Another further embodiment of present invention is (vi) a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 2 or R 3 is hydroxyl; R 4 is hydrogen; R 1 , X, Ar, R 5 /R 9 , R 6 /R 8 , R 7 , R 10 , R 11 or R 12 is as defined above in (i) or (ii).
  • More further embodiment of present invention is (vii) a compound of formula (I) or a pharmaceutically acceptable salt thereof , wherein Ar is selected from
  • R 5 /R 9 is hydrogen or halogen
  • R 6 /R 8 is halogen, trifluoromethyl, trifluoromethoxy, cyano, -S(0) 2 - H 2 , or -S(0) 2 -Ci_ ealkyl
  • R 7 is hydrogen, cyano, or halogen
  • Rl, R 2 /R3 , X, R10 , R11 or R12 is as defined above in (i) or (ii).
  • Preferred compound of embodiment (vii) or a pharmaceutically acceptable salt thereof is a compound of formula (I), wherein R 2 or R 3 is hydroxyl and R 4 is hydrogen. Still preferred compound of embodiment (vii) or a pharmaceutically acceptable salt th ound of
  • R 5 /R 9 is hydrogen, chloro, or fluoro
  • R 6 /R 8 is halogen, trifluoromethyl, cyano, -S(0)2- H 2 , or -S(0) 2 -methyl
  • R 7 is hydrogen, chloro, or fluoro.
  • Still further embodiment of present invention is (viii) a compound of formula (I) or a pharmaceutically acceptable salt thereof , wherein X is -CH 2 -; R 1 , R 2 /R 3 , R 4 , Ar, R 5 /R 9 , R 6 /R 8 ,
  • R , R , R or R is as defined above in embodiment (i) or (ii).
  • Preferred compound of embodiment (viii) is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein
  • R 2 or R 3 is hydroxyl
  • R 4 is hydrogen
  • Ar is selected from wherein R 5 /R 9 is hydrogen or halogen
  • R 6 /R 8 is halogen, trifluoromethyl, trifluoromethoxy, cyano, -S(0) 2 - H 2 , or -S(0) 2 - Ci. ealkyl;
  • R 7 is hydrogen, cyano, or halogen.
  • Still preferred compound of embodiment (viii) is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein
  • R 5 /R 9 is hydrogen, chloro, or fluoro
  • R 6 /R 8 is halogen, trifluoromethyl, cyano, -S(0)2- H 2 , or -S(0) 2 -methyl; R 7 is hydrogen, chloro, or fluoro.
  • Preferred embodiment of present invention is a compound of formula (I) or a
  • IIIb-1 4.12 >50.00000 methyl] -3 ,5,5 -trimethyl-cyclohexanol c/5-7, 3 )-3-(benzooxazol-2-ylaminomethyl)-
  • chloro-phenyl)-amide a Compound concentration preventing virus infection caused CPE at a 50% level based OD measurement. Values are mean of triplicate experiments. b Half maximal cytotoxicity concentration of the compounds to MDCK cells.
  • DIPEA diisopropylethylamine
  • FBS fetal bovine serum
  • HATU 0-(7-azabenzotriazol- 1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
  • One category of the compounds described herein relates to (3,3-dimethyl- cyclohexylmethyl)phenylamines having the formula II wherein R 1 is hydrogen, methyl; R 2 /R 3 is hydrogen, halogen, Ci -6 alkoxy, or NR U R 12 ; and R 4 is hydrogen:
  • Reagents and conditions (a): KCN, NH 4 C1, H 2 0, DMF; (b): L1AIH 4 , THF, reflux; (c): Cul, K3PO4, L-Proline, DMSO, microwave.
  • Compounds of interest Ila can be prepared according to the scheme above.
  • 1- C ⁇ aUcyl- 3,3-dimethyl-5-oxo-cyclohexanecarbonitrile V can be prepared by the Michael addition of cyanide to 3- Ci- 6 alkyl-5,5-dimethyl-cyclohex-2-enone.
  • the reduction of Compound V by L1AIH 4 under refluxing conditions gives 3-aminomethyl-3- Ci- 6 alkyl-5,5-dimethyl-cyclohexanol VI.
  • the target compounds Ila can be obtained by a copper-assisted Ullmann type cross coupling of amine VI with phenyl bromide VII.
  • Reagents and conditions (a): aldehyde, THF, NaBH 3 CN.
  • Compounds of interest lib can be prepared by reductive alkylation of Ila with aldehyde and NaBH 3 CN.
  • V VIII Me Reagents and conditions (a): Zn, HCl, Et 2 0, -20 °C to 0 °C; (b): LiAlH 4 , THF, reflux; (c): VII, Cul, K 3 P0 4 , L-Proline, DMSO, microwave.
  • Compounds of interest lid can be prepared by acylation of Ila with acyl chloride and triethylamine.
  • Reagents and conditions (a): NaBH 4 , THF; (b): R 1U I, NaH, THF; (c): LiAlH 4 , THF, reflux; (d): VII, Cul, K 3 P0 4 , L-Proline, DMSO, microwave.
  • Compounds of interest Ilf can be prepared by the method shown above. Following the reduction of the ketone functional group and alkylation of secondary alcohol, the ether intermediate can be reduced by LiAlH to give amine X. Compound Ilf is obtained by the copper catalyzed cross-coupling of amine X and phenyl bromide VII.
  • Reagents and conditions (a): R MgBr, THF; (b): LiAlH 4 , THF, reflux; (c): VII, Cul, K 3 P0 4 , L-Proline, DMSO, microwave.
  • the tertiary alcohol Ilg can be prepared by the method shown above. Following the addition reaction of Grignard reagent to the ketone functional group, the cyano intermediate is reduced by LiAlH to give amine Compound XI, which is coupled with phenyl bromide VII to give target compound Ilg.
  • Reagents and conditions (a): HNR U R 12 , THF, NaBH 3 CN; (b): LiAlH 4 , THF, reflux; (c): VII, Cul, K 3 P0 4 , L-Proline, DMSO, microwave.
  • Compounds of interest Ilh can be prepared by the method shown above. Following the reductive amination of the ketone functional group, the cyano intermediate is reduced by L1AIH 4 to give amine XII.
  • Compounds Ilh are prepared by the copper catalyzed cross-coupling of XII and phenyl bromide VII.
  • Reagents and conditions (a): POCl 3 , CHC1 3 , r.t. to reflux; (b): Zn, MeOH, KI, r.t; (c): KCN, NH 4 CI, H 2 0, DMF; (d): 1. HNR U R 12 , THF, NaBH 3 CN; or 2. R 3 MgBr, THF; or 3. R 10 I, NaH, THF; or 4. DAST, DCM, r.t.; or 5. Zn, HC1, Et 2 0; 6. LiAlH 4 , THF, reflux; (e): VII , Cul, K 3 P0 4 , L-Proline, DMSO, microwave.
  • Reagents and conditions (a): pyridine, DMSO, microwave.
  • Compounds of interest Ilia can be prepared by the method shown above.
  • the substituted 2-halogen pyrimidine or 2-halogen pyridine XVI is reacted with primary amine XV in microwave reactor to offer 2-aminopyrimidine (or pyridine) product Ilia.
  • the primary amine XV can be prepared according to the methods shown in Scheme 1 and can be anyone of VI, VIII, IX, X, XI, XII, and XIV.
  • Reagents and conditions (a): pyridine, DMSO, microwave.
  • Compounds of interest Illb can be prepared by the replacement reaction between substituted 2-halogen pyridazine XVII and primary amine XV.
  • the amine XV is prepared according to the methods shown in Scheme 1 and can be anyone of VI, VIII, IX, X, XI, XII, and XIV.
  • Reagents and conditions (a): pyridine, DMSO, microwave.
  • Compounds of interest IIIc can be prepared by the replacement reaction between substituted 2-chlorobenzothiazole (or 2-chlorobenzoxazole) XVIII and primary amine XV.
  • the amine XV is prepared according to the methods shown in Scheme 1 and can be anyone of VI, VIII, IX, X, XI, XII, and XIV.
  • Compounds of interest Hid can be prepared by the synthesis method shown above.
  • the primary amine XV is prepared according to the methods shown in Scheme 1 and can be anyone of VI, VIII, IX, X, XI, XII, and XIV. It can be coupled with 2-fluorobenzoic acid to give amide XIX.
  • the thioamide XX is obtained by treating XIX with Lawesson's reagent. When thioamide XX is treated with hydrazine, it gives lH-indazole target compound Hid.
  • benzoisoxazole Hid can be prepared in two steps by the condensation of thioamide XX with hydroxylamine, and Na 2 C0 3 treatment of the oxime product for benzoisoxazole ring formation.
  • Reagents and conditions (a): pyridine, DMSO, microwave.
  • Compounds of interest Hie can be prepared by the replacement reaction between substituted 2-chloroquinazoline XXI and primary amine XV.
  • the amine XV is prepared according to the methods shown in Scheme 1 and can be anyone of VI, VIII, IX, X, XI, XII, and XIV.
  • Reagents and conditions (a): pyridine, DMSO, microwave.
  • Compounds of interest lllf can be prepared by the replacement reaction between substituted 2-chloroisoquinoline XXII and primary amine XV.
  • the amine XV can be prepared according to the methods shown in Scheme 1 and can be anyone of VI, VIII, IX, X, XI, XII, and XIV.
  • the heterocyclic aromatic amines are prepared according to general synthesis method as shown in the Scheme 3.
  • Reagents and conditions (a): HC1 (cone), reflux; (b); step 1. SOCl 2 , DMF, DCM; step 2. XXIV, DIPEA; (c): NaBH 4 , MeOH.
  • amides with general structure IVa starts from 3,3-dimethyl-5-oxo- cyclohexanecarboxylic acid XXIV, which can be obtained through acidic hydrolysis of 3,3- dimethyl-5-oxo-cyclohexanecarbonitrile V by concentrated HC1.
  • the acid XXIII is treated with thionyl chloride to give acyl chloride, which coupled with aniline XXIV to afford amide XXV.
  • the reduction of the ketone functional group by NaBH 4 gives IVa, the alcohol functional group can be further derived by the methods shown in the Scheme 1 to give O- Ci- 6 alkyl analogs.
  • Reagents and conditions (a): step 1. H 4 OAc, NaBH 3 CN, AcOH; step 2. acyl chloride, DIPEA. Or (a): step 1. H 4 OAc, NaBH 3 CN, AcOH; step 2. sulfonyl chloride, DIPEA. Or (a): HNR U R 12 , NaBH 3 CN, AcOH.
  • R 11 or R 12 is hydrogen, Ci- 6 alkyl, carbonyl-Ci- 6 alkyl, or sulfonyl
  • the amino group can be incorporated by reductive amination of keto amide XXV. And the amino group is further derived by reaction with acyl chloride or sulfonyl chloride to give target compounds IVb.
  • the invention also relates to a compound of formula (I) for use as therapeutically active substance.
  • the invention also relates to a pharmaceutical composition comprising a compound of formula (I) and a therapeutically inert carrier.
  • the invention relates in particular to the use of a compound of formula (I) for the preparation of a medicament for the treatment or prophylaxis of influenza.
  • Said medicaments e.g. in the form of pharmaceutical preparations, can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions with an effective amount of a compound as defined above.
  • the above-mentioned pharmaceutical composition can be obtained by processing the compounds according to this invention with pharmaceutically inert inorganic or organic carriers.
  • Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semisolid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • the pharmaceutical composition can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • the dosage depends on various factors such as manner of administration, species, age and/or individual state of health.
  • the doses to be administered daily are about 5-400 mg/kg, preferably about 10-100 mg/kg, and can be taken singly or distributed over several
  • a compound of formula (I) when manufactured according to the above process is also an object of the invention.
  • the invention also relates to a method for the treatment or prophylaxis of diseases that are related to HA inhibition, which method comprises administering an effective amount of a compound of formula (I).
  • the invention further relates to a method for the treatment or prophylaxis of influenza, which method comprises administering an effective amount of a compound of formula (I).
  • Acidic condition A: 0.1% formic acid in H 2 0; B: 0.1% formic acid in acetonitrile;
  • the microwave assisted reactions were carried out in a Biotage Initiator Sixty.
  • NMR Spectra were obtained using Bruker Avance 400MHz. All reactions involving air-sensitive reagents were performed under an argon atmosphere. Reagents were used as received from commercial suppliers without further purification unless otherwise noted.
  • IIa-1 was prepared according to Synthetic route 1.
  • the copper catalyzed cross coupling between bromide and amine was generally applied to the synthesis of other examples of Ila scaffold.
  • the title compound, IIa-34 was prepared according to the method shown in Synthetic route 2.
  • the substituted benzenesulfonyl chlorides can be made by the Sandmeyer reaction of corresponding anilines.
  • the synthesis method was generally applied to other examples such as IIa-35, IIa-36 and IIa-37, which also have the sulfonamide functional group.
  • the aqueous phase was extracted by ethyl acetate, and the combined organic solution was washed with water and aqueous NaHC0 3 solution, dried over Na 2 S0 4 , and concentrated.
  • the crude product from Sandmeyer reaction was used in the next step reaction without further purification.
  • the so obtained sulfonyl chloride was dissolved in 50 mL of DCM. H 3 was bubbled into this solution at -78 °C for lOmin, and the mixture was brought to room temperature and stirred for 16 h.
  • the reaction mixture was washed by water (50 mL), and dried under vacuum to give 1.2 g of 5- bromo-2-chloro-benzenesulfonamide (46% yield for two steps).
  • Reagents and conditions (a): Zn, HC1, Et 2 0, -20 °C to 0 °C; (b): LiAlH 4 , THF, reflux; (c): 3-trifluoromethyl-5-fluoro-bromobenzene, Cul, K 3 P0 4 , L-Proline, DMSO, microwave.
  • Acetic acid (icis-2,5 -3,3,5-trimethyl-5-phenylaminomethyl-cyclohexyl ester
  • Compound of interest lid can be prepared by acylation of Ila with acyl chloride and triethylamine.
  • MS(ESI) calc'd (M+H) + 290.2, exp (M+H) + 290.1.
  • Reagents and conditions (a): DAST, DCM, r.t.; (b): LiAlH 4 , THF, reflux; (c): 3- trifluoromethyl-5-fluoro-bromobenzene, Cul, K 3 P0 4 , L-Proline, DMSO, microwave.
  • the intermediate 3,3-difluoro-5,5-dimethyl-cyclohexyl)-methylamine XXIX was prepared by following procedures. To a stirred solution of XXVI (1.0 g, 6.0 mmol) in 3 mL of dry DCM under nitrogen was added a solution of DAST (2.4 g, 14.4 mmol) in 2 mL of dry DCM, and the mixture was stirred for 2 h at r.t. The reaction mixture was washed with a.q. NaHC0 3 until C0 2 evolution ceased. The organic phase was dried over Na 2 S0 4 and concentrated to give 1.1 g of crude product as yellow oil. It was used in the reduction by LiAlH without further purification. Under similar reaction conditions to example IIa-1, the copper catalyzed cross-coupling of
  • Compound of interest IIf-1 can be prepared by the synthesis route in Synthetic route 5.
  • Reagents and conditions (a): NaBH 4 , THF; (b): RI, NaH, THF; (c): LiAlH 4 , THF, reflux; (d): 3-trifluoromethyl-5-fluoro-bromobenzene, Cul, K 3 P0 4 , L-Proline, DMSO, microwave.
  • the Intermediate XXX was prepared in three steps from XXVI, by reduction of the ketone functional group, alkylation of secondary alcohol, and reduction of cyano group by LiAlH .
  • XXVI (1.65 g, 10.0 mmol) in 15 mL of EtOH was added 760 mg of NaBH 4 (20.0 mmol).
  • the reaction mixture was stirred overnight at r.t. 5 mL of water was added to quench excess of NaBH . After the mixture was concentrated in vacuo, the residue was dissolved in 10 mL of water and extracted with ether. The combined organic layer was evaporated to give the secondary alcohol which was used in the alkylation reaction without further purification.
  • the tertiary alcohol IIg-1 was prepared according to the method in Synthetic route 6. Synthetic route 6 to example IIg-1
  • XXVI XXXI iig-1 Reagents and conditions: (a): MeMgBr, THF; (b): LiAlH 4 , THF, reflux; (c): 3- trifluoromethyl-5-fluoro-bromobenzene, Cul, K 3 P0 4 , L-Proline, DMSO, microwave.
  • the Intermediate XXXI was prepared in two steps from XXVI by addition reaction of Grignard reagent to the ketone functional group, and reduction of the cyano functional group by LiAlH 4 .
  • a solution of MeMgBr (3M in Et 2 0) was added into a solution of XXVI (1.65 g, 10.0 mmol) in 20 mL of dry THF at -40 °C.
  • the reaction mixture was stirred for 2 h at -40 °C. After 4 mL of water was added into the mixture, the aqueous phase was extracted with EtOAc twice. The combined organic layer was dried over Na 2 S0 4 and concentrated to give 1.7 g of tertiary alcohol as solid.
  • Reagents and conditions (a): dimethylamine, THF, NaBH 3 CN; (b): LiAlH 4 , THF, reflux;
  • the amine Intermediate XXXII was prepared by following procedures. A solution of 1.65 g of XXX (10.0 mmol) and 0.9 g of dimethylamine (20.0 mmol) in 10 mL of dry THF was stirred for 30 min at 0 °C. Then 0.8 g of NaBH 3 CN (12.0 mmol) was added into the solution in several portions. After stirred overnight at r.t., the reaction mixture was poured into water and extracted with DCM. The combined organic layer was extracted with HCl (IN, 20 mL x3). And the aqueous phase was neutralized to pH > 9 with NaOH (2N) and extracted with DCM (20 mL x3).
  • Reagents and conditions (a): POCl 3 , CHC1 3 , r.t. to reflux; (b): Zn, MeOH, KI, r.t; (c): KCN, H 4 C1, H 2 0, DMF; (d): LiAlH 4 , THF, reflux; (e): 3-trifluoromethyl-5-fluoro- bromobenzene, Cul, K 3 P0 4 , L-Proline, DMSO, microwave.
  • 3-Hydroxy-5,5-dimethyl-cyclohex-2-enone was treated with POCl 3 to give 3-chloro-5,5- dimethyl-cyclohex-2-enone, which was reduced by zinc to afford 5,5-dimethyl-cyclohex-2- enone.
  • the addition reaction of cyanide to 5,5-dimethyl-cyclohex-2-enone gave the cyano intermediate XXXIII, which was reduced by LiAlH 4 to give 5-aminomethyl-3,3-dimethyl- cyclohexanol XXXIV.
  • example IIIa-1 was carried out by the substitution of 2-chloropyridine by XXVII as shown in Synthetic route 9.
  • the method provided a general access to other heterocyclic aromatic analogs of Ilia to Illf.
  • Reagents and conditions (a): pyridine, DMSO, 150 °C, microwave.
  • XXXV XXXVI IIIa-7 Reagents and conditions: (a): phenylmethylthiol, NaH, THF; (b): Cl 2 , DCM, H 2 0, 0 °C; (c): H 3 , DCM, -78 ° C (degrees Celsius) ; (d): XXVII, pyridine, DMSO, 150 °C , microwave.
  • 2-Benzylthio-6-fluoropyridine was prepared by starting from 2,6-difluoropyridine. To a cold solution of NaH (1.06 g, 43.96 mmol) in 170mL of THF, was added dropwise of
  • 6-Fluoropyridine-2-sulfonamide XXXVI was prepared by the oxidation of 2-benzylthio-6- fluoropyridine to sulfonyl chloride and treatment with ammonia.
  • a solution of 2-benzylthio-6- fluoropyridine (3g, 13.7 mmol) in 75mL of DCM and 60mL of H 2 0 was cooled under an ice- water bath, to this cold solution was bubbled chlorine gas for a total of 1.5 hours. Then aqueous sodium metabisulphite solution was added to the mixture.
  • Reagents and conditions (a): pyridine, DMSO, microwave, 150 °C.
  • Reagents and conditions (a): HATU, Et 3 , DCM, r.t, 3 h, (b): Lawesson's reagent, toluene, refluxing, (c): step 1. H 2 OH, MeOH, step 2. Na 2 C0 3 , DMSO.
  • the title compound was prepared by treating the thioamide XXXVIII with hydrazine for ring formation (Synthetic route 13).
  • XXXIX was obtained by the hydrolysis of XXVI with concentrated HCl. After treatment with thionyl chloride, it was coupled with aniline to give amide XL. Compound IVa-1 was made by treating XL with NaBH 4 .
  • Reagents and conditions (a): HCl (cone), reflux; (b): step 1. SOCl 2 , DMF, DCM; step 2. aniline, DIPEA; (c): NaBH 4 , MeOH.
  • MDCK Madin-Darby canine kidney cell
  • MDCK cells were seeded into 96-well plates at a density of 5,000 cells per well. Next day, compounds were serially half-log diluted with Gibco SFM containing trypsin. Compounds and 50 pfu of virus were added into corresponding wells to make m.o.i at 0.01 and a final trypsin concentration of 2.5 ⁇ / ⁇ 1.
  • the testing plates also contained medium control, cell control, virus control, and compound toxicity control. After a 3 -day treatment, cell viability was measured with a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method.
  • a compound of formula (I) can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:
  • a compound of formula (I) can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:

Abstract

A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R4 and Ar are as defined in description and in claims, can be used as a medicament.

Description

Compounds for the Treatment and Prevention of Influenza
The invention relates to compounds which are inhibitors of hemagglutinin (HA) and which are useful in the treatment or prophylaxis of influenza.
The invention relates in particular to (i) a compound of formula (I)
Figure imgf000002_0001
wherein
R is hydrogen, Ci-6alkyl, or trifluoromethyl;
R2/R3 are hydrogen, halogen, OR10, or R1 R12;
R is hydrogen, Ci-6alkyl, or trifluoromethyl;
X is -CH2-, or carbonyl;
Ar is selected from
Figure imgf000002_0002
Wherein
R5/R9 is hydrogen, halogen, trifluoromethyl, or Ci-6alkyl;
R6/R8 is hydrogen, halogen, trifluoromethyl, trifluoromethoxy, Ci_6alkoxy, cyano, Ci_ salkyl, -C(0)- H2, -S(0)2- H2, or -S(0)2- Ci-6alkyl; R7 is hydrogen, halogen, Ci-6alkyl, cyano, Ci-6alkoxy, or -S(0)2- H2;
R10 is hydrogen, Ci-6alkyl, carbonyl-Ci-6alkyl, or trifluoromethyl;
R11 or R12 is hydrogen, Ci-6alkyl, carbonyl-Ci-6alkyl, or sulfonyl; provided that R1, R2, R3, R4, R5, R6, R7, R8 and R9 are not hydrogen simultaneously; and pharmaceutically acceptable salt and stereoisomers thereof.
The invention also relates to a process for the manufacture of these novel compounds and medicaments containing them. These compounds are inhibitors of hemagglutinin (HA) and useful in the treatment or prophylaxis of influenza.
Influenza viruses belong to the Orthomyxoviridae family of RNA viruses. Based on antigenic differences of viral nucleocapsid and matrix proteins, influenza viruses are further divided into three types named influenza A, B, and C viruses. All influenza viruses have an envelope, and their genomes are composed of eight or seven single-stranded, negative-sensed RNA segments. These viruses cause respiratory diseases in human and animals with a significant morbidity and mortality. Influenza pandemic of 1918, Spanish flu, is thought to have killed up to 100 million human beings. The reassortment of avian flu RNA fragments with circulating human viruses caused the other two pandemic, 1957 H2N2 "Asian influenza" and 1968 H3N2 "Hong Kong influenza". Now, people around the world face the challenges of influenza from various angles: seasonal influenza epidemics affect about 5-15% of the world's population with an annual mortality ranging from 250,000 to 500,000. Infections of avian flu strains, mostly H5N1, have been reported in many Asian countries. Though no frequent human-to-human spreading was observed, avian flu infection was serious and associated with a high mortality of -60% of infected persons. More recently, an H1N1 swine flu infection appeared initially in North
America. Its infection has already evolved into a new pandemic and more people will be affected by this virus in the coming seasons. Currently, seasonal trivalent influenza vaccines and vaccines specific for H5N1 or swine flu are either available or in the phase of clinical trials. The prophylaxis is an effective method, at least in some populations, for preventing influenza virus infection and its potentially severe complications. However, due to continuous viral antigenicity shifting and drafting that makes future circulating flu strains unpredictable, and the limitations of massive production of vaccines within a relatively short period of time during a pandemic, other anti-flu approaches such as anti- flu drugs are highly desirable. On the market, there are two types of anti-flu drugs available: neuraminidase inhibitors such as oseltamivir phosphate (Tamilflu) and zanamivir (Relenza); and M2 ion channel blockers such as amantadine and rimantadine. To increase the effectiveness of current anti-flu drugs and prevent or attenuate appearance of drug-resistant viruses, it is invaluable to discover compounds with new mechanisms of anti-influenza actions, that can be used as a therapeutical or prophylactic agent alone or combined with current anti-flu drugs.
HA is a viral glycoprotein, located on the surface of virus particles. HA is synthesized as a precursor molecule, HAo, and is cleaved by a cellular protease to yield two subunits, HAi and HA2. This cleavage is indispensible for the function of HA. Individual HAi and HA2, that are linked by one disulfide bond, assemble to form homotrimers on mature virus envelope. The life cycle of influenza virus infection begins with binding between the receptor binding pocket located in the membrane distal region of HA and sialic acid sugars on the surface of host epithelial cells. One of two types of sialic acids, N-acetylneuraminic acid a - (2,3)-Gal and N- acetylneuraminic acid a - (2,6)-Gal, is preferably recognized, dependent on host species involved. After HA-receptor binding, virus enters into cell by a process of endocytosis, resulting in the formation of virus-containing endosome. To release virus genomes into cytoplasm, fusion between viral envelope and endosome membrane occurs in an acidic environment within endosome that triggers an irreversibly conformational change of HA protein in which the hydrophobic fusion peptide at the N-terminus of HA2 is released from a buried position to a position that is 100 A away from its original location. The exposed fusogenic domain interacts with endosomal membrane and leads a series of structural rearrangements of HA2, which finally leads to fusion and release of viral RNP complexes into cytoplasm. Viral genomes then are translocated into nucleus where they act as the templates for virus RNA replication.
Since HA-mediated fusion is essential for influenza virus replication, HA has been used as a feasible target in the development of anti-influenza drugs. In general, there are two types of fusion inhibitors that block influenza infection by means of two different mechanisms:
nonspecifically increasing pH in endosome or directly targeting at HA protein. The examples of the first mechanism include chloroquine (Ooi et al, 2006), triperiden (Oka et al, 2001), and maybe arbidol, a compound with a broad spectrum of anti-viral activities (Boriskin et al, 2006; Leneva et al, 2008). By interfering the process of H+ pumping into endosome, these compounds elevate energy barrier of endosome acidification. When intra-vesicle pH is higher than the critical point required for HA conformational change, fusion is blocked. For the second mechanism, small molecules bind and stabilize the pre-fusion structure of HA, resulting in inhibition at the step of viral membrane fusion. The following are several examples. BMY 27709 was discovered by a group of researchers at BMS Pharmaceutical Research Institute (Luo et al, 1997). This compound had a moderate anti-flu activity with an EC50 of 6-8 μΜ for HI and H2 viruses, but not H3 viruses. Resistant selection showed that resistant mutations were located around a position where HA2 fusion peptide is hidden. Other mutations were scattered in both HA2 and HAi regions. Studies of hemolysis and trypsin sensitivity assays suggested that HA itself was the target of the compound. Photoaffinity labeling indicated the presence of a binding pocket close to HA2 N-terminal fusion peptide, but this site was not confirmed yet. Around the same time when BMS revealed BMY 27709, a group of scientists at Lilly Research Laboratories (Staschke et al, 1998) reported a novel HA inhibitor 180299, a podocarpic acid derivative. By isolating reassortment in co-infections with different viruses and mutation analysis, HA was assumed as the target of 180299. The study of pH-inactivation profiles of wild-type and some resistant variants and human erythrocyte fusion suggested that 180299 might bind to HA and stabilize its overall structure as BMY 27709 does. Another HA inhibitor, stachyflin, was found by Shionogi Discovery Research Laboratories (Yoshimoto et al, 1999). Based on mechanism of action studies, this compound showed similar profiles to BMY 27709. This compound only blocked HI and H2 influenza virus replication, but not H3 viruses.
Besides library screening that was used to find several series of HA inhibitors described above, structure-based approach also joined in the journey and contributed to the discovery of HA inhibitors. A group of scientists at the University of California, San Francisco, using biostructure modeling and visual screen, found several HA fusion inhibitors and some of them were confirmed in both molecular based and cell based assays (Bodian et al, 1993; Hoffman et al, 1997). Most of those compounds had a behavior of an HA stabilizer but a compound named C22 might work through a different mechanism. The phenotype of resistants and the data of biochemical study suggested that this compound triggered a pre-matured conformational change of HA and irreversibly inactivated the virus. Based on this character, this type of compounds was named as HA destabilizer. Recently, a group of Chinese scientists also reported a series of thiazolidinone compounds and their analogs that showed fusion inhibition activities through destabilizing HA homotrimers (Yang and Luo, 2009).
Most recently, a specific binding site of tert-butyl hydroquinone (TBHQ) on HA2 peptide of both H3 and H14 strains has been revealed in a co-crystallization study (Russell et al, 2008). This small molecule binds at a hydrophobic pocket located at an interface of two prefusion HA monomers. By means of an increase of the energy barrier required for HA fusogenic
conformational changes in endosome low-pH environment, TBHQ inhibits fusion of H3 influenza viruses.
Taken together, though the extensive study of HA inhibitors has been carried out over 15 years, majority of these chemical series did not go beyond the stage of drug discovery except arbidol series that has been put into clinic in Russia.
It has been found that the compounds of the present invention belong to a new class of influenza inhibitors. In a one-cycle time-course study, these compounds acted at an early step of influenza virus replication. Results from HA-mediated hemolysis of chicken red blood cells and trypsin sensitivity of isolated HA in the presence of the compounds clearly showed that they targeted at HA. In cell-based assays involving multiple rounds of virus replication, the compounds inhibited an established influenza infection by dramatically reducing the production of progeny viruses by an order of more than 8-log when compared with a negative control.
Considering current situations that people around the world are exposed to huge risks of infections of pandemic H1N1 swine flu, highly pathogenic H5N1 avian flu, and drug-resistant seasonal flu, it should be invaluable to study and develop HA inhibitors, including some compounds in this invention, for further clinical use.
As used herein, the term "Ci-6alkyl" alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, preferably 1 to 4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, 1 -butyl, 2-butyl, tert-butyl and the like. Preferred "Ci-6alkyl" groups are methyl, ethyl, isopropyl, tert-butyl.
The term "Ci-6alkoxy" alone or in combination signifies a group Ci-6alkyl-0-, wherein the "Ci-6alkyl" is as defined above; for example methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, i- butoxy, 2-butoxy, t-butoxy and the like. Preferred Ci_6alkoxy groups are methoxy and ethoxy and more preferably methoxy.
The term "halogen" means fluorine, chlorine, bromine or iodine. Halogen is preferably fluorine or chlorine.
The term "carbonyl" alone or in combination refers to the group -C(O)-.
The term "sulfonyl" alone or in combination refers to the group -S(0)2-.
The compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula (I) and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Acid-addition salts include for example those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide. The chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. It is for example described in Bastin R.J., et. al, Organic Process Research & Development 2000, 4, 427-435; or in Ansel, H., et. al, In: Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed. (1995), pp. 196 and 1456-1457. Preferred are the sodium salts of the compounds of formula (I).
"Pharmaceutically acceptable esters" means that compounds of general formula (I) may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compounds in vivo. Examples of such compounds include physiologically acceptable and metabolically labile ester derivatives, such as methoxymethyl esters, methylthiomethyl esters and pivaloyloxymethyl esters. Additionally, any physiologically acceptable equivalents of the compounds of general formula (I), similar to the metabolically labile esters, which are capable of producing the parent compounds of general formula (I) in vivo, are within the scope of this invention. Preferred are the methyl and ethyl esters of the compounds of formula (I).
Compounds of the general formula (I) which contain one or several chiral centers can either be present as racemates, diastereomeric mixtures, or optically active single isomers. The racemates can be separated according to known methods into the enantiomers. Preferably, diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid.
Another embodiment of present invention is (ii) a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein
R is hydrogen or C1-6 alkyl;
R2/R3 are hydrogen, halogen, OR10, or R1 lR is hydrogen or C1-6 alkyl;
X is -CH2-, or carbonyl;
Ar is selected from
Figure imgf000007_0001
Wherein R5/R9 is hydrogen, halogen, trifluoromethyl, or C1-6 alkyl;
R6/R8 is hydrogen, halogen, trifluoromethyl, trifluoromethoxy, C1-6 alkoxy, cyano, C1-6 alkyl, -C(0)- H2, -S(0)2- H2, or -S(0)2- d-e alkyl;
R7 is hydrogen, halogen, C1-6 alkyl, cyano, C1-6 alkoxy, or -S(0)2- H2 R10 is hydrogen, C1-6 alkyl, carbonyl-Ci-6 alkyl, or trifluoromethyl;
R11 or R12 is hydrogen, C1-6 alkyl, carbonyl- C1-6 alkyl, or sulfonyl; provided that R1, R2, R3, R4, R5, R6, R7, R8 and R9 are not hydrogen simultaneously, and compound with two chiral center is in cis configuration.
Further embodiment of present invention is (iii) a compound of formula (I) or a
pharmaceutically acceptable salt thereof , wherein R1 is C1-6 alkyl; preferably R1 is methyl;
R2/R3, R4, X, Ar, R5/R9, R6/R8, R7, R10, R11 or R12 is as defined above in embodiment (i) or (ii).
Another embodiment of present invention is (iv) a compound of formula (I) or a
2 3 10 2 3 pharmaceutically acceptable salt thereof, wherein R or R is OR ; preferably R or R is hydroxyl; Further embodiment of present invention is (v) a compound of formula (I) or a
pharmaceutically acceptable salt thereof , wherein R4 is hydrogen; R1, R2/R3, X, Ar, R5/R9, R6/R8, R7, R10, R11 or R12 is as defined above in embodiment (i) or (ii).
Another further embodiment of present invention is (vi) a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 or R3 is hydroxyl; R4 is hydrogen; R1, X, Ar, R5/R9, R6/R8, R7, R10, R11 or R12 is as defined above in (i) or (ii).
More further embodiment of present invention is (vii) a compound of formula (I) or a pharmaceutically acceptable salt thereof , wherein Ar is selected from
Figure imgf000008_0001
wherein R5/R9 is hydrogen or halogen; R6/R8 is halogen, trifluoromethyl, trifluoromethoxy, cyano, -S(0)2- H2, or -S(0)2-Ci_ ealkyl; R 7 is hydrogen, cyano, or halogen; Rl, R 2 /R3 , X, R10 , R11 or R12 is as defined above in (i) or (ii). Preferred compound of embodiment (vii) or a pharmaceutically acceptable salt thereof, is a compound of formula (I), wherein R2 or R3 is hydroxyl and R4 is hydrogen. Still preferred compound of embodiment (vii) or a pharmaceutically acceptable salt th ound of
formula (I) or a pharmaceutically acceptable salt thereof , wherein Ar is
Figure imgf000009_0001
R5/R9 is hydrogen, chloro, or fluoro; R6/R8 is halogen, trifluoromethyl, cyano, -S(0)2- H2, or -S(0)2-methyl; R7 is hydrogen, chloro, or fluoro.
Still further embodiment of present invention is (viii) a compound of formula (I) or a pharmaceutically acceptable salt thereof , wherein X is -CH2-; R1, R2/R3, R4, Ar, R5/R9, R6/R8,
1 10 11 12
R , R , R or R is as defined above in embodiment (i) or (ii). Preferred compound of embodiment (viii) is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein
R2 or R3 is hydroxyl;
R4 is hydrogen;
Ar is selected from
Figure imgf000009_0002
wherein R5/R9 is hydrogen or halogen;
R6/R8 is halogen, trifluoromethyl, trifluoromethoxy, cyano, -S(0)2- H2, or -S(0)2- Ci. ealkyl;
R7 is hydrogen, cyano, or halogen. Still preferred compound of embodiment (viii) is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein
Ar is
Figure imgf000010_0001
R5/R9 is hydrogen, chloro, or fluoro;
R6/R8 is halogen, trifluoromethyl, cyano, -S(0)2- H2, or -S(0)2-methyl; R7 is hydrogen, chloro, or fluoro.
Preferred embodiment of present invention is a compound of formula (I) or a
pharmaceutically acceptable salt thereof, as listed below:
(cis-1, 5) -3 , 3 , 5 -Trimethyl-5 -phenylaminomethyl-cyclohexanol,
(cis-1, 3) -3 -[(2-Chloro-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(cis-1, 3)-3-[(3 -Chloro-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(cis-1, 3) -3 -[(4-Chloro-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(cis-1, 5) -3 , 3 , 5 -Trimethyl-5 - [(2 -trifluoromethyl-phenylamino)-methyl] -cyclohexanol,
(cis-1, 5) -3,3 , 5-Trimethyl-5 - [(3 -trifluoromethyl-phenylamino)-methyl] -cyclohexanol,
(cis-1, 5) -3 , 3 , 5 -Trimethyl-5 -(p-tolylamino-methyl)-cyclohexanol, c/5-7,3)-3-[(3-Methoxy-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol,
3 -[{(cis-1, 5) -5-Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -benzonitrile,
4-[{(cis-l, 5) -5-Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -benzonitrile, (cis-1, 3) -3 -[(3 -Isopropoxy-phenylamino)-methyl] -3,5 , 5-trimethyl-cyclohexanol, c/5-7,3)-3-[(3-Isopropyl-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol,
3 -[{(cis-1, 5) -5-Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -benzamide, c/5-7,3)-3-[(3-Methanesulfonyl-phenylamino)-methyl]-3, 5, 5-trimethyl-cyclohexanol,
3 -[{(cis-1, 5) -5-Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -benzenesulfonamide, (cis-1, 3)-3-[(3 -Chloro-5 -fluoro-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(¾/5-7,3 -3-[(3-Fluoro-5-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol,
(cis-1, 3)-3-[(3 -Chloro-5 -methyl-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(cis-1, 3)-3-[(3 , 5-Dichloro-phenylamino)-methyl]-3 , 5, 5 -trimethyl-cyclohexanol,
(¾/5-7,3)-3-[(3-Chloro-5-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol,
(¾/5-7,3)-3-[(3-Bromo-5-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol,
3-Fluoro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile,
3- Chloro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile,
3 -[{(cis-1, 5) -5-Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -5 -trifluoromethyl- benzonitrile,
(cis-1, 3)-3-[(3 , 5-Bis-trifluoromethyl-phenylamino)-methyl]-3 , 5, 5 -trimethyl-cyclohexanol, (cis-1, 3) -3 -[(2, 3 -Dichloro-phenylamino)-methyl] -3 , 5 , 5 -trimethyl-cyclohexanol, c/5-7,3)-3-[(3,4-Dichloro-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol, 2-Fluoro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile, 2-Chloro-4-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile, 2-Chloro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile,
4- [((cis-l, 5) -5-Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -phthalonitrile,
(¾/5-7,3)-3-[(4-Chloro-3-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol,
4-[((¾/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-2-trifluoromethyl- benzonitrile,
2-Chloro-5-[( c/5-7,5)-5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide, 3-Chloro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide,
3 -[{(cis-1, 5) -5-Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -5 -trifluoromethyl- benzenesulfonamide,
3- Fluoro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide,
5-[((¾/5-7,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-2-methyl- benzenesulfonamide,
5-[((¾/5-7,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-2-methoxy- benzenesulfonamide,
4- [((cis-l, 5) -5-Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -2-trifluoromethoxy- benzenesulfonamide,
(cis-1, 3) -3 -{[(3 -Chloro-phenyl)-methyl-amino] -methyl } -3 , 5 , 5 -trimethyl-cyclohexanol, (3 -Fluoro-5-trifluoromethyl-phenyl)-( 1,3,3 -trimethyl-cyclohexylmethyl)-amine, Acetic acid (¾/5-7,5 -3,3,5-trimethyl-5-phenylaminomethyl-cyclohexyl ester, (3 , 3 -Difluoro- 1,5,5 -trimethyl-cyclohexylmethyl)-(3 -fluoro-5 -trifluoromethyl-phenyl)- amine,
(3 -Bromo-5 -trifluoromethyl-phenyl)-(3 , 3 -difluoro- 1 , 5 , 5-trimethyl-cyclohexylmethyl)- amine,
(3-Fluoro-5-trifluoromethyl-phenyl)-( c/5-7,5)-5-methoxy-l,3,3-trimethyl- cyclohexylmethyl)-amine,
(¾/5-7,3 -3-[(3-Fluoro-5-trifluoromethyl-phenylamino)-methyl]-l,3,5,5-tetra cyclohexanol,
((¾/5-7,5 -5-Dimethylamino-l,3,3-trimethyl-cyclohexylmethyl)-(3^
trifluoromethyl-phenyl)-amine,
(cis-1, 5) -5-[(3-Fluoro-5-trifluoromethyl-phenylamino)-methyl]-3,3-dimethyl- cyclohexanol, (^ra«5-7,5 -5-[(3-fluoro-5-trifluoromethyl-phenylamino)-methyl]-3,3-dimethyl- cyclohexanol,
(cis-1, 5) -3 , 3 , 5 -Trimethyl-5 -(pyridin-2-ylaminomethyl)-cyclohexanol,
(¾/5-7,3 -3-[(5-Bromo-pyridin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexano
(cis-1, 5) -3 , 3 , 5 -Trimethyl-5 - [(6-trifluoromethyl-pyridin-2-ylamino)-methyl] -cyclohexanol, c/5-7,3)-3-[(4-Chloro-pyridin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol,
(cis-1, 5) -3 , 3 , 5 -Trimethyl-5 - [(3 -trifluoromethyl-pyridin-2-ylamino)-methyl] -cyclohexanol,
(cis-1, 5) -3 , 3 , 5 -Trimethyl-5 - [(5 -trifluoromethyl-pyridin-2-ylamino)-methyl] -cyclohexanol,
6-[((¾/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-pyridine-2-sulfonic acid amide,
2-[((¾/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-pyridine-4-sulfonic acid amide,
(cis-1, 5^-3,3,5 -Trimethyl-5 - [(4-methyl-pyrimidin-2-ylamino)-methyl] -cyclohexanol,
(cis-1, 5^-3,3,5 -Trimethyl-5 - [(4-trifluoromethyl-pyrimidin-2-ylamino)-methyl] - cyclohexanol,
(cis-1, 3) -3 -[(4-Methoxy-pyrimidin-2-ylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(cis-1, 3) -3 -[(4, 6-Dimethoxy-pyrimidin-2-ylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(cis-1, 3) -3 -[(4, 6-Dimethyl-pyrimidin-2-ylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(¾/5-7,3)-3-[(4-Chloro-5-methoxy-pyrimidin-2-ylamino)-methyl]-3,5,5-trimethyl- cyclohexanol, c/5-7,3)-3-[(6-Chloro-pyrazin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol, (cis-1, 5^-3,3,5 -Trimethyl-5 - [(6-methyl-pyrazin-2-ylamino)-methyl] -cyclohexanol, (cis-1, 3) -3 -[(6-Methoxy-pyrazin-2-ylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol, c/5-7,3)-3-(Benzoxazol-2-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol, Benzoxazol-2-yl-(3,3-difluoro-l,5,5-trimethyl-cyclohexylmethyl)-amine, Benzoxazol-2-yl-((¾/5-7,5 -5-methoxy-l,3,3-trimethyl-cyclohexylmethyl)-ami (¾/5-7,3 -3-(Benzothiazol-2-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol, (¾/ ,3 -3-[(6-Fluoro-benzothiazol-2-ylamino)-m
(¾/5-7,3 -3-(Benzo[d]isoxazol-3-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol,
(cis-1, 3) -3 -[( 1 H-Indazol-3 -ylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(cis-1, 5) -3 , 3 , 5 -Trimethyl-5 -(quinazolin-2-ylaminomethyl)-cyclohexanol,
(cis-1, 3) -3 -(Isoquinolin- 1 -ylaminomethyl)-3 ,5,5 -trimethyl-cyclohexanol, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid phenylamide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (4-fluoro-phenyl)-amide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-chloro-phenyl)-amide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-trifluoromethyl- phenyl)-amide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-isopropyl-phenyl)- amide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-tert-butyl-phenyl)- amide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-ethoxy-phenyl)-amide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-trifluoromethoxy- phenyl)-amide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-methanesulfonyl- phenyl)-amide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-sulfamoyl-phenyl)- amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 , 5 -difluoro-phenyl)- amide, (t/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-chloro-5-fluoro- phenyl)amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -fluoro-5 - trifluoromethyl-phenyl)-amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-chloro-5- trifluoromethyl-phenyl)-amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -bromo-5 - trifluoromethyl-phenyl)-amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -methoxy-5 - trifluoromethyl-phenyl)-amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 , 5 -dichloro-phenyl)- amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3, 5-dimethoxy-phenyl)- amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (4-chloro-3 -fluoro- phenyl)amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3,4-dichloro-phenyl)- amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (4-fluoro-3- trifluoromethyl-phenyl)-amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (4-chloro-3- trifluoromethyl-phenyl)-amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (4-methoxy-3- trifluoromethyl-phenyl)-amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (4-cyano-3- trifluoromethyl-phenyl)-amide,
(t/. '-y.J -S-Amino-l^^-trimethyl-cyclohexanecarboxylic acid (3-chloro-phenyl)-amide,
(cis-1, 5) -5 - Acetylamino- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -chloro-phenyl)- amide, (cis-1, 5) -Diacetylamino- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -chloro-phenyl)- amide, or
(t/^-y.J -S-Methanesulfonylamino-l^^-trimethyl-cyclohexanecarboxylic acid (3-chloro- phenyl)-amide. Particular preferred embodiment of present invention is a compound of formula (I) or a pharmaceutically acceptable salt thereof, as listed in Table 1 :
Table 1
CPE_EC50 a Cytotoxicy
Ex. # Compd Name
(μΜ) IC50 b (μΜ)
(cis-1, 5) -3 , 3 , 5-Trimethyl-5 -
IIa-1 0.43 37.36
phenylaminomethyl-cyclohexanol
(cis-1, 3) -3 - [(2-Chloro-phenylamino)-methyl] -
IIa-2 0.52 6.80
3,5,5 -trimethyl-cyclohexanol
(cis-1, 3) -3 - [(3 -Chloro-phenylamino)-methyl] -
IIa-3 0.06 8.04
3,5,5 -trimethyl-cyclohexanol
(cis-1, 3) -3 - [(4-Chloro-phenylamino)-methyl] -
IIa-4 0.44 8.38
3,5,5 -trimethyl-cyclohexanol
(cz ,5 3,3,5-Trimethyl-5-[(2-
IIa-5 trifluoromethyl-phenylamino)-methyl]- 0.15 6.60
cyclohexanol
(cz ,5 3,3,5-Trimethyl-5-[(3-
IIa-6 trifluoromethyl-phenylamino)-methyl]- 0.042 7.75
cyclohexanol
(cis-1, 3) -3 -[(3 -Methoxy-phenylamino)-
IIa-8 0.20 >50.0
methyl] -3 ,5,5 -trimethyl-cyclohexanol 3 -[{(cis-1, 5) -5-Hydroxy- 1,3,3 -trimethyl-
IIa-9 0.25 46.87 cyclohexylmethyl)-amino]-benzonitrile
(cis-1, 3) -3 - [(3 -Isopropyl-phenylamino)-
IIa-12 0.090 6.68 methyl] -3 ,5,5 -trimethyl-cyclohexanol
(cis-1, 3) -3 - [(3 -Methanesulfonyl-
IIa-14 phenylamino)-methyl] -3, 5, 5 -trimethyl- 0.93 >50 cyclohexanol
3 -[{(cis-1, 5) -5-Hydroxy- 1,3,3 -trimethyl-
IIa-15 cyclohexylmethyl)-amino] - 0.28 >50 benzenesulfonamide c/5-7,3)-3-[(3-Chloro-5-fluoro-
IIa-16 phenylamino)-methyl] -3, 5, 5 -trimethyl- 0.017 4.40 cyclohexanol
(cis-1, 3) -3 - [(3 -Fluoro-5 -trifluoromethyl-
IIa-17 phenylamino)-methyl] -3, 5, 5 -trimethyl- 0.018 3.66 cyclohexanol
(c/ , 3 3-[(3-Chloro-5-methyl-
IIa-18 phenylamino)-methyl] -3, 5, 5 -trimethyl- 0.025 >3.16 cyclohexanol
(cis-1, 3) -3 - [(3 , 5 -Dichloro-phenylamino)-
IIa-19 0.032 7.19 methyl] -3 ,5,5 -trimethyl-cyclohexanol c/5-7,3)-3-[(3-Chloro-5-trifluoromethyl-
IIa-20 phenylamino)-methyl] -3, 5, 5 -trimethyl- 0.044 6.70 cyclohexanol
(cis-1, 3)-3-[(3 -Bromo-5 -trifluoromethyl-
IIa-21 phenylamino)-methyl] -3, 5, 5 -trimethyl- 0.058 >3.16 cyclohexanol 3-Fluoro-5-[( c/5-7,5)-5-hydroxy-l,3,3-
IIa-22 trimethyl-cyclohexylmethyl)-amino]- 0.050 23.89 benzonitrile
3-Chloro-5-[( c/5-7,5)-5-hydroxy- 1,3,3-
IIa-23 trimethyl-cyclohexylmethyl)-amino]- 0.034 13.87 benzonitrile
3 -[{(cis-1, 5) -5-Hydroxy- 1,3,3 -trimethyl-
IIa-24 cyclohexylmethyl)-amino]-5-trifluoromethyl- 0.040 13.17 benzonitrile
(cis-1, 3) -3 - [(3 , 5 -Bis-trifluoromethyl-
IIa-25 phenylamino)-methyl] -3,5,5 -trimethyl- 0.095 2.83 cyclohexanol c/5-7,3)-3-[(3,4-Dichloro-phenylamino)-
IIa-27 0.068 2.49 methyl] -3 ,5,5 -trimethyl-cyclohexanol
2-Fluoro-5-[( c/5-7,5)-5-hydroxy-l,3,3-
IIa-28 trimethyl-cyclohexylmethyl)-amino]- 0.190 27.64 benzonitrile
2-Chloro-4-[(fc/5-7, 5 5-hydroxy- 1 ,3 ,3 -
IIa-29 trimethyl-cyclohexylmethyl)-amino]- 0.180 8.22 benzonitrile
2-Chloro-5-[(fc/5-7,5 5-hydroxy-l,3,3-
IIa-30 trimethyl-cyclohexylmethyl)-amino]- 0.140 7.99 benzonitrile
(cis-1, 3) -3 - [(4-Chloro-3 -trifluoromethyl-
IIa-32 phenylamino)-methyl] -3, 5, 5 -trimethyl- 0.018 2.75 cyclohexanol
4-[((cis-l, 5j -5-Hydroxy- 1 ,3,3-trimethyl-
IIa-33 cyclohexylmethyl)-amino]-2-trifluoromethyl- 0.049 8.354 benzonitrile 2-Chloro-5-[((cz ,5 5-hydroxy-l,3,3-
IIa-34 trimethyl-cyclohexylmethyl)-amino]- 0.086 >50 benzenesulfonamide
3-Chloro-5-[( c/5-7,5)-5-hydroxy- 1,3,3-
IIa-35 trimethyl-cyclohexylmethyl)-amino]- 0.044 8.422 benzenesulfonamide
3-Fluoro-5-[( c/5-7,5)-5-hydroxy-l,3,3-
IIa-37 trimethyl-cyclohexylmethyl)-amino]- 0.089 55 benzenesulfonamide
(cis-1, 3)-3-{ [(3-Chloro-phenyl)-methyl-
IIb-1 0.60 7.58 amino] -methyl } -3 , 5 , 5 -trimethyl-cyclohexanol
(3 -Fluoro-5 -trifluoromethyl-phenyl)-( 1,3,3-
IIc-1 0.237 2.32 trimethyl-cyclohexylmethyl)-amine
Acetic acid (¾s-/,5 -3,3,5-trimethyl-5-
IId-1 0.492 64.44 phenylaminomethyl-cyclohexyl ester
(3 , 3 -Difluoro- 1 , 5 , 5 -trimethy 1-
IIe-1 cyclohexylmethyl)-(3-fluoro-5- 0.264 >3.16 trifluoromethyl-phenyl)-amine
(3-Fluoro-5-trifluoromethyl-phenyl)-( (cis-
IIf-1 1,5) -5 -methoxy- 1,3,3 -trimethy 1- 0.129 >3.16 cyclohexylmethyl)-amine
(cis-1, 3) -3 - [(3 -fluoro-5 -trifluoromethyl-
IIg-1 phenylamino)-methyl] - 1,3,5,5 -tetramethyl- 0.089 >3.16 cyclohexanol
((cis-1, 5 -5-Dimethylamino- 1 ,3,3-trimethyl-
IIh-1 cyclohexylmethyl)-(3-fluoro-5- 1.70 8.39 trifluoromethyl-phenyl)-amine Isomer 1 : (cis-1 ,5)-5-[(3-fluoro-5- trifluoromethyl-phenylamino)-methyl] -3 , 3 - <0.31 (Isomer 8.16 (Isomer dimethyl-cyclohexanol 1), 1),
Hi- 1/2
Isomer 2: (trans-l,5)-5-[(3-fluoro-5- <0.31 (Isomer 16.8 (Isomer trifluoromethyl-phenylamino)-methyl] -3 , 3 - 2) 2) dimethyl-cyclohexanol c/5-7,5)-3,3,5-trimethyl-5-[(6-
IIIa-3 trifluoromethyl-pyridin-2-ylamino)-methyl]- 0.27 13.46
cyclohexanol
(cis-1, 5) -3 , 3 , 5-trimethyl-5 - [(3 -
IIIa-5 trifluoromethyl-pyridin-2-ylamino)-methyl]- <0.15868 22.08
cyclohexanol
2-[((cis-l, 5 5-Hydroxy- 1 ,3,3-trimethyl-
IIIa-8 cyclohexylmethyl)-amino]-pyridine-4- 0.98 >100
sulfonic acid amide
(cz ,5 3,3,5-trimethyl-5-[(4-
Ilia- 10 trifluoromethyl-pyrimidin-2-ylamino)- 0.12 47.82
methyl] -cyclohexanol c/5-7, 3 )-3-[(4-methoxy-pyrimidin-2-
Ilia- 1 1 ylamino)-methyl] -3,5,5 -trimethyl- 1.50 >50.00000 cyclohexanol
(cis-1, 3) -3 - [(4, 6-dimethyl-pyrimidin-2-
Ilia- 13 ylamino)-methyl] -3,5,5 -trimethyl- 1.37 >100.00000 cyclohexanol c/5-7, 3 )-3-[(6-chloro-pyrazin-2-ylamino)-
IIIb-1 4.12 >50.00000 methyl] -3 ,5,5 -trimethyl-cyclohexanol c/5-7, 3 )-3-(benzooxazol-2-ylaminomethyl)-
IIIc-1 1.42 83.00
3,5,5 -trimethyl-cyclohexanol Benzooxazol-2-yl-(3 , 3 -difluoro- 1,5,5-
IIIc-2 3.36 10.87 trimethyl-cyclohexylmethyl)-amine
Benzooxazol-2-yl-( c/5-7, 5) -5 -methoxy- 1,3,3-
IIIc-3 7.43 >50.00000 trimethyl-cyclohexylmethyl)-amine c/5-7,3)-3-(benzothiazol-2-ylaminomethyl)-
IIIc-4 2.12 36.80
3,5,5 -trimethyl-cyclohexanol c/5-7,3)-3-[(6-fluoro-benzothiazol-2-
IIIc-5 ylamino)-methyl] -3, 5, 5 -trimethyl- 2.50 16.21 cyclohexanol c/5-7,3)-3-(benzo[d]isoxazol-3-
IIId-1 0.40 >50
ylaminomethyl)-3 ,5,5 -trimethyl-cyclohexanol
(cis-1, 3) -3 - [( 1 H-indazol-3 -ylamino)-methyl] -
IIId-2 6.90 >100
3,5,5 -trimethyl-cyclohexanol c/5-7,5)-3,3,5-trimethyl-5-(quinazolin-2-
IIIe-1 8.51 26.72 ylaminomethyl)-cyclohexanol c/5-7,3)-3-(Isoquinolin-l-ylaminomethyl)-
IIIf-1 2.37 43.74
3,5,5 -trimethyl-cyclohexanol
( is-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-3 cyclohexanecarboxylic acid (3-chloro- 0.460 82.07 phenyl)-amide
( is-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-4 cyclohexanecarboxylic acid (3- 0.340 68.31 trifluoromethyl-phenyl)-amide ( cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-5 cyclohexanecarboxylic acid (3-isopropyl- 1.04 21.62 phenyl)-amide
( is-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-8 cyclohexanecarboxylic acid (3- 0.861 60.03 trifluoromethoxy-phenyl)-amide
( is-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-10 cyclohexanecarboxylic acid (3-sulfamoyl- 7.96 >100 phenyl)-amide
( cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-11 cyclohexanecarboxylic acid (3,5-difluoro- 0.320 >100 phenyl)-amide
( cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-12 cyclohexanecarboxylic acid (3-chloro-5- 0.055 56.43 fluoro-phenyl)amide
( cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-13 cyclohexanecarboxylic acid (3-fluoro-5- 0.054 52.84 trifluoromethyl-phenyl)-amide
( cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-14 cyclohexanecarboxylic acid (3-chloro-5- 0.019 22.16 trifluoromethyl-phenyl)-amide
( cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-15 cyclohexanecarboxylic acid (3-bromo-5- 0.055 7.31 trifluoromethyl-phenyl)-amide
( cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-16 cyclohexanecarboxylic acid (3-methoxy-5- 0.060 74.77 trifluoromethyl-phenyl)-amide
( cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-17 cyclohexanecarboxylic acid (3,5-dichloro- 0.049 23.21 phenyl)-amide ( cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-19 cyclohexanecarboxylic acid (4-chloro-3- 1.80 30.85
fluoro-phenyl)amide
( is-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-20 cyclohexanecarboxylic acid (3,4-dichloro- 0.627 9.63
phenyl)-amide
( is-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-21 cyclohexanecarboxylic acid (4-fluoro-3- 0.454 29.59
trifluoromethyl-phenyl)-amide
( cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethy 1-
IVa-22 cyclohexanecarboxylic acid (4-chloro-3- 0.165 7.49
trifluoromethyl-phenyl)-amide
(cis-1, J -5-Acetylamino- 1 ,3,3-trimethyl-
IVb-2 cyclohexanecarboxylic acid (3-chloro- 4.61 >100
phenyl)-amide
(cis-1, J -Diacetylamino- 1 ,3,3-trimethyl-
IVb-3 cyclohexanecarboxylic acid (3-chloro- 3.15 22.90
phenyl)-amide
(cis-1, 5) -5 -Methanesulfonylamino- 1,3,3-
IVb-4 trimethyl-cyclohexanecarboxylic acid (3- 2.77 >100
chloro-phenyl)-amide a Compound concentration preventing virus infection caused CPE at a 50% level based OD measurement. Values are mean of triplicate experiments. b Half maximal cytotoxicity concentration of the compounds to MDCK cells.
The compounds of the present invention as well as their starting materials can be synthesized according to the following general reaction schemes 1 to 3. All substituents, in particular, R1 to R12, X, and Ar are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry. Abbreviations
bp: boiling point
DAST: diethylamino sulfur trifluoride
DIPEA: diisopropylethylamine
DCM: dichloromethylene
DMF: dimethylformamide
DMSO: dimethylsulfoxide
EDCI: l-ethyl-3-(3-dimethylaminopropyl)carbodiimide
EtOAc: ethyl acetate
FBS: fetal bovine serum
g: gram
μg: microgram
EC50: concentration required for 50% growth inhibition
IC50: concentration required for 90% growth inhibition
h: hour
HATU: 0-(7-azabenzotriazol- 1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
HO Ac: acetic acid
HOBt: 1-hydroxybenzotriazole
HPLC: high performance liquid chromatography
Hz: Hertz
MeOD: deuterated methanol
MeOH: methanol
mg: milligram MHz: megahertz mL: milliliter mmol: millimole
MS(ESI): mass spectroscopy (electron spray ionization) MW: molecular weight MP: N-methylmorpholine MR: nuclear magnetic resonance PET or Pet: petroleum ether r.t.: room temperature t-BuOK: potassium tert-butoxide
TEA: triethylamine THF: tetrahydrofuran TLC: thin layer chromatography μί: microliter General synthetic route for phenyl based analogues II (scheme 1)
One category of the compounds described herein relates to (3,3-dimethyl- cyclohexylmethyl)phenylamines having the formula II wherein R1 is hydrogen, methyl; R2/R3 is hydrogen, halogen, Ci-6alkoxy, or NRUR12; and R4 is hydrogen:
Figure imgf000025_0001
Scheme 1
Figure imgf000026_0001
Figure imgf000026_0002
VI VII Ila
Reagents and conditions: (a): KCN, NH4C1, H20, DMF; (b): L1AIH4, THF, reflux; (c): Cul, K3PO4, L-Proline, DMSO, microwave.
Compounds of interest Ila can be prepared according to the scheme above. 1- C^aUcyl- 3,3-dimethyl-5-oxo-cyclohexanecarbonitrile V can be prepared by the Michael addition of cyanide to 3- Ci-6alkyl-5,5-dimethyl-cyclohex-2-enone. The reduction of Compound V by L1AIH4 under refluxing conditions gives 3-aminomethyl-3- Ci-6alkyl-5,5-dimethyl-cyclohexanol VI. The target compounds Ila can be obtained by a copper-assisted Ullmann type cross coupling of amine VI with phenyl bromide VII.
Figure imgf000026_0003
Ila Mb
Reagents and conditions: (a): aldehyde, THF, NaBH3CN.
Compounds of interest lib can be prepared by reductive alkylation of Ila with aldehyde and NaBH3CN.
Figure imgf000026_0004
V VIII Me Reagents and conditions: (a): Zn, HCl, Et20, -20 °C to 0 °C; (b): LiAlH4, THF, reflux; (c): VII, Cul, K3P04, L-Proline, DMSO, microwave.
Compounds of interest lie can be prepared by the method shown above. Following the reduction of ketone V by zinc in aqueous HCl, the so obtained cyano compound is refluxed with LiAlH to give (3,3-dimethyl-cyclohexyl)-methylamine VIII. The copper catalyzed coupling of VIII and phenyl bromide VII affords lie by microwave reactor.
Figure imgf000027_0001
Ma
Reagents and conditions: (a): acyl chloride, Et3, r.t.
Compounds of interest lid can be prepared by acylation of Ila with acyl chloride and triethylamine.
Figure imgf000027_0002
V IX Me Reagents and conditions: (a): DAST, DCM, r.t.; (b): LiAlH4, THF, reflux; (c): VII, Cul,
K3P04, L-Proline, DMSO, microwave.
Compounds of interest He can be prepared through the synthesis route shown above. Following the conversion of ketone functional group to gem-difluoro, the so obtained cyano compound is refluxed with LiAlH to give (3,3-difluoro-5,5-dimethyl-cyclohexyl)-methylamine IX. The copper catalyzed cross-coupling of IX and phenyl bromide VII gives target Compound He
Figure imgf000028_0001
V
Reagents and conditions: (a): NaBH4, THF; (b): R1UI, NaH, THF; (c): LiAlH4, THF, reflux; (d): VII, Cul, K3P04, L-Proline, DMSO, microwave. Compounds of interest Ilf can be prepared by the method shown above. Following the reduction of the ketone functional group and alkylation of secondary alcohol, the ether intermediate can be reduced by LiAlH to give amine X. Compound Ilf is obtained by the copper catalyzed cross-coupling of amine X and phenyl bromide VII.
Figure imgf000028_0002
Reagents and conditions: (a): R MgBr, THF; (b): LiAlH4, THF, reflux; (c): VII, Cul, K3P04, L-Proline, DMSO, microwave.
The tertiary alcohol Ilg can be prepared by the method shown above. Following the addition reaction of Grignard reagent to the ketone functional group, the cyano intermediate is reduced by LiAlH to give amine Compound XI, which is coupled with phenyl bromide VII to give target compound Ilg.
Figure imgf000028_0003
Reagents and conditions: (a): HNRUR12, THF, NaBH3CN; (b): LiAlH4, THF, reflux; (c): VII, Cul, K3P04, L-Proline, DMSO, microwave. Compounds of interest Ilh can be prepared by the method shown above. Following the reductive amination of the ketone functional group, the cyano intermediate is reduced by L1AIH4 to give amine XII. Compounds Ilh are prepared by the copper catalyzed cross-coupling of XII and phenyl bromide VII.
Figure imgf000029_0001
Reagents and conditions: (a): POCl3, CHC13, r.t. to reflux; (b): Zn, MeOH, KI, r.t; (c): KCN, NH4CI, H20, DMF; (d): 1. HNRUR12, THF, NaBH3CN; or 2. R3MgBr, THF; or 3. R10I, NaH, THF; or 4. DAST, DCM, r.t.; or 5. Zn, HC1, Et20; 6. LiAlH4, THF, reflux; (e): VII , Cul, K3P04, L-Proline, DMSO, microwave. Compounds of interest Hi (R1 = H) can be prepared by the method shown above. 3-
Hydroxy-5,5-dimethyl-cyclohex-2-enone is treated with POCl3 to give 3-chloro-5,5-dimethyl- cyclohex-2-enone, which is reduced by zinc to afford 5,5-dimethyl-cyclohex-2-enone. After the addition of cyanide to the enone gave the cyano intermediate XIII, the ketone functional group can be derived to R2/R3 in a similar way as scaffolds lie, and He, Ilf, Ilg and Ilh. Compound XIII is reduced by LiAlH to give amine XIV. Compounds of interest Hi can be obtained by the copper catalyzed cross-coupling of XIV and phenyl bromide VII.
Scheme 2: General synthetic route for heterocycle based analogues with formula III
One category of the compounds described herein relates to 3,3-dimethyl-
2 3 10 11 12 cyclohexylmethylamines having the formula III (R /R = hydrogen, halogen, OR , or R R ). The heterocyclic aromatic amines are prepared according to general synthesis method as shown in the Scheme 2.
Figure imgf000030_0001
Figure imgf000030_0002
Scheme 2
Figure imgf000030_0003
Z = CI, F Ilia
Reagents and conditions: (a): pyridine, DMSO, microwave.
Compounds of interest Ilia can be prepared by the method shown above. The substituted 2-halogen pyrimidine or 2-halogen pyridine XVI is reacted with primary amine XV in microwave reactor to offer 2-aminopyrimidine (or pyridine) product Ilia. The primary amine XV can be prepared according to the methods shown in Scheme 1 and can be anyone of VI, VIII, IX, X, XI, XII, and XIV.
Figure imgf000030_0004
XV XVII Z = CI, F 1Mb
Reagents and conditions: (a): pyridine, DMSO, microwave.
Compounds of interest Illb can be prepared by the replacement reaction between substituted 2-halogen pyridazine XVII and primary amine XV. The amine XV is prepared according to the methods shown in Scheme 1 and can be anyone of VI, VIII, IX, X, XI, XII, and XIV.
Figure imgf000031_0001
XV XVIII T = o, s lllc
Reagents and conditions: (a): pyridine, DMSO, microwave. Compounds of interest IIIc can be prepared by the replacement reaction between substituted 2-chlorobenzothiazole (or 2-chlorobenzoxazole) XVIII and primary amine XV. As with other cases of Ilia and Illb, the amine XV is prepared according to the methods shown in Scheme 1 and can be anyone of VI, VIII, IX, X, XI, XII, and XIV.
Figure imgf000031_0002
XX Mid Reagents and conditions: (a): HATU, Et3, DCM, r.t, 3 h, (b): Lawesson's reagent, toluene, refluxing, (c): condition 1 : H2 H2.H20, DMSO, 150 °C (W = H); or condition 2: step 1, H2OH, MeOH, step 2. Na2C03, DMSO (W = O).
Compounds of interest Hid can be prepared by the synthesis method shown above. The primary amine XV is prepared according to the methods shown in Scheme 1 and can be anyone of VI, VIII, IX, X, XI, XII, and XIV. It can be coupled with 2-fluorobenzoic acid to give amide XIX. The thioamide XX is obtained by treating XIX with Lawesson's reagent. When thioamide XX is treated with hydrazine, it gives lH-indazole target compound Hid. Whereas
benzoisoxazole Hid can be prepared in two steps by the condensation of thioamide XX with hydroxylamine, and Na2C03 treatment of the oxime product for benzoisoxazole ring formation.
Figure imgf000032_0001
Reagents and conditions: (a): pyridine, DMSO, microwave.
Compounds of interest Hie can be prepared by the replacement reaction between substituted 2-chloroquinazoline XXI and primary amine XV. The amine XV is prepared according to the methods shown in Scheme 1 and can be anyone of VI, VIII, IX, X, XI, XII, and XIV.
Figure imgf000032_0002
XXII lllf
Reagents and conditions: (a): pyridine, DMSO, microwave.
Compounds of interest lllf can be prepared by the replacement reaction between substituted 2-chloroisoquinoline XXII and primary amine XV. The amine XV can be prepared according to the methods shown in Scheme 1 and can be anyone of VI, VIII, IX, X, XI, XII, and XIV.
Scheme 3 : General synthetic route for amide-based analogues IV
One category of the compounds described herein relates to 3,3-dimethyl- cyclohexanecarboxylic acid phenylamides having the formula IV (R2/R3 = hydrogen, halogen, OR10, or RUR12). The heterocyclic aromatic amines are prepared according to general synthesis method as shown in the Scheme 3.
Figure imgf000032_0003
IV
Scheme 3
Figure imgf000033_0001
Figure imgf000033_0002
IVa
Reagents and conditions: (a): HC1 (cone), reflux; (b); step 1. SOCl2, DMF, DCM; step 2. XXIV, DIPEA; (c): NaBH4, MeOH.
The preparation of amides with general structure IVa starts from 3,3-dimethyl-5-oxo- cyclohexanecarboxylic acid XXIV, which can be obtained through acidic hydrolysis of 3,3- dimethyl-5-oxo-cyclohexanecarbonitrile V by concentrated HC1. The acid XXIII is treated with thionyl chloride to give acyl chloride, which coupled with aniline XXIV to afford amide XXV. The reduction of the ketone functional group by NaBH4 gives IVa, the alcohol functional group can be further derived by the methods shown in the Scheme 1 to give O- Ci-6alkyl analogs.
Figure imgf000033_0003
XXV IVb
Reagents and conditions: (a): step 1. H4OAc, NaBH3CN, AcOH; step 2. acyl chloride, DIPEA. Or (a): step 1. H4OAc, NaBH3CN, AcOH; step 2. sulfonyl chloride, DIPEA. Or (a): HNRUR12, NaBH3CN, AcOH.
Compounds of interest IVb (R11 or R12 is hydrogen, Ci-6alkyl, carbonyl-Ci-6alkyl, or sulfonyl) can be prepared by the method shown above. The amino group can be incorporated by reductive amination of keto amide XXV. And the amino group is further derived by reaction with acyl chloride or sulfonyl chloride to give target compounds IVb.
The invention also relates to a compound of formula (I) for use as therapeutically active substance. The invention also relates to a pharmaceutical composition comprising a compound of formula (I) and a therapeutically inert carrier.
The use of a compound of formula (I) for the preparation of medicaments useful in the treatment or prophylaxis diseases that are related to HA inhibition is an object of the invention.
The invention relates in particular to the use of a compound of formula (I) for the preparation of a medicament for the treatment or prophylaxis of influenza.
Said medicaments, e.g. in the form of pharmaceutical preparations, can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions with an effective amount of a compound as defined above.
The above-mentioned pharmaceutical composition can be obtained by processing the compounds according to this invention with pharmaceutically inert inorganic or organic carriers. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules.
Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semisolid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
The pharmaceutical composition can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances. The dosage depends on various factors such as manner of administration, species, age and/or individual state of health. The doses to be administered daily are about 5-400 mg/kg, preferably about 10-100 mg/kg, and can be taken singly or distributed over several
administrations. A compound of formula (I) when manufactured according to the above process is also an object of the invention.
Furthermore, the invention also relates to a method for the treatment or prophylaxis of diseases that are related to HA inhibition, which method comprises administering an effective amount of a compound of formula (I).
The invention further relates to a method for the treatment or prophylaxis of influenza, which method comprises administering an effective amount of a compound of formula (I).
The invention is illustrated by the following examples which have no limiting character. Unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.
Examples
Intermediates and final compounds were purified by flash chromatography using one of the following instruments: i) Biotage SP1 system and the Quad 12/25 Cartridge module, ii) ISCO combi-flash chromatography instrument. Silica gel Brand and pore size: i) KP-SIL 60 A, particle size: 40-60 μΜ; ii) CAS registry NO: Silica Gel: 63231-67-4, particle size: 47-60 micron silica gel; iii) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore: 200-300 or 300-400.
Intermediates and final compounds were purified by preparative HPLC on reversed phase column using X Bridge™ Perp C18 (5 μιη, OBD™ 30 χ 100 mm) column or SunFire™ Perp C18 (5 m, OBD™ 30 100 mm) column. LC/MS spectra were obtained using a MicroMass Plateform LC (WatersTM alliance 2795-
ZQ2000). Standard LC/MS conditions were as follows (running time 6 min):
Acidic condition: A: 0.1% formic acid in H20; B: 0.1% formic acid in acetonitrile;
Basic condition: A: 0.01% ΝΗ3Ή20 in H20; B: acetonitrile;
Neutral condition: A: H20; B: acetonitrile. Mass spectra (MS): generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion (M+H)+.
The microwave assisted reactions were carried out in a Biotage Initiator Sixty.
NMR Spectra were obtained using Bruker Avance 400MHz. All reactions involving air-sensitive reagents were performed under an argon atmosphere. Reagents were used as received from commercial suppliers without further purification unless otherwise noted.
The following examples were prepared by the general methods outlined in the schemes above. They are intended to illustrate the meaning of the present invention but should by no means represent a limitation within the meaning of the present invention:
EXAMPLE IIa-1
(icis-2,5 -3,3,5-Trimethyl-5-phenylaminomethyl-cyclohexanol
Figure imgf000036_0001
IIa-1 was prepared according to Synthetic route 1. The copper catalyzed cross coupling between bromide and amine was generally applied to the synthesis of other examples of Ila scaffold.
Synthetic route 1 to example IIa-1
Figure imgf000036_0002
XXVI XXVII IIa-1 Reagents and conditions: (a): KCN, H4C1, H20, DMF, 80 °C ; (b): LiAlH , THF, reflux;
(c): bromobenzene, Cul, K3P04, L-Proline, DMSO, microwave.
The Intermediate XXVI, l,3,3-trimethyl-5-oxo-cyclohexanecarbonitrile, was made by the following procedure. To a stirring solution of isophorone (40 g, 0.289 mol) in 1.5 L of DMF was added H4C1 (24 g, 0.434 mol), KCN (54.4 g, 0.579 mol) and 200 mL of water. The mixture was stirred at 80 °C for 20 h. When the reaction was completed, the mixture was concentrated. The residue was dissolved into 300 mL of water and ethyl acetate. The aqueous phase was extracted by ethyl acetate. The combined organic phase was washed by water, dried over anhydrous Na2S04, filtered and concentrated. The residue was purified by silica gel column (hexane : petroleum ether = 50: 1 -10: 1) to give Compound XXVI (24 g, yield 50%). 1H NMR (CDC13, 400MHz), 2.64 (dt, 1H, Jl = 14.4 Hz, J2 = 2.0 Hz), 2.22 (dt, 1H, Jl = 13.6 Hz, J2 = 2.0 Hz), 2.16 (dd, 1H, Jl = 12.0 Hz, J2 = 1.2 Hz), 2.13 (m, 1H), 2.02 (dt, 1H, Jl = 14.0 Hz, J2 = 2.0 Hz), 1.58 (d, 1H, J= 14.4 Hz), 1.46 (s, 3H), 1.15 (s, 3H), 1.04 (s, 3H). The synthesis of Intermediate XXVII, 3-aminomethyl-3,5,5-trimethyl-cyclohexanol, was carried out by the following procedure. To a solution of Compound XXVI (10 g, 60 mmol) in THF (400 mL) was added LiAlH4 (7 g, 0.18 mol) in portions. The mixture was refluxed for 16 h until no starting material remains (monitored by TLC, petroleum ether: ethyl acetate = 5: 1). After the mixture was cooled to 0 °C, 20 mL of water was added dropwise under 0 °C, followed by dropwise addition of 20 mL of NaOH (2N) at 0 °C. The mixture was filtered and the filtrate was acidified by addition of aqueous HC1 (2N). After washed by ethyl acetate, the aqueous phase was neutralized to pH >7 by addition of NaOH, and extracted by ethyl acetate and
dichloromethylene. The combined organic layers were dried over Na2S04, filtered and concentrated to give Compound XXVII (4 g, yield 39%). 1H NMR (CDC13, 400MHz), 3.97-3.91 (m, 1H), 2.38 (s, 2H), 1.74 (m, 1H), 1.64 (m, 1H), 1.16 (dt, 1H, J = 14.0 Hz, J2 = 2.0 Hz), 1.04- 0.97 (m, 9H), 0.94 (s, 3H).
A mixture of bromobenzene (91 mg, 0.58 mmol), amine XXVII (150 mg, 0.88 mmol), K3P04 (250 mg, 1.16 mmol), Cul (11 mg, 0.058 mmol), and L-proline (13 mg, 0.116 mmol) in 3 mL of DMSO was heated in microwave at 80 °C for 30 min. The reaction was monitored by LCMS(ESI). When the reaction was complete, it was send to HPLC separation without further work-up. After HPLC separation, the eluent was concentrated under vacuum to remove the organic solution. The residue was dried by lyophylization to give example IIa-1. 1H NMR (d4- MeOD, 400MHz), 7.46 (t, 2H, J= 7.6 Hz), 7.28 (d, 2H, J= 8.0 Hz), 7.02 (t, 1H, J= 7.6 Hz), 3.99-3.96 (m, 1H), 3.14 (s, 2H), 1.46-1.42 (m, 2H), 1.30-1.03 (m, 13H). MS(ESI): calc'd
(M+H)+ 248.2, exp (M+H)+ 248.1.
EXAMPLE IIa-2 c/5-7,3)-3-[(2-Chloro-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000037_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 2-chloro-bromobenzene instead of bromobenzene. 1H NMR (<¾-MeOD, 400MHz), 7.21 (d, lH, J= 8.0 Hz), 7.11 (t, lH, J= 8.0 Hz), 6.77 (d, lH, J= 8.0 Hz), 6.58 (t, 1H, J = 8.0 Hz), 3.97- 3.93 (m, 1H), 2.98 (s, 2H), 1.79-1.73 (m, 2H), 1.33-1.03 (m, 10H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 282.2, exp (M+H)+ 282.1. EXAMPLE IIa-3 c/5-7,3)-3-[(3-Chloro-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000038_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-chloro-bromobenzene instead of bromobenzene. 1H MR (i¾-MeOD, 400MHz), 7.01 (t, 1H, J= 8.0 Hz), 6.62 (s, 1H), 6.55 (d, 1H, J= 8.0 Hz), 6.55 (d, 1H, J= 8.0 Hz), 3.94-3.91 (m, 1H), 2.84 (s, 2H), 1.75-1.71 (m, 2H), 1.31-1.03 (m, 10H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 282.2, exp (M+H)+ 282.1.
EXAMPLE IIa-4 c/5-7,3)-3-[(4-Chloro-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000038_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 4-chloro-bromobenzene instead of bromobenzene. 1H MR (i¾-MeOD, 400MHz), 7.03 (d, 2H, J= 8.4 Hz), 6.61 (d, 2H, J= 8.4 Hz), 3.96-3.91 (m, 1H), 2.83 (s, 2H), 1.73 (d, 2H, J= 10.8 Hz), 1.31-1.02 (m, 10H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 282.2, exp (M+H)+ 282.1.
EXAMPLE IIa-5
-2,5 -3,3,5-Trimethyl-5-[(2-trifluoromethyl-phenylamino)-methyl]-cyclohexanol
Figure imgf000038_0003
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 2-trifluoromethyl-bromobenzene instead of bromobenzene. 1H NMR (i¾-MeOD, 400MHz), 7.41-7.36 (m, 2H), 6.88 (d, 1H, J= 8.0 Hz), 6.71 (d, 1H, J= 8.0 Hz), 3.97-3.94 (m, 1H), 3.00 (s, 2H), 1.78-1.75 (m, 2H), 1.29-1.03 (m, 10H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 316.2, exp (M+H)+ 316.2.
EXAMPLE IIa-6
(cis-1,5) -3,3,5-Trimethyl-5-[(3-trifluoromethyl-phenylamino)-methyl]-cyclohexanol
Figure imgf000039_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-trifluoromethyl-bromobenzene instead of bromobenzene. 1H NMR (i¾-MeOD, 400MHz), 7.22 (t, 1H, J= 8.0 Hz), 6.86 (s, 1H), 6.85 (d, 1H, J= 7.6 Hz), 6.78 (d, 1H, J= 7.6 Hz), 3.96- 3.92 (m, 1H), 2.89 (s, 2H), 1.74 (m, 2H), 1.33-1.03 (m, 10H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 316.2, exp (M+H)+ 316.1.
EXAMPLE IIa-7
-2,5 -3,3,5-Trimethyl-5-(p-tolylamino-methyl)-cyclohexanol
Figure imgf000039_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 4-methyl-bromobenzene instead of bromobenzene. 1H NMR (<¾-MeOD, 400MHz), 6.90 (d, 2H, J= 8.0 Hz), 6.57 (d, 2H, J= 8.0 Hz), 3.96-3.93 (m, 1H), 2.83 (s, 2H), 2.19 (s, 3H), 1.75-1.72 (m, 2H), 1.28-1.02 (m, 10H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 262.2, exp (M+H)+ 262.2.
EXAMPLE IIa-8
-7,3)-3-[(3-Methoxy-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000039_0003
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 4-methoxy-bromobenzene instead of bromobenzene. 1H MR (i¾-MeOD, 400MHz), 6.97 (t, 1H, J= 8.0 Hz), 6.26-6.22 (m, 2H), 6.15 (J, 1H, J= 8.0 Hz), 3.96-3.90 (m, 1H), 3.73 (s, 3H), 2.84 (s, 2H), 1.75-1.72 (m, 2H), 1.28-1.03 (m, 10H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 278.2, exp (M+H)+ 278.2.
EXAMPLE IIa-9
3- [((cis-1, 5 -5-Hydroxy- 1 ,3,3-trimethyl-cyclohexylmethyl)-amino] -benzonitrile
Figure imgf000040_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-nitrile-bromobenzene instead of bromobenzene. 1H MR (<¾-MeOD, 400MHz), 7.21 (t, 1H, J= 8.0 Hz), 6.94-6.90 (m, 2H), 6.84 (d, 1H, J= 7.6 Hz), 3.96-3.90 (m, 1H), 2.88 (s, 2H), 1.76-1.72 (m, 2H), 1.30-0.99 (m, 13H). MS(ESI): calc'd (M+H)+ 273.2, exp (M+H)+ 273.2.
EXAMPLE IIa-10
-1, 5 -5-Hydroxy- 1 ,3,3-trimethyl-cyclohexylmethyl)-amino] -benzonitrile
Figure imgf000040_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 4-nitrile-bromobenzene instead of bromobenzene. 1H MR (i¾-MeOD, 400MHz), 7.35 (d, 1H, J= 7.2 Hz), 6.69 (d, 1H, J= 7.2 Hz), 3.94-3.85 (m, 1H), 2.91 (s, 2H), 1.74-1.68 (m, 2H), 1.26 (d, 1H, J= 13.6 Hz), 1.18 (d, 1H, J= 13.6 Hz), 1.10-0.99 (m, 8H), 0.95 (s, 3H). MS(ESI): calc'd (M+H)+ 273.0, exp (M+H)+ 273.0.
EXAMPLE IIa-11
-2,J^-3-[(3-Isopropoxy-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000041_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-isopropoxy-bromobenzene instead of bromobenzene. 1H MR (i¾-MeOD, 400MHz), 6.93 (t, 1H, J= 8.0 Hz), 6.22 (dt, 1H, J = 8.4 Hz, J2 = 1.6 Hz), 6.18 (t, 1H, J= 1.6 Hz), 6.11 (dt, 1H, J = 8.4 Hz, J2 = 1.6 Hz), 4.52-4.48 (pent, 1H, J= 6.4 Hz), 3.95-3.86 (m, 1H), 2.81 (s, 2H), 1.74-1.66 (m, 2H), 1.26 (d, 6H, J= 6.0 Hz), 1.23-1.18 (m, 1H), 1.15-1.00 (m, 8H), 0.95 (s, 3H). MS(ESI): calc'd (M+H)+ 306, exp (M+H)+ 306.2.
EXAMPLE IIa-12
-2,J^-3-[(3-Isopropyl-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000041_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-isopropyl-bromobenzene instead of bromobenzene. 1H MR (i¾-MeOD, 400MHz), 7.35 (t, 1H, J= 8.0 Hz), 7.16-7.14 (m, 2H), 7.07 (d, 1H, J= 8.0 Hz), 4.00-3.92 (m, 1H), 3.11 (s, 2H), 2.92 (m, lH, J= 7.2 Hz), 1.82-1.71 (m, 2H), 1.41 (d, 1H, J= 13.6 Hz), 1.31-1.21 (m, 10H), 1.19-1.10 (m, 2H), 1.09 (s, 3H), 1.01 (s, 3H). MS(ESI): calc'd (M+H)+ 290.0, exp (M+H)+ 290.0.
EXAMPLE IIa-13
-1, 5 -5-Hydroxy- 1 ,3,3-trimethyl-cyclohexylmethyl)-amino] -benzamide
Figure imgf000041_0003
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-formamide-bromobenzene instead of bromobenzene. 1H NMR (i¾-MeOD, 400MHz), 7.18-7.13 (m, 2H), 7.04 (d, lH, J= 7.6 Hz), 6.83 (d, lH, J= 7.6 Hz), 3.96-3.91 (m, 1H), 2.92 (s, 2H), 1.78-1.71 (m, 2H), 1.34-1.03 (m, 10H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 291.2, exp (M+H)+ 291.2. EXAMPLE IIa-14
(icis-2,J^-3-[(3-Methanesulfonyl-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000042_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-methanesulfonyl-bromobenzene instead of bromobenzene. 1H MR (i¾-MeOD, 400MHz), 7.31 (t, 1H, J= 8.0 Hz), 7.15 (s, 1H), 7.06 (d, 1H, J= 7.6 Hz), 6.94 (d, 1H, J= 8.0 Hz), 3.96-3.90 (m, 1H), 3.08 (s, 3H), 2.93 (s, 2H), 1.78-1.72 (m, 2H), 1.34-1.03 (m, 10H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 326.2, exp (M+H)+ 326.2.
EXAMPLE IIa-15
3-[((icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide
Figure imgf000042_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-sulfonamide-bromobenzene instead of bromobenzene. 1H MR (i¾-MeOD, 400MHz), 7.22 (t, 1H, J= 8.0 Hz), 7.15 (t, 1H, J= 2.0 Hz), 7.06 (dt, 1H, Jl = 8.0 Hz, J2 = 0.8 Hz), 6.85 (dt, 1H, J = 8.0 Hz, J2 = 1.2 Hz), 3.95-3.87 (m, 1H), 2.88 (s, 2H), 1.74-1.68 (m, 2H), 1.27 (d, 1H, J = 13.6 Hz), 1.18 (d, 1H, J= 13.6 Hz), 1.08 (s, 3H), 1.06-0.95 (m, 5H), 0.94 (s, 3H). MS(ESI): calc'd (M+H)+ 327.2, exp (M+H)+ 327.2.
EXAMPLE IIa-16
(icis-2,Ji -3-[(3-Chloro-5-fluoro-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000042_0003
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-chloro-5-fluoro-bromobenzene instead of bromobenzene. 1H MR (i¾-MeOD, 400MHz), 6.46 (s, 1H), 6.31-6.24 (m, 2H), 3.965-3.92 (m, 1H), 2.83 (s, 2H), 1.73 (d, 2H, J= 12.0 Hz), 1.34-1.03 (m, 10H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 300.2, exp (M+H)+ 300.2. EXAMPLE IIa-17
(icis-2,J^-3-[(3-Fluoro-5-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol
Figure imgf000043_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-fluoro-5-trifluoromethyl-bromobenzene instead of bromobenzene. 1H MR (CDC13, 400MHz), 6.62-6.59 (m, 2H), 6.45 (d, 1H, J= 11.2 Hz), 4.09-3.95 (m, 1H), 2.90 (s, 2H), 1.82- 1.79 (m, 2H), 1.31 (d, 1H, J= 14 Hz), 1.18-1.00 (m, 12H). MS(ESI): calc'd (M+H)+ 334, exp (M+H)+ 334.
EXAMPLE IIa-18
-2,J^-3-[(3-Chloro-5-methyl-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000043_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-chloro-5-methyl-bromobenzene instead of bromobenzene. 1H MR (i¾-MeOD,
400MHz), 6.55 (d, 1H, J= 1.8 Hz), 6.49 (m, 2H), 3.91 (m, 1H), 2.85 (s, 2H), 2.21 (s, 3H), 1.74- 1.69 (m, 2H), 1.26 (d, 1H, J= 13.2 Hz), 1.20-1.05 (m, 9H), 0.96 (s, 3H). MS(ESI): calc'd
(M+H)+ 296.1, exp (M+H)+ 296.1.
EXAMPLE IIa-19
(icis-2,Ji -3-[(3,5-Dichloro-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000044_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3,5-dichloro-bromobenzene instead of bromobenzene. 1H MR (i¾-MeOD, 400MHz), 6.54 (d, 1H, J= 1.6 Hz), 6.48 (t, 1H, J= 1.6 Hz), 3.82-3.98 (m, 1H), 2.79(s, 2H), 1.65-1.72 (m, 2H), 1.25 (d, 1H, J= 13.6 Hz), 1.18 (d, 1H, J= 13.6 Hz), 1.12-0.98 (m, 8H), 0.95 (s, 3H).
MS(ESI): calc'd (M+H)+ 316, exp (M+H)+ 315.9.
EXAMPLE IIa-20
(icis-2,J^-3-[(3-Chloro-5-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol
Figure imgf000044_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-chloro-5-trifluoromethyl-bromobenzene instead of bromobenzene. 1H MR (CDC13, 400MHz), 6.81 (s, 1H), 6.66 (s, 1H), 6.63 (s, 1H), 3.98 (m, 1H), 2.84 (s, 2H), 1.77-1.74 (m, 2H), 1.26-1.22 (d, 1H, J= 13.6 Hz), 1.09-0.98 (m, 9H), 0.93 (s, 3H). MS(ESI): calc'd (M+H)+ 350.1, exp (M+H)+ 350.1.
EXAMPLE IIa-21
(icis-2,Ji -3-[(3-Bromo-5-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol
Figure imgf000044_0003
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using l,3-dibromo-5-trifluoromethyl-benzene instead of bromobenzene. 1H NMR (i¾-MeOD, 400MHz), 7.00 (s, 1H), 6.87 (s, 1H), 6.85 (s, 1H), 3.96-3.91 (m, 1H), 2.88 (s, 2H), 1.77-1.72 (m, 2H), 1.33-1.03 (m, 10H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 394.1, exp (M+H)+ 394.0. EXAMPLE IIa-22
3-Fluoro-5-[((icis-2,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzonitrile
Figure imgf000045_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-bromo-5-fluoro-benzonitrile instead of bromobenzene. 1H NMR (i¾-MeOD, 400MHz), 6.73 (m, 1H, J= 1.2 Hz), 6.62 (dt, 1H, J = 12 Hz, J2 = 1.2 Hz), 6.53 (dt, 1H, J = 8 Hz, J2 = 1.2 Hz), 3.94-3.85 (m, 1H), 2.84 (s, 2H), 1.74-1.67 (m, 2H), 1.26 (d, 1H, J= 13.6 Hz), 1.15 (d, 1H, J = 13.6 Hz), 1.10-0.99 (m, 8H), 0.94 (s, 3H). MS(ESI): calc'd (M+H)+ 291, exp (M+H)+ 290.8.
EXAMPLE IIa-23 3-Chloro-5-[((icis-2,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzonitrile
Figure imgf000045_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-bromo-5-chloro-benzonitrile instead of bromobenzene. 1H NMR (i¾-MeOD, 400MHz), 6.89 (t, 1H, J= 2.0 Hz), 6.84 (t, 1H, J= 2.0 Hz), 6.80 (t, 1H, J= 1.6 Hz), 3.94-3.87 (m, 1H), 2.85 (s, 2H), 1.75-1.68 (m, 2H), 1.28 (d, 1H, J= 13.6 Hz), 1.17 (d, 1H, J= 13.6 Hz), 1.12-1.01 (m, 8H), 0.96 (s, 3H). MS(ESI): calc'd (M+H)+ 307, exp (M+H)+ 307.2.
EXAMPLE IIa-24 3-[((icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-5-trifluoromethyl- benzonitrile
Figure imgf000046_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3-bromo-5-trifluoromethyl-benzonitrile instead of bromobenzene. 1H MR (CDCI3, 400MHz), 7.07 (s, 1H), 6.94 (s, 1H), 6.91 (s, 1H), 3.94 (m, 1H), 2.85 (s, 2H), 1.77-1.74 (m, 2H), 1.26-1.22 (d, 1H, J= 13.2 Hz), 1.09-0.98 (m, 9H), 0.93 (s, 3H). MS(ESI): calc'd (M+H)+ 341.1, exp (M+H)+ 341.1.
EXAMPLE IIa-25
(icis-2,Ji -3-[(3,5-Bis-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol
Figure imgf000046_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by g 3,5-bistrifluoromethyl-bromobenzene instead of bromobenzene. 1H NMR (CDCI3, 400MHz), 7.14 (s, 1H), 6.96 (s, 2H), 4.14-4.01 (m, 1H), 2.96 (s, 2H), 1.84-1.81 (m, 2H), 1.33 (d, 1H, J= 14 Hz), 1.20-1.00 (m, 12H). MS(ESI): calc'd (M+H)+ 384, exp (M+H)+ 384.
EXAMPLE IIa-26
(icis-2,Ji -3-[(2,3-Dichloro-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000046_0003
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 2,3-dichloro-bromobenzene instead of bromobenzene. 1H NMR (CDC13, 400MHz), 7.07- 7.03 (m, 1H), 6.78 (dd, 1H, Jl = 1.2Hz, J2 = 3.6Hz), 6.58 (dd, 1H, Jl = 0.8Hz, J2 = 8.4 Hz), 4.05- 3.99 (m, 1H), 2.95 (s, 2H), 1.86-1.79 (m, 2H), 1.35 (d, 1H, J= 14Hz), 1.21-1.00 (m, 12H).
MS(ESI): calc'd (M+H)+ 316, exp (M+H)+ 316.
EXAMPLE IIa-27
(icis-2,Ji -3-[(3,4-Dichloro-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000047_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 3,4-dichloro-bromobenzene instead of bromobenzene. 1H NMR (CDCI3, 400MHz), 7.18(d, 1H, J= 8.8Hz), 6.69 (d, 1H, J= 2.8Hz), 6.47-6.44 (m, 1H), 4.03-3.97 (m, 1H), 2.85 (s, 2H), 1.82-1.77 (m, 1H), 1.29 (d, 1H, J= 14Hz), 1.17-0.99 (m, 13H). MS(ESI): calc'd (M+H)+ 316, exp (M+H)+ 316.
EXAMPLE IIa-28 2-Fluoro-5-[((icis-2,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzonitrile
Figure imgf000047_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 2-fluoro-4-bromo-benzonitrile instead of bromobenzene. 1H NMR (CDCI3, 400MHz), 6.97-6.91 (m, 1H), 6.78-6.72 (m, 1H), 6.69-6.67 (m, 1H), 3.98 (m, 1H), 2.85 (s, 2H), 2.77 (s, 2H), 1.77-1.74 (m, 2H), 1.26-1.22 (d, 1H, J= 13.6 Hz), 1.11 (d, 1H, J= 13.6 Hz), 1.09-0.94 (m, 8H), 0.89 (s, 3H). MS(ESI): calc'd (M+H)+ 291, exp (M+H)+ 290.9.
EXAMPLE IIa-29
2-Chloro-4-[((icis-2,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]
benzonitrile
Figure imgf000048_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 2-chloro-4-bromo-benzonitrile instead of bromobenzene. 1H NMR (CDC13, 400MHz), 7.34 (d, 1H, J= 8.8 Hz), 6.62 (d, 1H, J= 2.4 Hz), 6.47 (dd, 1H, Jl = 8.8 Hz, J2 = 2.4 Hz), 3.98 (m, 1H), 2.90 (s, 2H), 1.78-1.75 (m, 2H), 1.26 (d, 1H, J= 13.6 Hz), 1.12-0.97 (m, 9H), 0.96 (s, 3H). MS(ESI): calc'd (M+H)+ 307, exp (M+H)+ 307.2.
EXAMPLE IIa-30
2-Chloro-5-[((icis-2,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzonitrile
Figure imgf000048_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 2-chloro-5-bromo-benzonitrile instead of bromobenzene. 1H NMR (CDCI3, 400MHz), 7.17 (d, 1H, J= 8.8 Hz), 6.80-6.79 (d, 1H, J= 2.8 Hz), 6.72 (dd, 1H, Jl = 8.8 Hz, J2 = 2.8 Hz), 3.98 (m, 1H), 3.17 (bs, OH), 2.82 (s, 2H), 1.77-1.74 (m, 2H), 1.25 (d, 1H, J= 13.6 Hz), 1.15-0.92 (m, 9H), 0.92 (s, 3H). MS(ESI): calc'd (M+H)+ 307, exp (M+H)+ 307.2.
EXAMPLE IIa-31
-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-phthalonitrile
Figure imgf000048_0003
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 4-bromo-phthalonitrile instead of bromobenzene. 1H NMR (<¾-MeOD, 400MHz), 7.52 (d, 1H, J= 8.8 Hz), 7.07 (d, 1H, J= 2.4 Hz), 6.95 (dd, 1H, J = 8.8 Hz, J2 = 2.4 Hz), 3.94-3.86 (m, 1H), 2.96 (s, 2H), 1.74-1.68 (m, 2H), 1.30 (d, 1H, J= 13.6 Hz), 1.16 (d, 1H, J= 13.6 Hz), 1.12- 1.03 (m, 8H), 0.96 (s, 3H). MS(ESI): calc'd (M+H)+ 298, exp (M+H)+ 298. EXAMPLE IIa-32
(icis-2,Ji -3-[(4-Chloro-3-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol
Figure imgf000049_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 4-bromo-l-chloro-2-trifluoromethyl-benzene instead of bromobenzene. 1H MR (<¾- MeOD, 400MHz), 7.20 (d, 1H, J= 8.8 Hz), 6.98 (d, 1H, J= 3.2 Hz), 6.79 (dd, 1H, Jl = 8.8 Hz, J2 = 2.8 Hz), 3.82-3.98 (m, 1H), 2.85 (s, 2H), 1.64-1.75 (m, 2H), 1.29 (d, 1H, J= 13.6 Hz), 1.17 (d, 1H, J= 13.6 Hz), 1.15-0.98 (m, 8H), 0.95 (s, 3H). MS(ESI): calc'd (M+H)+ 350, exp (M+H) 350.0.
EXAMPLE IIa-33
4-[((icis-2,5^-5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-2-trifluoromethyl- benzonitrile
Figure imgf000049_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 4-bromo-2-trifluoromethyl-benzonitrile instead of bromobenzene. 1H MR (i¾-MeOD, 400MHz), 7.54 (d, 1H, J= 8.8 Hz), 7.03 (d, 1H, J= 2.4 Hz), 6.85 (dd, 1H, Jl = 8.8 Hz, J2 = 2.4 Hz), 3.94-3.85 (m, 1H), 2.95 (s, 2H), 1.75-1.68 (m, 2H), 1.29 (d, 1H, J= 13.6 Hz), 1.17 (d, 1H, J = 13.6 Hz), 1.12-0.99 (m, 8H), 0.94 (s, 3H). MS(ESI): calc'd (M+H)+ 341, exp (M+H)+ 341.1. EXAMPLE IIa-34
2-Chloro-5-[((icis-2,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide
Figure imgf000050_0001
The title compound, IIa-34 was prepared according to the method shown in Synthetic route 2. The substituted benzenesulfonyl chlorides can be made by the Sandmeyer reaction of corresponding anilines. The synthesis method was generally applied to other examples such as IIa-35, IIa-36 and IIa-37, which also have the sulfonamide functional group.
Synthetic route 2 to example IIa-34
Figure imgf000050_0002
lla-34
Reagents and conditions: (a): 1. NaN02, HC1; 2. CuCl, AcOH, S02; (b): H3, DCM; (c): XXVII, Cul, K3P04, L-Proline, DMSO, microwave, 80 °C. 5-Bromo-2-chloro-benzenesulfonyl chloride was prepared by the following procedures.
To a stirring mixture of 5-bromo-2-chloro-phenylamine (2 g, 9.6 mmol) in 10 mL of HC1, a solution of NaN02 (0.8 g, 11.6 mmol) in 10 mL of water was added dropwise to keep the temperature below 5 °C. The diazonium salt solution was added into a S02 gas saturated acetic acid solution of CuCl (0.28 g, 2.88 mmol), and the mixture was stirred at room temperature for 2h. The mixture was treated with water when the reaction was complete. The aqueous phase was extracted by ethyl acetate, and the combined organic solution was washed with water and aqueous NaHC03 solution, dried over Na2S04, and concentrated. The crude product from Sandmeyer reaction was used in the next step reaction without further purification. The so obtained sulfonyl chloride was dissolved in 50 mL of DCM. H3 was bubbled into this solution at -78 °C for lOmin, and the mixture was brought to room temperature and stirred for 16 h. The reaction mixture was washed by water (50 mL), and dried under vacuum to give 1.2 g of 5- bromo-2-chloro-benzenesulfonamide (46% yield for two steps). 1H NMR (dg-DMSO, 400MHz), 8.04 (d, 1H, J= 2.4 Hz), 7.81 (dd, 1H, Jl = 8.4 Hz, Jl = 2.4 Hz), 7.65(bs, 2H), 7.60 (d, 1H, J = 8.4 Hz). The copper catalyzed coupling reaction between amine XXVII and 5-bromo-2-chloro- benzenesulfonamide gave title compound IIa-34 as white solid. 1H NMR (<¾-MeOD, 400MHz), 7.34 (d, 1H, J= 2.8 Hz), 7.20 (d, 1H, J= 8.4 Hz), 6.77 (dd, 1H, J = 8.4 Hz, J = 2.8 Hz), 3.96- 3.85 (m, 1H), 2.86 (s, 2H), 1.73-1.68 (m, 2H), 1.31-1.19 (m, 3H), 1.10 (s, 3H), 1.06 (s, 3H), 1.04-1.00 (m, 1H), 0.96 (s, 3H). MS(ESI): calc'd (M+H)+ 361.1, exp (M+H)+ 361.1.
EXAMPLE IIa-35 3-Chloro-5-[((icis-2,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide
Figure imgf000051_0001
The title compound was prepared in analogy to example IIa-34 in Synthetic route 2 by using 3-bromo-5-chloro-phenylamine instead of 5-bromo-2-chloro-phenylamine. 1H MR (<¾- MeOD, 400MHz), 7.03 (t, 1H, J= 2.0 Hz), 6.96 (t, 1H, J= 1.6 Hz), 6.77 (t, 1H, J= 2.0 Hz), 3.94-3.85 (m, 1H), 2.85 (s, 2H), 1.73-1.65 (m, 2H), 1.27 (d, 1H, J= 13.6 Hz), 1.18 (d, 1H, J = 13.6 Hz), 1.08 (s, 3H), 1.06-0.95 (m, 5H), 0.94 (s, 3H). MS(ESI): calc'd (M+H)+ 361.0, exp (M+H)+ 361.0. EXAMPLE IIa-36
3-[((icis-2,5^-5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-5-trifluoromethyl- benzenesulfonamide
Figure imgf000051_0002
The title compound was prepared in analogy to example IIa-34 in Synthetic route 2 by using 3-bromo-5-trifluoromethyl-phenylamine instead of 5-bromo-2-chloro-phenylamine. 1H NMR (i¾-MeOD, 400MHz), 7.32 (s, 1H), 7.25 (s, 1H), 7.06 (s, 1H), 3.97-3.89 (m, 1H), 2.93 (s, 2H), 1.76-1.68 (m, 2H), 1.29 (d, 1H, J= 13.2 Hz), 1.20 (d, 1H, J= 13.2 Hz), 1.13-1.00 (m, 8H), 0.96 (s, 3H). MS(ESI): calc'd (M+H)+ 395, exp (M+H)+ 394.9.
EXAMPLE IIa-37
3-Fluoro-5-[((cis-l,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide
Figure imgf000052_0001
The title compound was prepared in analogy to example IIa-34 in Synthetic route 2 by using 3-bromo-5-fluoro-phenylamine instead of 5-bromo-2-chloro-phenylamine. 1H MR (<¾- MeOD, 400MHz), 6.95 (t, 1H, J= 1.6 Hz), 6.69 (dt, 1H, Jl = 8.4 Hz, J2 = 0.8 Hz), 6.51 (dt, 1H, J = 12.0 Hz, J2 = 0.8 Hz), 3.94-3.85 (m, 1H), 2.86 (s, 2H), 1.83-1.67 (m, 2H), 1.28 (d, 1H, J = 13.6 Hz), 1.17 (d, 1H, J= 13.6 Hz), 1.08 (s, 3H), 1.06-0.96 (m, 5H), 0.94 (s, 3H). MS(ESI): calc'd (M+H)+ 345.1, exp (M+H)+ 345.1.
EXAMPLE IIa-38
5- [((cis-1, 5 -5-Hydroxy- 1 ,3,3-trimethyl-cyclohexylmethyl)-amino] -2-methyl- benzenesulfonamide
Figure imgf000052_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 5-bromo-2-methyl-benzenesulfonamide instead of bromobenzene. 1H MR (i¾-MeOD, 400MHz), 8.11 (d, 1H, J= 2.4 Hz), 7.4 (dd, 1H, Jl = 8.4 Hz, J2 = 2.4 Hz), 7.59 (d, 1H, J= 8.4 Hz), 4.02-3.93 (m, 1H), 3.25 (d, 2H, J= 5.6 Hz), 2.71 (s, 3H), 1.85-1.72 (m, 2H), 1.48 (d, 1H, J = 13.6 Hz), 1.31 (s, 3H), 1.29-1.12 (m, 3H), 1.10 (s, 3H), 1.02 (s, 3H). MS(ESI): calc'd (M+H)+ 341.1, exp (M+H)+ 341.1.
EXAMPLE IIa-39 5-[((icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-2-methoxy- benzenesulfonamide
Figure imgf000053_0001
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 5-bromo-2-methoxy-benzenesulfonamide instead of bromobenzene. 1H NMR (i¾-MeOD, 400MHz), 7.17 (s, 1H), 6.99 (d, 1H, J= 8.8 Hz), 6.87 (d, 1H, J= 8.8 Hz), 3.94-3.89 (m, 4H), 2.84 (s, 2H), 1.75-7.71 (m, 2H), 1.29-0.98 (m, 13H). MS(ESI): calc'd (M+H)+ 357.2, exp (M+H)+ 357.2.
EXAMPLE IIa-40 4- [((cis-1, 5 -5-Hydroxy- 1 ,3,3-trimethyl-cyclohexylmethyl)-amino] -2- trifluoromethoxy-benzenesulfonamide
Figure imgf000053_0002
The title compound was prepared in analogy to example IIa-1 in Synthetic route 1 by using 4-bromo-2-trifluoromethoxy-benzenesulfonamide instead of bromobenzene. 1H NMR (<¾- MeOD, 400MHz), 7.67 (d, 1H, J= 9.2 Hz), 6.69 (s, 1H), 6.60 (d, 1H, J= 8.8 Hz), 3.95-3.93 (m, 1H), 2.93 (s, 2H), 1.75-1.72 (m, 2H), 1.31 (d, 1H, J= 13.6 Hz), 1.21 (d, 1H, J= 14.0 Hz), 1.15- 1.03 (m, 8H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 411.2, exp (M+H)+ 411.1.
EXAMPLE IIb-1
(cis-ijJ^-S-i^S-Chloro-pheny^-methyl-aminol-methylj-S^^-trimethyl-cyclohexanol
Figure imgf000053_0003
The title compound was prepared by the N-methylation of example IIa-3 according to the method shown in Scheme 1. 1H NMR (<¾-MeOD, 400MHz), 7.10 (t, 1H, J= 8.0 Hz), 6.74-6.69 (m, 2H), 6.59 (d, 1H, J= 8.0 Hz), 3.90-3.88 (m, 1H), 3.18-3.06 (m, 2H), 3.00 (s, 3H), 1.80-1.71 (m, 2H), 1.31-1.18 (m, 4H), 1.08-0.96 (m, 9H). MS(ESI): calc'd (M+H)+ 296.2, exp (M+H)+ 296.2.
EXAMPLE IIc-1
(3-Fluoro-5-trifluoromethyl-phenyl)-(l,3,3-trimethyl-cyclohexylmethyl)-amine
Figure imgf000054_0001
Compound of interest lie was prepared according to Synthetic route 3. Synthetic route 3 to example IIc-1
Figure imgf000054_0002
Reagents and conditions: (a): Zn, HC1, Et20, -20 °C to 0 °C; (b): LiAlH4, THF, reflux; (c): 3-trifluoromethyl-5-fluoro-bromobenzene, Cul, K3P04, L-Proline, DMSO, microwave.
3,3-Dimethyl-cyclohexyl)-methylamine XXVIII was prepared by the following procedure. Intermediate XXVI (2.5 g , 15.1 mmol) was dissolved into 60 mL of diethyl ether that was charged and saturated with hydrogen chloride. To this solution at -20 °C, 7.2 g activated zinc (110.0 mmol) was added in several portions. After stirred at 0 °C for 2 hours, the reaction mixture was poured slowly onto crushed ice. The aqueous solution was extracted with ethyl ether; and the organic phase was combined, washed with saturated NaCl, dried over Na2S04 and concentrated. The residue was dissolved in 50 mL of anhydrous THF, to this solution was added 1.1 g of LiAlH (30 mmol), and the reaction mixture was brought to refluxing and stirred overnight. After cooled to 0°C (degrees Celsius) , the mixture was quenched by adding of 5 mL of water and 10 mL of NaOH (2N) at 0 °C dropwisely. The mixture was filtered and the filtrate was acidified by addition of aqueous HC1 (2N). After washed by ethyl acetate, the aqueous phase was neutralized to pH > 9 by addition of aqueous NaOH. The aqueous phase was extracted by dichloromethylene. The combined organic layer was dried over Na2S04, filtered and concentrated to give amine XXVIII. The amine was used in the copper catalyzed coupling reaction in analogy to example IIa-1 in Synthetic route 1 by using 3-trifluoromethyl-5-fluoro- bromobenzene instead of bromobenzene. The cross coupling reaction gave IIc-1 as wax. 1H NMR (i¾-MeOD, 400MHz), 6.72 (s, 1H), 6.55 (d, 1H, J= 12.0 Hz), 6.46 (d, 1H, J= 8.8 Hz), 2.95-2.86 (m, 2H), 1.61-1.57 (m, 2H), 1.37-1.32 (m, 4H), 1.26-1.22 (m, 2H), 1.03 (s, 3H), 1.01 (s, 3H), 0.94 (s, 3H). MS(ESI): calc'd (M+H)+ 318.2, exp (M+H)+ 318.1.
EXAMPLE IId-1
Acetic acid (icis-2,5 -3,3,5-trimethyl-5-phenylaminomethyl-cyclohexyl ester
Figure imgf000055_0001
Compound of interest lid can be prepared by acylation of Ila with acyl chloride and triethylamine. 1H NMR (<¾-MeOD, 400MHz), 7.24 (t, 2H, J= 8.0 Hz), 6.92-6.86 (m, 3H), 5.16- 5.10 (m, 1H), 3.00 (s, 2H), 2.02 (s, 3H), 1.81-1.76 (m, 2H), 1.38-1.23 (m, 4H), 1.20 (s, 3H), 1.14 (s, 3H), 1.02 (s, 3H). MS(ESI): calc'd (M+H)+ 290.2, exp (M+H)+ 290.1.
EXAMPLE IIe-1
(3,3-Difluoro-l,5,5-trimethyl-cyclohexylmethyl)-(3-fluoro-5-trifluoromethyl-phenyl)- amine
Figure imgf000055_0002
Compound of interest IIe-1 was prepared according to Synthetic route 4. Synthetic route 4 to example IIe-1
Figure imgf000055_0003
Reagents and conditions: (a): DAST, DCM, r.t.; (b): LiAlH4, THF, reflux; (c): 3- trifluoromethyl-5-fluoro-bromobenzene, Cul, K3P04, L-Proline, DMSO, microwave.
The intermediate 3,3-difluoro-5,5-dimethyl-cyclohexyl)-methylamine XXIX was prepared by following procedures. To a stirred solution of XXVI (1.0 g, 6.0 mmol) in 3 mL of dry DCM under nitrogen was added a solution of DAST (2.4 g, 14.4 mmol) in 2 mL of dry DCM, and the mixture was stirred for 2 h at r.t. The reaction mixture was washed with a.q. NaHC03 until C02 evolution ceased. The organic phase was dried over Na2S04 and concentrated to give 1.1 g of crude product as yellow oil. It was used in the reduction by LiAlH without further purification. Under similar reaction conditions to example IIa-1, the copper catalyzed cross-coupling of
XXIX and 3-trifluoromethyl-5-fluoro-bromobenzene gave target compound IIe-1. 1H MR (<¾- MeOD, 400MHz), 6.75 (s, 1H), 6.59 (d, 1H, J= 12.0 Hz), 6.50 (d, 1H, J= 8.8 Hz), 3.01 (s, 2H), 1.87-1.63 (m, 4H), 1.53 (d, 1H, J= 14.4 Hz), 1.39 (d, 1H, J= 14.4 Hz), 1.18 (s, 3H), 1.14 (s, 3H), 1.06 (s, 3H). MS(ESI): calc'd (M+H)+ 354.2, exp (M+H)+ 354.1.
EXAMPLE IIe-2
(3-Bromo-5-trifluoromethyl-phenyl)-(3,3-difluoro-l,5,5-trimethyl-cyclohexylmethyl)- amine
Figure imgf000056_0001
The title compound was prepared in analogy to example IIe-1 in Synthetic route 4 by using l,3-dibromo-5-trifluoromethyl-benzene instead of 3-trifluoromethyl-5-fluoro- bromobenzene. 1H NMR (d4-MeOO, 400MHz), 7.02 (s, 1H), 6.90 (s, 1H), 6.87 (s, 1H), 3.01 (s, 2H), 1.87-1.63 (m, 4H), 1.53 (d, 1H, J= 14.4 Hz), 1.39 (d, 1H, J= 14.4 Hz), 1.18 (s, 3H), 1.14 (s, 3H), 1.06 (s, 3H). MS(ESI): calc'd (M+H)+ 414.1, exp (M+H)+ 413.9.
EXAMPLE IIf-1
(3-Fluoro-5-trifluoromethyl-phenyl)-( fcis-l,5)-5-methoxy-l,3,3-trimethyl- cyclohexylmethyl)-amine
Figure imgf000056_0002
Compound of interest IIf-1 can be prepared by the synthesis route in Synthetic route 5.
Synthetic route 5 to example IIf-1
Figure imgf000057_0001
XXVI XXX IIf-1
Reagents and conditions: (a): NaBH4, THF; (b): RI, NaH, THF; (c): LiAlH4, THF, reflux; (d): 3-trifluoromethyl-5-fluoro-bromobenzene, Cul, K3P04, L-Proline, DMSO, microwave.
The Intermediate XXX was prepared in three steps from XXVI, by reduction of the ketone functional group, alkylation of secondary alcohol, and reduction of cyano group by LiAlH . To a solution of XXVI (1.65 g, 10.0 mmol) in 15 mL of EtOH was added 760 mg of NaBH4 (20.0 mmol). The reaction mixture was stirred overnight at r.t. 5 mL of water was added to quench excess of NaBH . After the mixture was concentrated in vacuo, the residue was dissolved in 10 mL of water and extracted with ether. The combined organic layer was evaporated to give the secondary alcohol which was used in the alkylation reaction without further purification.
837 mg of the residue was dissolved in 5 mL of dry THF and added into a suspension solution of NaH (300 mg, 7.5 mmol) in 10 mL of dry THF at 0 °C. After the mixture was stirred at r.t. for 0.5h, 0.6 mL of iodomethane was added into the flask. The reaction mixture was stirred at r.t. for 3 h, before 20 mL of water was added. The aqueous layer was extracted with DCM twice. The combined organic layer was dried and concentrated to gave 0.8 g of methyl ether as white solid. As in the preparation of XXVIII in Synthetic route 3, the reduction of the methylation product by LiAlH gave amine XXX. Compound IIf-1 was obtained by the copper catalyzed cross-coupling of XXX and 3-trifluoromethyl-5-fluoro-bromobenzene. 1H NMR (<¾- MeOD, 400MHz), 6.73 (s, 1H), 6.56 (d, 1H, J= 12.0 Hz), 6.48 (d, 1H, J = 8.8 Hz), 3.60-3.56 (m, 1H), 3.38 (s, 3H), 2.90 (s, 2H), 1.90-1.82 (m, 2H), 1.35-1.23 (m, 2H), 1.13 (s, 3H), 1.09 (s, 3H), 1.07-0.98 (m, 5H). MS(ESI): calc'd (M+H)+ 348.2, exp (M+H)+ 348.1.
EXAMPLE IIg-1 (icis-2,Ji -3-[(3-Fluoro-5-trifluoromethyl-phenylamino)-methyl]-l,3,5,5-tetramethyl- cyclohexanol
Figure imgf000058_0001
The tertiary alcohol IIg-1 was prepared according to the method in Synthetic route 6. Synthetic route 6 to example IIg-1
Figure imgf000058_0002
XXVI XXXI iig-1 Reagents and conditions: (a): MeMgBr, THF; (b): LiAlH4, THF, reflux; (c): 3- trifluoromethyl-5-fluoro-bromobenzene, Cul, K3P04, L-Proline, DMSO, microwave.
The Intermediate XXXI was prepared in two steps from XXVI by addition reaction of Grignard reagent to the ketone functional group, and reduction of the cyano functional group by LiAlH4. A solution of MeMgBr (3M in Et20) was added into a solution of XXVI (1.65 g, 10.0 mmol) in 20 mL of dry THF at -40 °C. The reaction mixture was stirred for 2 h at -40 °C. After 4 mL of water was added into the mixture, the aqueous phase was extracted with EtOAc twice. The combined organic layer was dried over Na2S04 and concentrated to give 1.7 g of tertiary alcohol as solid. The crude product was reduced by LiAlH to give amine XXXI. Under the same copper catalyzed reaction conditions as in the preparation of IIa-1, the title compound Ilg- 1 was obtained by the coupling reaction between XXXI and 3-trifluoromethyl-5-fluoro- bromobenzene. 1H MR (<¾-MeOD, 400MHz), 6.75 (s, 1H), 6.56 (d, 1H, J= 12.0 Hz), 6.45 (d, lH, J= 8.8 Hz), 3.64 (d, 1H, J= 12.8 Hz), 3.15 (d, 1H, J= 12.4 Hz), 1.79-1.93 (m, 2H), 1.60 (d, 1H, J= 14.0 Hz), 1.26-1.16 (m, 8H), 1.04 (d, 1H, J= 14.8 Hz), 0.99 (s, 3H), 0.94 (s, 3H).
MS(ESI): calc'd (M+H)+ 348.2, exp (M+H)+ 348.1. EXAMPLE IIh-1
((cis-2,5 -5-Dimethylamino-l,3,3-trimethyl-cyclohexylmethyl)-(3-fluoro-5- trifluoromethyl-phenyl)-amine
Figure imgf000059_0001
Compound of interest IIh-1 was prepared by the method in Synthetic route 7. Synthetic route 7 to example IIh-1
Figure imgf000059_0002
Reagents and conditions: (a): dimethylamine, THF, NaBH3CN; (b): LiAlH4, THF, reflux;
(c): 3-trifluoromethyl-5-fluoro-bromobenzene, Cul, K3P04, L-Proline, DMSO, microwave.
The amine Intermediate XXXII was prepared by following procedures. A solution of 1.65 g of XXX (10.0 mmol) and 0.9 g of dimethylamine (20.0 mmol) in 10 mL of dry THF was stirred for 30 min at 0 °C. Then 0.8 g of NaBH3CN (12.0 mmol) was added into the solution in several portions. After stirred overnight at r.t., the reaction mixture was poured into water and extracted with DCM. The combined organic layer was extracted with HCl (IN, 20 mL x3). And the aqueous phase was neutralized to pH > 9 with NaOH (2N) and extracted with DCM (20 mL x3). The organic phase was washed with brine, dried over Na2S04 and evaporated to give 1.5 g of crude product, which was reduced to XXXII by LiAlH . In analogy to example IIa-1 in Synthetic route 1, the title compound IIh-1 was obtained by the copper catalyzed cross- coupling of XXXII and 3-trifluoromethyl-5-fluoro-bromobenzene. 1H NMR (<¾-MeOD, 400MHz), 6.74 (s, 1H), 6.60 (d, 1H, J= 12.0 Hz), 6.50 (d, 1H, J= 8.8 Hz), 3.18-3.14 (m, 1H), 2.94 (s, 2H), 2.59 (s, 6H), 1.77-1.72 (m, 2H), 1.40-1.19 (m, 4H), 1.16 (s, 3H), 1.13 (s, 3H), 1.04 (s, 3H). MS(ESI): calc'd (M+H)+ 361.2, exp (M+H)+ 361.1. EXAMPLE IIi-1/2
Isomer 1 : (cis-1,5) -5-[(3-Fluoro-5-trifluoromethyl-phenylamino)-methyl]-3,3- dimethyl-cyclohexanol
Isomer 2: (ifrans-2,5 -5-[(3-fluoro-5-trifluoromethyl-phenylamino)-methyl]-3,3- dimethyl-cyclohexanol
Figure imgf000060_0001
Compounds of interest IIi-1/2 (R1 = H) was prepared by the method shown in Synthetic route 8.
Synthetic route 8 to example IIi-1 and IIi-2
Figure imgf000060_0002
XXXIII XXXIV lli-1 and lli-2
Reagents and conditions: (a): POCl3, CHC13, r.t. to reflux; (b): Zn, MeOH, KI, r.t; (c): KCN, H4C1, H20, DMF; (d): LiAlH4, THF, reflux; (e): 3-trifluoromethyl-5-fluoro- bromobenzene, Cul, K3P04, L-Proline, DMSO, microwave.
3-Hydroxy-5,5-dimethyl-cyclohex-2-enone was treated with POCl3 to give 3-chloro-5,5- dimethyl-cyclohex-2-enone, which was reduced by zinc to afford 5,5-dimethyl-cyclohex-2- enone. The addition reaction of cyanide to 5,5-dimethyl-cyclohex-2-enone gave the cyano intermediate XXXIII, which was reduced by LiAlH4 to give 5-aminomethyl-3,3-dimethyl- cyclohexanol XXXIV. Under the same copper catalyzed reaction conditions as the example Ila- 1 in Synthetic route 1, the cross-coupling of XXXIV and 3-trifluoromethyl-5-fluoro- bromobenzene gave the cis/trans isomers IIi-1 and IIi-2, which were separated and purified by HPLC. Isomer 1 : 1H MR (i¾-MeOD, 400MHz), 6.66 (s, 1H), 6.51-6.48 (m, 2H), 3.79-3.73 (m, 1H), 2.99 (d, 2H, J= 6.8 Hz), 2.12-2.09 (m, 1H), 1.91-1.87 (m, 1H), 1.72-1.68 (m, 1H), 1.52- 1.49 (m, 1H), 1.10-1.02 (m, 1H), 1.00 (s, 3H), 0.95 (s, 3H), 0.91-0.81 (m, 2H). MS(ESI): calc'd (M+H)+ 319.2, exp (M+H)+ 318.9. Isomer 2: 1H NMR (i¾-MeOD, 400MHz), 6.67 (s, 1H), 6.52-6.47 (m, 2H), 4.16-4.14 (m,
1H), 2.99-2.94 (m, 2H), 2.24-2.21 (m, 1H), 1.92-1.88 (m, 1H), 1.65-1.58 (m, 2H), 1.36-1.32 (m, 1H), 1.22-1.19 (m, 1H), 1.18 (s, 3H), 1.06-0.99 (m, 1H), 0.96 (s, 3H). MS(ESI): calc'd (M+H)+ 319.2, exp (M+H)+ 318.9.
EXAMPLE IIIa-1 (cis-2,5 -3,3,5-Trimethyl-5-(pyridin-2-ylaminomethyl)-cyclohexanol
Figure imgf000061_0001
The synthesis of example IIIa-1 was carried out by the substitution of 2-chloropyridine by XXVII as shown in Synthetic route 9. The method provided a general access to other heterocyclic aromatic analogs of Ilia to Illf.
Synthetic route 9 to example IIIa-1
Figure imgf000061_0002
Reagents and conditions: (a): pyridine, DMSO, 150 °C, microwave.
To a solution of 2-chloropyridine (138 mg, 1.22 mmol) in 2 mL of DMSO was added amine XXVII (209 mg, 1.22 mmol) and pyridine (290 mg, 3.66 mmol). The reaction was heated in the microwave at 150 °C for 0.5h. The reaction mixture was purified by preparative HPLC to give example IIIa-1. 1H MR (d-MeOD, 400MHz), 7.84 (s, 1H), 7.70 (t, 1H, J= 7.6 Hz), 6.94 (d, 1H, J= 8.8 Hz), 6.74 (t, 1H, J= 7.2 Hz), 3.99-3.93 (m, 1H), 3.16 (s, 2H), 1.79-1.73 (m, 2H), 1.36 (d, 1H, J= 14.4 Hz), 1.24-1.00 (m, 12H). MS(ESI): calc'd (M+H)+ 249.2, exp (M+H)+ 249.2. EXAMPLE IIIa-2
(icis-2,Ji -3-[(5-Bromo-pyridin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000061_0003
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 5-bromo-2-fluoro-pyridine instead of 2-chloropyridine. 1H MR (<¾-MeOD, 400MHz), 7.97 (dd, 1H, Jl = 2.0 Hz, J2 = 0.8 Hz), 7.90 (dd, 1H, Jl = 9.2 Hz, J2 = 2.0 Hz), 7.04 (dd, 1H, Jl = 9.2 Hz, J2 = 0.8 Hz), 3.97-3.90 (m, 1H), 3.14 (AB, 2H, J= 12.4 Hz), 1.75-1.69 (m, 2H), 1.34 (d, 1H, 7= 13.6 Hz), 1.18 (d, 1H, 7= 13.6 Hz), 1.15-1.10 (m, 4H), 1.08-1.05 (m, 4H), 0.99 (s, 3H). MS(ESI): calc'd (M+H)+ 327, exp (M+H)+ 327.1. EXAMPLE IIIa-3 ficis-2,5 -3,3,5-Trimethyl-5-[(6-trifluoromethyl-pyridin-2-ylamino)-methyl]- cyclohexanol
Figure imgf000062_0001
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-fluoro-6-trifluoromethyl-pyridine instead of 2-chloropyridine. 1H NMR (i¾-MeOD, 400MHz), 7.48 (t, 1H, J= 8.0 Hz), 6.80 (d, 1H, J= 7.2 Hz), 6.69 (d, 1H, J= 8.4 Hz), 3.91 (m, 1H), 3.24-3.15 (AB, 2H, J= 13.2 Hz), 1.73-1.69 (m, 2H), 1.29-1.17 (m, 2H), 1.12-0.95 (m, 8H), 0.91 (s, 3H). MS(ESI): calc'd (M+H)+ 317.2, exp (M+H)+ 317.2.
EXAMPLE IIIa-4
-2,J^-3-[(4-Chloro-pyridin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000062_0002
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-fluoro-4-chloropyridine instead of 2-chloropyridine. 1H NMR (<¾-MeOD, 400MHz), 7.88 (dd, J = 8.0 Hz, J2 = 1.6 Hz), 7.83 (dd, J = 6.0 Hz, J2 = 1.6 Hz), 6.78 (dd, J = 8.0 Hz, J2 = 6.0 Hz), 3.92 (m, 1H), 3.44-3.29 (m, 2H), 1.75-1.66 (m, 2H), 1.30-1.18 (m, 2H), 1.15-1.07 (m, 5H), 1.05 (s, 3H), 0.99 (s, 3H). MS(ESI): calc'd (M+H)+ 283.1, exp (M+H)+ 283.1.
EXAMPLE IIIa-5
(cis-2,5 -3,3,5-Trimethyl-5-[(3-trifluoromethyl-pyridin-2-ylamino)-methyl]- cyclohexanol
Figure imgf000062_0003
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-fluoro-3-trifluoromethyl-pyridine instead of 2-chloropyridine. 1H MR (i¾-MeOD, 400MHz), 8.17-8.16 (d, 1H, 7= 4.8 Hz), 7.78-7.77 (d, 1H, 7= 7.6 Hz), 6.69-6.65 (q, 1H, 7= 5.2 Hz), 3.93 (m, 1H), 3.33-3.27 (m, 2H), 1.74-1.72 (m, 2H), 1.36-1.33 (d, 1H, 7= 13.6 Hz), 1.22- 1.04 (m, 9H), 0.94 (s, 3H). MS(ESI): calc'd (M+H)+ 316, exp (M+H)+ 316.
EXAMPLE IIIa-6 ficis-2,5^-3,3,5-Trimethyl-5-[(5-trifluoromethyl-pyridin-2-ylamino)-methyl]- cyclohexanol
Figure imgf000063_0001
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-fluoro-5-trifluoromethyl-pyridine instead of 2-chloropyridine. 1H MR (i¾-MeOD, 400MHz), 8.20 (s, 1H), 7.90 (d, 1H, 7= 9.6 Hz), 7.10 (d, 1H, 7= 9.6 Hz), 3.99-3.90 (m, 1H), 3.24 (AB, 2H, 7= 13.6 Hz), 1.77-1.69 (m, 2H), 1.35 (d, 1H, 7= 13.6 Hz), 1.20 (d, 1H, 7= 13.6 Hz), 1.15-1.12 (m, 4H), 1.14-1.05 (m, 4H), 0.99 (s, 3H). MS(ESI): calc'd (M+H)+ 317.2, exp (M+H)+ 317.2.
EXAMPLE IIIa-7
6- [((cis-1, 5 -5-Hydroxy- 1 ,3,3-trimethyl-cyclohexylmethyl)-amino] -pyridine-2-sulfonic acid amide
Figure imgf000063_0002
The title compound was prepared by the method shown in Synthetic route 10.
Synthetic route 10 to example IIIa-7
Figure imgf000063_0003
XXXV XXXVI IIIa-7 Reagents and conditions: (a): phenylmethylthiol, NaH, THF; (b): Cl2, DCM, H20, 0 °C; (c): H3, DCM, -78 °C (degrees Celsius) ; (d): XXVII, pyridine, DMSO, 150 °C , microwave.
2-Benzylthio-6-fluoropyridine was prepared by starting from 2,6-difluoropyridine. To a cold solution of NaH (1.06 g, 43.96 mmol) in 170mL of THF, was added dropwise of
phenylmethylthiol (3 g, 24.15 mmol) in 15mL of THF. After the mixture was stirred at 0 °C for 0.5h, a solution of 2,6-difluoropyridine (2.8 g, 24.15 mmol) in 15mL of THF was added into the flask. The reaction mixture was stirred at r.t for 3h before 100 mL of water was added. The aqueous phase was extracted by DCM, and the combined organic phase was washed with brine, dried over Na2S04, and concentrated. The residue was purified by silica gel chromatography to give 3.5g of 2-benzylthio-6-fluoropyridine.
6-Fluoropyridine-2-sulfonamide XXXVI was prepared by the oxidation of 2-benzylthio-6- fluoropyridine to sulfonyl chloride and treatment with ammonia. A solution of 2-benzylthio-6- fluoropyridine (3g, 13.7 mmol) in 75mL of DCM and 60mL of H20 was cooled under an ice- water bath, to this cold solution was bubbled chlorine gas for a total of 1.5 hours. Then aqueous sodium metabisulphite solution was added to the mixture. After the mixture was extracted by DCM, the combined organic phase was washed with water, dried over Na2S04, and concentrated to give sulfonyl chloride XXXV. The crude XXXV was used for the ammonia treatment without further purification. To a solution of crude sulfonyl chloride XXXV (2.7 g) in 250 mL of DCM at -78 °C , was bubbled NH3 for 10 minutes. Then the reaction was stirred at r.t overnight. The mixture was filtered and concentrated. The residue was purified by chromatography to give 1.0 g of sulfonamide XXXVI. 1H NMR ( 6-DMSO, 400MHz), 8.26 (dd, 1H, J = 15.6 Hz, J2 = 8.0 Hz), 7.88 (m, 1H), 7.62 (bs, 2H), 7.48 (dd, 1H, Jl = 8.4 Hz, J2 = 2.4 Hz).
The title compound IIIa-7 was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 6-fluoropyridine-2-sulfonamide XXXVI instead of 2-chloropyridine. 1H NMR (d4- MeOD, 400MHz), 7.54 (dd, 1H, Jl = 8.8 Hz, J2 = 7.6Hz), 7.08 (d, 1H, J= 7.2 Hz), 6.68 (d, 2H, J = 8.8 Hz), 3.91 (m, 1H), 2.66 (m, 2H), 1.72 (m, 2H), 1.26 (d, 1H, J= 13.2 Hz), 1.20 (d, 1H, J = 13.2 Hz), 1.16-0.97 (m, 8H), 0.93 (s, 3H). MS(ESI): calc'd (M+H)+ 327.8, exp (M+H)+ 327.8.
EXAMPLE IIIa-8
2- [((cis-1, 5 -5-Hydroxy- 1 ,3,3-trimethyl-cyclohexylmethyl)-amino] -pyridine-4-sulfonic acid amide
Figure imgf000064_0001
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-chloro-pyridine-4-sulfonamide instead of 2-chloropyridine. 1H NMR (<¾-MeOD, 400MHz), 7.96 (d,lH, J= 6.8Hz), 7.56 (s, 1H), 7.13 (d, 1H, J= 6.8 Hz), 3.97 (m, 1H), 3.26 (m, 2H), 1.75 (d, 2H), 1.38-1.28 (m, 2H), 1.21-1.06 (m, 8H), 0.99 (s, 3H). MS(ESI): calc'd (M+H)+ 328, exp (M+H)+ 328.2.
EXAMPLE IIIa-9
-2,5 -3,3,5-Trimethyl-5-[(4-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexanol
Figure imgf000065_0001
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-chloro-4-methyl-pyrimidine instead of 2-chloropyridine. 1H NMR (<¾-MeOD, 400MHz), 8.48-8.15 (m, 1H), 6.85 (d, 1H, J= 6.0 Hz), 4.09-3.88 (m, 1H), 3.42-3.31 (m, 2H), 2.54 (s, 3H), 1.75-1.69 (m, 2H), 1.28 (d, 1H, J= 13.6 Hz), 1.19-1.01 (m, 9H), 0.97 (s, 3H). MS(ESI): calc'd (M+H)+ 264.2, exp (M+H)+ 264.2.
EXAMPLE IIIa-10 (cis-2,5^-3,3,5-Trimethyl-5-[(4-trifluoromethyl-pyrimidin-2-ylamino)-methyl]- cyclohexanol
Figure imgf000065_0002
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-chloro-4-trifluoromethyl-pyrimidine instead of 2-chloropyridine. 1H NMR (i¾-MeOD, 400MHz), 8.47 (s, 1H), 6.83 (d, 1H, J= 8.8 Hz), 3.93-3.85 (m, 1H), 3.27-3.21 (m, 2H), 1.73- 1.68 (m, 2H), 1.20 (dd, 2H, Jl = 24.4 Hz, J2 = 13.6 Hz), 1.11-0.96 (m, 8H), 0.94 (s, 3H).
MS(ESI): calc'd (M+H)+ 318.2, exp (M+H)+ 318.9.
EXAMPLE IIIa-11
(cis-2,J^-3-[(4-Methoxy-pyrimidin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000066_0001
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-chloro-4-methoxy-pyrimidine instead of 2-chloropyridine. 1H NMR (i¾-MeOD, 400MHz), 8.0 (d, 1H, J= 7.6 Hz), 6.38 (d, 1H, J= 7.6 Hz), 4.09 (s, 3H), 3.91 (m, 1H), 3.42-3.29 (m, 2H), 1.74-1.71 (m, 2H), 1.28 (d, 1H, J= 13.6 Hz), 1.18 (d, 1H, J= 13.6 Hz), 1.12 (s, 3H), 1.05-0.94 (m, 8H). MS(ESI): calc'd (M+H)+ 280, exp (M+H)+ 280.2.
EXAMPLE IIIa-12
(icis-2,J^-3-[(4,6-Dimethoxy-pyrimidin-2-ylamino)-methyl]-3,5,5-trimethyl- cyclohexanol
Figure imgf000066_0002
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-chloro-4,6-dimethoxy-pyrimidine instead of 2-chloropyridine. 1H NMR (d6-OMSO, 400MHz), 7.17 (s, 1H), 5.77(bs, 1H), 3.77 (s, 6H), 3.66 (m, 1H), 3.14-3.00 (m, 2H), 1.55-1.49 (m, 2H), 1.12-1.06 (m, 2H), 0.99-0.83 (m, 11H). MS(ESI): calc'd (M+H)+ 310, exp (M+H)+ 310.2.
EXAMPLE IIIa-13
-2,J^-3-[(4,6-Dimethyl-pyrimidin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000066_0003
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-chloro-4,6-dimethyl-pyrimidine instead of 2-chloropyridine. 1H NMR (i¾-MeOD, 400MHz), 6.81 (m, 1H), 4.04-3.95 (m, 1H), 3.51-3.40 (m, 2H), 2.53 (s, 6H), 1.95-1.75 (m, 2H), 1.50-1.20 (m, 4H), 1.18-1.09 (m, 6H), 1.03 (s, 1H). MS(ESI): calc'd (M+H)+ 278, exp (M+H)+ 278.1. EXAMPLE IIIa-14
(icis-2,J^-3-[(4-Chloro-5-methoxy-pyrimidin-2-ylamino)-methyl]-3,5,5-trimethyl- cyclohexanol
Figure imgf000067_0001
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2,4-dichloro-5-methoxy-pyrimidine instead of 2-chloropyridine. 1H MR (i¾-MeOD, 400MHz), 7.62 (s, 1H), 3.93 (s, 3H), 3.41-3.35 (m, 1H), 3.49-3.36 (m, 1H), 3.26-3.13 (m, 1H), 1.72-1.65 (m, 2H), 1.25-1.17 (m, 2H), 1.07 (s, 3H), 1.04-0.98 (m, 5H), 0.95 (s, 3H). MS(ESI): calc'd (M+H)+ 314.2, exp (M+H)+ 314.2.
EXAMPLE IIIb-1
-2,J^-3-[(6-Chloro-pyrazin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000067_0002
The title compound IIIb-1 was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-chloro-6-fluoro-pyrazine instead of 2-chloropyridine. 1H NMR (i¾-MeOD, 400MHz), 7.78 (s, 1H), 7.54 (s, 1H), 3.88 (m, 1H), 3.15 (m, 2H), 1.71-1.67 (m, 2H), 1.22 (d, 1H, J= 13.2 Hz), 1.16 (d, 1H, J= 13.2 Hz), 1.06-0.96 (m, 8H), 0.93 (s, 3H). MS(ESI): calc'd (M+H)+ 284.2, exp (M+H)+ 284.2.
EXAMPLE IIIb-2
-2,5 -3,3,5-Trimethyl-5-[(6-methyl-pyrazin-2-ylamino)-methyl]-cyclohexanol
Figure imgf000067_0003
The title compound IIIb-2 was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-fluoro-6-methyl-pyrazine instead of 2-chloropyridine. 1H NMR (i¾-MeOD, 400MHz), 7.94 (s, 1H), 7.61 (s, 1H), 3.98-3.90 (m, 1H), 3.27-3.24 (m, 2H), 2.42 (s, 1H), 1.72-1.68 (m, 2H), 1.30 (d, 1H, J= 13.2 Hz), 1.22 (d, 1H, J= 13.2 Hz), 1.12-1.02 (m, 8H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 264.2, exp (M+H)+ 264.2.
EXAMPLE IIIb-3
-2,J^-3-[(6-Methoxy-pyrazin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000068_0001
The title compound IIIb-3 was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-fluoro-6-methoxy-pyrazine instead of 2-chloropyridine. 1H NMR (<¾-MeOD,
400MHz), 7.49 (s, 1H), 7.30 (s, 1H), 4.00 (s, 3H), 3.91 (m, 1H), 3.25 (m, 2H), 1.76-1.68 (m, 2H), 1.26-0.99 (m, 10H), 0.94 (s, 3H). MS(ESI): calc'd (M+H)+ 280.2, exp (M+H)+ 280.2.
EXAMPLE IIIc-1
-2,j^-3-(Benzoxazol-2-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol
Figure imgf000068_0002
The title compound IIIc-1 was prepared as shown in Synthetic route 11.
Synthetic route 11 to example IIIc-1
Figure imgf000068_0003
XXVII IIIc-1
Reagents and conditions: (a): pyridine, DMSO, microwave, 150 °C.
To a solution of 2-chloro-benzoxazole (230 mg, 1.5 mmol) in 2 mL of DMSO was added 3-aminomethyl-3,5,5-trimethyl-cyclohexanol XXVII (257 mg, 1.5 mmol) and pyridine (290 mg, 3.7 mmol). The reaction was heated in the microwave at 150 °C for 0.5h. The reaction mixture was purified by preparative HPLC to give example IIIc-1 as powder. 1H NMR (i¾-MeOD, 400MHz), 7.26 (t, 1H, J= 8.0 Hz), 7.15 (t, 1H, J= 7.6 Hz), 7.05 (t, 1H, J= 7.6 Hz), 3.96-3.91 (m, 1H), 3.33 (s, 2H), 1.77-1.73 (m, 2H), 1.29-1.17 (m, 2H), 1.14-0.98 (m, 11H). MS(ESI): calc'd (M+H)+ 289.2, exp (M+H)+ 289.1. EXAMPLE IIIc-2
Benzoxazol-2-yl-(3,3-difluoro-l,5,5-trimethyl-cyclohexylmethyl)-amine
Figure imgf000069_0001
The title compound IIIc-2 was prepared in analogy to example IIIc-1 in Synthetic route 11 by using (3,3-difluoro-l,5,5-trimethyl-cyclohexyl)-methylamine 5-1 instead of amine XXVII. 1H NMR (i¾-MeOD, 400MHz), 7.29-7.26 (m, 2H), 7.16 (t, 1H, J= 7.6 Hz), 7.04 (t, 1H, J= 7.6 Hz), 3.34 (m, 2H), 1.87-1.54 (m, 2H), 1.52-1.33 (m, 3H), 1.19-1.07 (m, 10H). MS(ESI): calc'd (M+H)+ 309.2, exp (M+H)+ 309.2.
EXAMPLE IIIc-3
Benzoxazol-2-yl-((icis-2,5 -5-methoxy-l,3,3-trimethyl-cyclohexylmethyl)-amine
Figure imgf000069_0002
The title compound IIIc-3 was prepared in analogy to example IIIc-1 in Synthetic route
11 by using (5-methoxy-l,3,3-trimethyl-cyclohexyl)-methylamine XXX instead of amine
XXVII. 1H NMR (<¾-MeOD, 400MHz), 7.26 (m, 2H), 7.15 (t, 1H, J= 8.0 Hz), 7.03 (t, 1H, J = 8.0 Hz), 3.63-3.50 (m, 1H), 3.37 (s, 3H), 3.21 (s, 2H), 1.88-1.86 (m, 2H), 1.32-1.26 (m, 2H), 1.15 (s, 3H), 1.14-0.99 (m, 8H). MS(ESI): calc'd (M+H)+ 303.2, exp (M+H)+ 303.2.
EXAMPLE IIIc-4
(icis-2,Ji -3-(Benzothiazol-2-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol
Figure imgf000070_0001
The title compound IIIc-4 was prepared in analogy to example IIIc-1 in Synthetic route1 by using 2-chloro-benzothiazole instead of 2-chloro-benzoxazole. 1H NMR (CDC13,
00MHz), 11.70 (s, 1H), 7.62-7.57 (m, 2H), 7.50 (t, 1H, J= 8.0 Hz), 7.31 (t, 1H, J= 8.0 Hz),.06-4.02 (m, 1H), 3.24 (m, 1H), 3.10 (m, 1H), 1.86-1.78 (m, 2H), 1.38 (d, 1H, J= 13.6 Hz),.26-1.03 (m, 13H). MS(ESI): calc'd (M+H)+ 305.2, exp (M+H)+ 305.1.
EXAMPLE IIIc-5
-2,J^-3-[(6-Fluoro-benzothiazol-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000070_0002
The title compound IIIc-4 was prepared in analogy to example IIIc-1 in Synthetic route1 by using 2-chloro-6-fluoro-benzothiazole instead of 2-chloro-benzoxazole. 1H NMR (CDCI3,00MHz), 11.4 (s, 1H), 7.55-7.52 (m, 1H), 7.36-7.34 (m, 1H), 7.22-7.18 (m, 1H), 4.06-3.96 (m,H), 3.20 (d, 1H, J= 13.2 Hz), 3.10 (d, 1H, J= 13.2 Hz), 1.87-1.78 (m, 2H), 1.36-1.01 (m,3H).MS(ESI): calc'd (M+H)+ 323.2, exp (M+H)+ 323.2
EXAMPLE IIId-1
(icis-2,Ji -3-(Benzo[d]isoxazol-3-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol
Figure imgf000070_0003
The title compound was prepared by synthetic methods described in Synthetic route 12. Synthetic route 12 to example IIId-1
Figure imgf000071_0001
Figure imgf000071_0002
XXXVIII llld-1
Reagents and conditions: (a): HATU, Et3, DCM, r.t, 3 h, (b): Lawesson's reagent, toluene, refluxing, (c): step 1. H2OH, MeOH, step 2. Na2C03, DMSO.
To a solution of 2-fluoro-benzoic acid (1.40 g, 10 mmol) and amine XXVII (1.71 g, 10 mmol) in 20 mL of DCM was added HATU (3.8 g, 10 mmol) and Et3 (1.4 mL, 10 mmol). The reaction was stirred at r.t. for 3 h and LC-MS(ESI) indicated that the reaction completed. The reaction was partitioned between water and DCM, the organic phase was dried and concentrated. The residue was purified with silica-gel column chromatography to afford amide XXXVII (2.89 g, yield: 98%). The solution of XXXVII (1.46 g, 5 mmol) and Lawesson's reagent (2.02 g, 5 mmol) in toluene (20 mL) was stirred under refluxing overnight. The solvent was removed and the residue was purified with preparative HPLC to give thioamide XXXVIII (0.46 g, yield: 30%).
To a solution of XXXVIII (62 mg, 0.2 mmol) in MeOH (5 mL) was added hydroxylamine (0.2 mL). The reaction mixture was stirred at 80 °C for 15 hours. The solvent was removed and the residue was partitioned between water and ethyl acetate. The organic phase was dried and concentrated. The residue was dissolved in 3 mL of DMSO, and to this solution was added Na2C03 (32 mg, 0.3 mmol). After stirred at 140 °C overnight, the reaction mixture was partitioned between water and ethyl acetate, and the organic phase was dried and concentrated. The residue was purified with preparative HPLC to give IIId-1 (14 mg, yield: 24%). 1H MR (i¾-MeOD, 400MHz), 7.86 (d, 1H, J= 7.6 Hz), 7.54 (t, 1H, J= 7.6 Hz), 7.38 (d, 1H, J= 8.0 Hz), 7.26 (t, 1H, J= 7.6 Hz), 3.96-3.93 (m, 1H), 3.15 (s, 2H), 1.82-1.72 (m, 2H), 1.33-1.20 (m, 3H), 1.17 (s, 3H), 1.10 (s, 3H), 1.07-1.03 (m, 1H), 0.99 (s, 3H). MS(ESI): calc'd (M+H)+ 289.2, exp (M+H)+ 289.2.
EXAMPLE IIId-2
(cis-2,Ji -3-[(lH-Indazol-3-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol
Figure imgf000072_0001
The title compound was prepared by treating the thioamide XXXVIII with hydrazine for ring formation (Synthetic route 13).
Synthetic route 13 to example IIId-2
Figure imgf000072_0002
XXXVIII llld-2
Reagents and conditions: (a): H2 H2.H20, DMSO, 150 °C
To a solution of Compound XXXVIII (40 mg, 0.13 mmol) in DMSO (2 mL) was added hydrazine (0.5 mL). The reaction mixture was stirred at 150 °C for 2 hours. LC-MS(ESI) indicated that the reaction was completed. The mixture was purified with preparative HPLC to give IIId-2 (23 mg, yield: 62%). 1H NMR (i¾-MeOD, 400MHz), 7.74 (d, 1H, J= 8.0 Hz), 7.30- 7.25 (m, 2H), 6.97 (t, 1H, J = 7.6 Hz), 3.96-3.93 (m, 1H), 3.18 (s, 2H), 1.80-1.72 (m, 2H), 1.34- 1.24 (m, 3H), 1.21 (s, 3H), 1.10 (s, 3H), 1.09-1.04 (m, 1H), 0.99 (s, 3H). MS(ESI): calc'd (M+H)+ 288.2, exp (M+H)+ 288.2.
EXAMPLE IIIe-1 (icis-2,5 -3,3,5-Trimethyl-5-(quinazolin-2-ylaminomethyl)-cyclohexanol
Figure imgf000072_0003
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 2-chloro-quinazoline instead of 2-chloropyridine. 1H NMR (<¾-MeOD, 400MHz), 9.03 (s, 1H), 7.77-7.69 (m, 2H), 7.53 (d, 1H, J =8.4 Hz), 7.26 (t, 1H, J =8.0 Hz), 3.96-3.92 (m, 1H), 3.38 (s, 2H), 1.79-1.71 (m, 2H), 1.38-1.08 (m, 10H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 300.2, exp (M+H)+ 300.1. EXAMPLE IIIf-1
(icis-ijJ^-S-^soquinolin-l-ylaminomethy^-S^^-trimethyl-cyclohexanol
Figure imgf000073_0001
The title compound was prepared in analogy to example IIIa-1 in Synthetic route 9 by using 1-chloro-isoquinoline instead of 2-chloropyridine. 1H NMR (CDC13, 400MHz), 8.76 (m, 1H), 8.45 (d, 1H, J= 8.4 Hz), 7.76 (t, 1H, J= 8.0 Hz), 7.77 (t, 1H, J= 8.0 Hz), 7.39 (d, 1H, J = 7.2 Hz), 6.81 (d, 1H, J= 6.8 Hz), 6.48 (bs, 1H), 4.12 (bs, 1H), 3.92 (m, 1H), 3.39 (m, 1H), 1.53 (m, 2H), 1.48-1.32 (m, 2H), 1.29-1.23 (m, 2H), 1.07 (s. 3H), 1.01 (s, 3H), 0.92 (s, 3H). MS(ESI): calc'd (M+H)+ 299.2, exp (M+H)+ 299.2. EXAMPLE IVa-1
-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid phenylamide
Figure imgf000073_0002
The title compound was prepared by the procedures as Synthetic route 14. The acid
XXXIX was obtained by the hydrolysis of XXVI with concentrated HCl. After treatment with thionyl chloride, it was coupled with aniline to give amide XL. Compound IVa-1 was made by treating XL with NaBH4.
Synthetic route 14 to example IVa-1
Figure imgf000073_0003
XXVI XXXIX XL IVa-1
Reagents and conditions: (a): HCl (cone), reflux; (b): step 1. SOCl2, DMF, DCM; step 2. aniline, DIPEA; (c): NaBH4, MeOH.
The Intermediate XXXIX, l,3,3-trimethyl-5-oxo-cyclohexanecarboxylic acid, was made from XXVI by following procedure. The solution of 10.2 g of XXVI (61.7 mmol) in 100 mL of conc. HC1 was heated to reflux overnight with stirring. When the reaction was complete, the solution was neutralized to pH = 3 with NaOH (3N), and the precipitate was collected, washed with water and dried in vacuo to give 11.0 g of XXXIX as white solid (96.5 % yield). 1H NMR (CDC13, 400MHz), 2.95 (d, 1H, J= 14.4 Hz), 2.32 (d, 1H, J= 14.4 Hz), 2.17 (s, 2H), 2.05 (d, 1H, J= 14.8 Hz), 1.64 (d, 1H, J= 14.4 Hz), 1.38 (s, 3H), 1.07 (s, 3H), 0.90 (s, 3H).
To a solution of the acid XXXIX (145 mg, 0.79 mmol) in 5 mL of CH2C12 was added SOCl2 (0.5 mL), and the mixture was heated to reflux for 1 hr. After cooling, the solvent and excess SOCl2 was evaporated under reduced pressure. The residue was dissolved in 10 mL of C1CH2CH2C1. To this solution was added aniline (88 mg, 0.95 mmol) and N-methylmorpholine (0.2 mL) at r.t. After refluxed for 2 hr, the reaction mixture was cooled down and washed with 10 mL of HC1 (IN) and saline. The organic layer was dried over anhydrous Na2S04 and concentrated. The residue was dissolved in 10 mL of MeOH, to which was added NaBH (50 mg, 1.3 mmol) at r.t. The mixture was stirred for 1 hr before evaporated and worked up with water and ethyl acetate. The organic phase was dried and concentrated, the so obtained residue was purified by column chromatography to afford IVa-1 as wax solid (250 mg). 1H NMR (CDC13, 400MHz), 8.45 (bs, 1H), 7.49 (d, 2H, J= 8.4 Hz), 7.30 (t, 2H, J= 7.2 Hz), 7.11 (t, 1H, J= 7.2 Hz), 4.20-4.18 (m, 1H), 2.35-2.30 (m, 1H), 2.03-2.00 (m, 1H), 1.62-1.44 (m, 3H), 1.34-1.25 (m, 4H), 1.05 (s, 3H), 0.95 (s, 3H). MS(ESI): calc'd (M+H)+ 262, exp (M+H)+ 262.
EXAMPLE IVa-2 (icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (4-fluoro-phenyl)- amide
Figure imgf000074_0001
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 4-fluoro-phenylamine instead of aniline. 1H NMR (<¾-MeOD, 400MHz), 7.48-7.52 (m, 2H), 7.03-7.07 (m, 2H), 4.06 (m, 1H), 1.89-1.85 (m, 2H), 1.74 (d, 1H, J= 14 Hz), 1.655-1.612 (m, 1H), 1.55 (d, 1H, J= 13.6Hz), 1.512 (s, 3H), 1.34-1.29 (m, 1H), 1.06 (s, 3H), 1.02 (s, 3H). MS(ESI): calc'd (M+H)+ 280, exp (M+H)+ 280.
EXAMPLE IVa-3
(icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-chloro-phenyl)- amide
Figure imgf000075_0001
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-chloro-phenylamine instead of aniline. 1H NMR (CDC13, 400MHz), 8.67 (bs, 1H), 7.62 (s, 1H), 7.36 (d, 1H, J= 8.4 Hz), 7.21 (t, 1H, J= 8.0 Hz), 7.07 (d, 1H, J= 8.0 Hz), 4.25-4.23 (m, 1H), 2.35-2.30 (m, 1H), 2.03-2.00 (m, 1H), 1.62-1.44 (m, 3H), 1.34-1.25 (m, 4H), 1.04 (s, 3H), 0.97 (s, 3H). MS(ESI): calc'd (M+H)+ 296, exp (M+H)+ 296.
EXAMPLE IVa-4
(icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-trifluoromethyl- phenyl)-amide
Figure imgf000075_0002
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-trifluoromethyl-phenylamine instead of aniline. 1H MR (CDC13, 400MHz), 8.71 (bs, 1H), 7.80 (s, 1H), 7.72 (d, 1H, J= 8.0 Hz), 7.42 (t, 1H, J= 8.0 Hz), 7.35 (d, 1H, J= 8.0 Hz), 4.28-4.26 (m, 1H), 2.37-2.32 (m, 1H), 2.11-2.03 (m, 1H), 1.65-1.46 (m, 3H), 1.36-1.24 (m, 4H), 1.04 (s, 3H), 0.97 (s, 3H). MS(ESI): calc'd (M+H)+ 330, exp (M+H)+ 330.
EXAMPLE IVa-5
(cis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-isopropyl-phenyl)- amide
Figure imgf000075_0003
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-isopropyl-phenylamine instead of aniline. 1H MR (CDC13, 400MHz), 7.96 (s, 1H), 7.38-7.23 (m, 3H), 7.02-7.00 (m, 1H), 4.23-4.18 (m, 1H), 2.94-2.87 (m, 1H), 2.33 (dd, 1H, Jl = 14.4Hz, J2 = 4.8Hz), 1.94 (d, 1H, J= 14.4Hz), 1.64-1.46 (m, 7H), 1.36 (m, 6H), 1.05 (s, 3H), 0.99 (s, 3H). MS(ESI): calc'd (M+H)+ 304, exp (M+H)+ 304.
EXAMPLE IVa-6
(cis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-terf-butyl-phenyl)- amide
Figure imgf000076_0001
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-fert-butyl-phenylamine instead of aniline. 1H NMR (CDC13, 400MHz), 7.85 (s, 1H), 7.49.7.48 (m, 1H), 7.48-7.11 (m, 3H), 4.23-4.19 (m, 1H), 2.35-2.30 (m, 1H), 1.93 (d, 1H, J = 14Hz) 1.65-1.32 (m, 16H), 1.04 (s, 3H), 1.00 (s, 3H). MS(ESI): calc'd (M+H)+ 318, exp (M+H) 318.
EXAMPLE IVa-7
(cis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-ethoxy-phenyl)- amide
Figure imgf000076_0002
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-ethoxy-phenylamine instead of aniline. 1H NMR (<¾-MeOD, 400MHz), 7.27-7.21 (m, 2H), 7.07-7.04 (m, 1H), 6.69-6.66 (m, 1H), 4.08-4.01 (m, 3H), 1.95-1.85 (m, 2H), 1.78-1.57 (m, 3H), 1.42 -1.30 (m, 7H), 1.06 (s, 3H), 1.03 (s, 3H). MS(ESI): calc'd (M+H)+ 306, exp (M+H)+ 306.
EXAMPLE IVa-8
(icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-trifluoromethoxy- phenyl)-amide
Figure imgf000077_0001
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-trifluoromethoxy-phenylamine instead of aniline. 1H MR (i¾-MeOD, 400MHz), 7.68 (s, 1H), 7.52-7.49 (m, 1H), 7.40 (t, 1H, J= 8.0 Hz), 7.03-7.00 (m, 1H), 4.08-4.05 (m, 1H), 1.95-1.85 (m, 2H), 1.78-1.57 (m, 3H), 1.42 (s, 3H), 1.35-1.30 (m, 1H), 1.08 (s, 3H), 1.04 (s, 3H). MS(ESI): calc'd (M+H)+ 346, exp (M+H)+ 346.
EXAMPLE IVa-9
(cis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-methanesulfonyl- phenyl)-amide
Figure imgf000077_0002
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using l-bromo-3-methanesulfonyl-benzene instead of aniline. 1H MR (CDC13, 400MHz), 9.32 (s, 1H) , 8.38-8.35 (m, 2H), 8.02 (d, 1H, J= 7.6 Hz), 7.90-7.86 (m, 1H), 4.64-4.61 (m, 1H), 3.46 (s, 3H), 2.69-2.64 (m, 1H), 2.39 (d, 1H, J= 14 Hz), 2.05-2.00 (m, 1H), 1.90-1.70 (m, 6H), 1.39 (s, 3H), 1.37 (s, 3H). MS(ESI): calc'd (M+H)+ 340, exp (M+H)+ 340.
EXAMPLE IVa-10
(cis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-sulfamoyl-phenyl)- amide
Figure imgf000077_0003
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-bromo-benzenesulfonamide instead of aniline. 1H NMR (<f6-DMSO, 400MHz), 9.58 (s, 1H), 8.18 (s, 1H), 7.85-7.83 (m, 2H), 7.51-7.46 (m, 2H), 7.33 (s, 2H), 3.91-3.82 (m, 1H), 1.81 (d, 1H, 7= 9.6 Hz), 1.62-1.56 (m, 3H), 1.47 (d, 1H, 7= 13.6 Hz), 1.33 (s, 3H), 1.10-1.05 (m, 1H), 1.02 (s, 3H), 0.97 (s, 3H). MS(ESI): calc'd (M+H)+ 341, exp (M+H)+ 341.
EXAMPLE IVa-11
(cis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3,5-difluoro-phenyl)- amide
Figure imgf000078_0001
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3,5-difluoro-phenylamine instead of aniline. 1H MR (CDC13, 400MHz), 8.84 (s, 1H), 7.15-7.12 (m, 2H), 6.56-6.52 (m, 1H), 4.29-4.27 (m, 1H), 2.32-2.31 (m, 1H), 2.06-2.02 (m, 1H) 1.63-1.28 (m, 7H), 1.02 (s, 3H), 0.95 (s, 3H). MS(ESI): calc'd (M+H)+ 298, exp (M+H)+ 298.
EXAMPLE IVa-12
(icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-chloro-5-fluoro- phenyl)amide
Figure imgf000078_0002
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-chloro-5-fluoro-phenylamine instead of aniline. 1H MR (CDC13, 400MHz), 8.80 (s, 1H), 7.37-7.27 (m, 2H), 6.84-6.81 (m, 1H), 4.30-4.28 (m, 1H), 2.38-2.31 (m, 1H), 2.05 (d, 1H, 7 = 14.4 Hz), 1.63-1.28 (m, 7H), 1.02 (s, 3 H), 0.96 (s, 3H). MS(ESI): calc'd (M+H)+ 314, exp (M+H)+ 314.
EXAMPLE IVa-13
(icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-fluoro-5- trifluoromethyl-phenyl)-amide
Figure imgf000079_0001
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-fluoro-5-trifluoromethyl-phenylamine instead of aniline. 1H MR (CDC13, 400MHz), 8.92 (s, 1H), 7.74-7.71 (m, 1H), 7.45 (s, 1H), 7.06(d, 1H, J= 8.4Hz), 4.33-4.31 (m, 1H), 2.37- 2.33 (m, 1H), 2.10-2.07 (m, 1H), 1.66-1.29 (m, 7H), 1.03 (s, 3H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 348, exp (M+H)+ 348.
EXAMPLE IVa-14
(icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-chloro-5- trifluoromethyl-phenyl)-amide
Figure imgf000079_0002
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-chloro-5-trifluoromethyl-phenylamine instead of aniline. 1H MR (i¾-MeOD, 400MHz), 7.98 (s, 1H), 7.90 (s, 1H), 7.41 (s, 1H), 4.08-4.05 (m, 1H), 1.89-1.87 (m, 2H), 1.74-1.64 (m, 3H), 1.41 (s, 3H), 1.33-1.24 (m, 1H), 1.08 (s, 3H), 1.02 (s, 3H). MS(ESI): calc'd (M+H)+ 364, exp (M+H)+ 364.
EXAMPLE IVa-15
(cis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-bromo-5- trifluoromethyl-phenyl)-amide
Figure imgf000079_0003
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-bromo-5-trifluoromethyl-phenylamine instead of aniline. 1H MR (i¾-MeOD, 400MHz), 8.12 (s, 1H), 7.95 (s, 1H), 7.54 (s, 1H), 4.08-4.05 (m, 1H), 1.89-1.87 (m, 2H), 1.74-1.64 (m, 3H), 1.41 (s, 3H), 1.33-1.24 (m, 1H), 1.08 (s, 3H), 1.02 (s, 3H). MS(ESI): calc'd (M+H)+ 408, exp (M+H)+ 408.
EXAMPLE IVa-16
(icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-methoxy-5- trifluoromethyl-phenyl)-amide
Figure imgf000080_0001
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-methoxy-5-trifluoromethyl-phenylamine instead of aniline. 1H MR (i¾-MeOD, 400MHz), 7.52 (s, 1H), 7.49 (s, 1H), 6.92 (s, 1H), 4.08-4.05 (m, 1H), 3.86 (s, 3H), 1.89-1.87 (m, 2H), 1.74-1.64 (m, 3H), 1.41 (s, 3H), 1.33-1.24 (m, 1H), 1.08 (s, 3H), 1.02 (s, 3H). MS(ESI): calc'd (M+H)+ 360, exp (M+H)+ 360.
EXAMPLE IVa-17
(cis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3,5-dichloro-phenyl)- amide
Figure imgf000080_0002
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3,5-dichloro-phenylamine instead of aniline. 1H MR (CDC13, 400MHz), 8.69 (bs, 1H), 7.50 (d, 2H, J= 2.0 Hz), 7.10 (t, 1H, 7= 2.0 Hz), 4.31-4.29 (m, 1H), 2.34-2.29 (m, 1H), 1.97- 1.93 (m, 2H), 1.64-1.48 (m, 3H), 1.32 (s, 3H), 1.06 (s, 3H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 320, exp (M+H)+ 320.
EXAMPLE IVa-18
(cis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3, 5-dimethoxy- phenyl)-amide
Figure imgf000081_0001
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3,5-dimethoxy-phenylamine instead of aniline. 1H NMR (CDC13, 400MHz), 8.03 (bs, 1H), 6.77 (d, 2H, J= 2.4 Hz), 6.26 (t, 1H, J= 2.4 Hz), 4.23-4.21 (m, 1H), 3.80 (s, 6H), 2.34-2.29 (m, 1H), 1.97-1.93 (m, 2H), 1.64-1.48 (m, 3H), 1.32 (s, 3H), 1.06 (s, 3H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 322, exp (M+H)+ 322.
EXAMPLE IVa-19
(icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (4-chloro-3-fluoro- phenyl)amide
Figure imgf000081_0002
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-fluoro-4-chloro-phenylamine instead of aniline. 1H NMR (CDCI3, 400MHz), 8.41 (s, 1H), 7.69-7.67 (m, 1H), 7.35-7.31 (m, 1H), 7.11-7.06 (m, 1H), 4.28-4.26 (m, 1H), 2.36-2.31 (m, 1H), 2.02 (d, 1H, J= 14Hz), 1.64-1.31 (m, 7H), 1.04 (s, 3H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 314, exp (M+H)+ 314.
EXAMPLE IVa-20
(cis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3,4-dichloro-phenyl)- amide
Figure imgf000081_0003
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3,4-dichloro-phenylamine instead of aniline. 1H NMR (CDCI3, 400MHz), 8.56 (s, 1H) , 7.74 (d, 1H, J= 1.2Hz), 7.38-7.36 (m, 2H), 4.30-4.27 (m, 1H), 2.36-2.31 (m, 1H), 2.03 (d, 1H, J = 14Hz), 1.64-1.30 (m, 7H), 1.03 (s, 3H), 0.97 (s, 3H). MS(ESI): calc'd (M+H)+ 330, exp
(M+H)+ 330.
EXAMPLE IVa-21
(icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (4-fluoro-3- trifluoromethyl-phenyl)-amide
Figure imgf000082_0001
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-trifluoromethyl-4-fluoro-phenylamine instead of aniline. 1H MR (i¾-MeOD, 400MHz), 7.97-7.95 (m, 1H), 7.83-7.79 (m, 1H), 7.29 (t, 1H, J= 9.6 Hz), 4.08-4.05 (m, 1H), 1.89-1.87 (m, 2H), 1.74-1.64 (m, 3H), 1.41 (s, 3H), 1.33-1.24 (m, 1H), 1.08 (s, 3H), 1.02 (s, 3H). MS(ESI): calc'd (M+H)+ 348, exp (M+H)+ 348.
EXAMPLE IVa-22
(icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (4-chloro-3- trifluoromethyl-phenyl)-amide
Figure imgf000082_0002
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-trifluoromethyl-4-chloro-phenylamine instead of aniline. 1H MR (i¾-MeOD, 400MHz), 8.09 (d, 1H, J= 2.4 Hz), 7.82 (dd, 1H, Jl = 8.8 Hz, J2 = 2.4 Hz), 7.55 (d, 1H, J= 8.8 Hz), 4.08- 4.05 (m, 1H), 1.89-1.87 (m, 2H), 1.74-1.64 (m, 3H), 1.41 (s, 3H), 1.33-1.24 (m, 1H), 1.08 (s, 3H), 1.02 (s, 3H). MS(ESI): calc'd (M+H)+ 364, exp (M+H)+ 364.
EXAMPLE IVa-23
(icis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (4-methoxy-3- trifluoromethyl-phenyl)-amide
Figure imgf000083_0001
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 3-trifluoromethyl-4-methoxy-phenylamine instead of aniline. 1H MR (i¾-MeOD,
400MHz), 7.77 (d, 1H, J= 2.4 Hz), 7.71 (dd, 1H, J = 8.8 Hz, J2 = 3.2 Hz), 7.15 (d, 1H, J= 3.2 Hz), 4.08-4.05 (m, 1H), 3.90 (s, 3H), 1.89-1.87 (m, 2H), 1.74-1.64 (m, 3H), 1.41 (s, 3H), 1.33- 1.24 (m, 1H), 1.08 (s, 3H), 1.02 (s, 3H). MS(ESI): calc'd (M+H)+ 360, exp (M+H)+ 360.
EXAMPLE IVa-24
(cis-2,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (4-cyano-3- trifluoromethyl-phenyl)-amide
Figure imgf000083_0002
The title compound was prepared in analogy to example IVa-1 in Synthetic route 14 by using 4-amino-2-trifluoromethyl-benzonitrile instead of aniline. 1H NMR (i¾-MeOD, 400MHz), 8.27 (d, 1H, J= 2.0 Hz), 8.07 (dd, 1H, Jl = 8.4 Hz, J2 = 2.0 Hz), 7.92 (d, 1H, J= 8.4 Hz), 4.08- 4.05 (m, 1H), 1.89-1.87 (m, 2H), 1.74-1.64 (m, 3H), 1.41 (s, 3H), 1.33-1.24 (m, 1H), 1.08 (s, 3H), 1.02 (s, 3H). MS(ESI): calc'd (M+H)+ 355, exp (M+H)+ 355.
EXAMPLE IVb-1
(icis-2,5 -5-Amino-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-chloro-phenyl)- amide
Figure imgf000083_0003
The title compound was prepared by the method as shown in Synthetic route 15.
Synthetic route 15 to example IVb-1
Figure imgf000084_0001
XXXIX XLI IVb-1
Reagents and conditions: (a): 1. SOCl2, DMF, DCM; 2. 3-chloroaniline, MP; (b):
H4OAc, NaBH3CN, AcOH.
Intermediate XXXIX was treated with thionyl chloride and coupled with 3-chloroaniline to give amide XLI. To a solution of XLI (200 mg, 0.68 mmol) and 1.0 g of ammonium formate in 20 mL of methanol, was added NaBH3CN (30 mg, 0.5 mmol). The reaction mixture was stirred at r.t. overnight before concentrated in vacuo. The residue was dissolved in water and basified by NaOH (2N) to pH > 13. The aqueous solution was extracted with DCM. The organic phase was washed with brine, dried over Na2S04 and concentrated. HPLC separation of the residue gave the target compound IVb-1. 1H NMR (CDC13, 400MHz), 8.52 (bs, 1H), 7.66 (t, 1H, J= 2.0 Hz), 7.41 (d, 1H, J= 8.0 Hz), 7.25 (t, 1H, J= 8.0 Hz), 7.10 (d, 1H, J= 8.0 Hz), 3.27-3.23 (m, 1H), 1.99-1.91 (m, 1H), 1.69-1.64 (m, 3H), 1.50-1.46 (m, 1H), 1.40 (s, 3H), 1.15-1.03 (m, 4H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 295, exp (M+H)+ 295.
EXAMPLE IVb-2 (icis-2,5 -5-Acetylamino-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-chloro-phenyl)- amide
Figure imgf000084_0002
The title compound was prepared by treating IVa-1 with acetyl chloride and NMP at r.t. 1H NMR (CDC13, 400MHz), 7.81 (bs, 1H), 7.66 (t, 1H, J= 2.0 Hz), 7.39 (d, 1H, J= 8.0 Hz), 7.25 (t, lH, J= 8.0 Hz), 7.10 (d, 1H, J= 8.0 Hz), 6.71 (bs, 1H), 4.17-4.13 (m, 1H), 2.03 (s, 3H), 1.99-
1.91 (m, 1H), 1.78-1.72 (m, 2H), 1.57-1.52 (m, 2H), 1.49-1.43 (m, 4H), 1.06 (s, 3H), 0.98 (s, 3H). MS(ESI): calc'd (M+H)+ 337, exp (M+H)+ 337.
EXAMPLE IVb-3
(cis-2,5 -Diacetylamino-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-chloro-phenyl)- amide
Figure imgf000085_0001
The title compound was prepared by treating IVa-1 with excess acetyl chloride and NMP under refluxing conditions. 1H NMR (CDC13, 400MHz), 7.81 (bs, 1H), 7.66 (t, 1H, J= 2.0 Hz), 7.39 (d, 1H, 7= 8.0 Hz), 7.25 (t, 1H, 7= 8.0 Hz), 7.10 (d, 1H, 7= 8.0 Hz), 4.17-4.13 (m, 1H), 2.41 (s, 6H), 1.99-1.91 (m, 1H), 1.78-1.72 (m, 2H), 1.57-1.52(m, 2H), 1.49-1.43 (m, 4H), 1.06 (s, 3H), 0.98(s, 3H). MS: calc'd (M+H)+ 379, exp (M+H)+ 379.
EXAMPLE IVb-4
(icis-2,5 -5-Methanesulfonylamino-l,3,3-trimethyl-cyclohexanecarboxylic acid (3- chloro-phenyl)-amide
Figure imgf000085_0002
The title compound was prepared by treating IVa-1 with sulfonyl chloride and NMP at r.t. 1H NMR (CDCI3, 400MHz), 7.66 (t, 1H, 7= 2.0 Hz), 7.42 (bs, 1H), 7.39 (d, 1H, 7= 8.0 Hz), 7.25 (t, 1H, 7= 8.0 Hz), 7.10 (d, 1H, 7= 6.4 Hz), 5.22 (bs, 1H), 3.75-3.73 (m, 1H), 3.07 (s, 3H), 2.03-1.97 (m, 1H), 1.90-1.86 (m, 1H), 1.70-1.66 (m, 2H), 1.54-1.50 (m, 1H), 1.43-1.39 (m, 4H), 1.11 (s, 3H), 1.03 (s, 3H). MS(ESI): calc'd (M+H)+ 373, exp (M+H)+ 373.
Example V
Cells and viruses. Madin-Darby canine kidney cell (MDCK) was purchased from
American type culture collection (ATCC) and was maintained in minimal essential medium (MEM) containing 10% fetal bovine serum and antibiotics. Influenza A/Weiss/43 (H1N1), A/PR/8/34 (H1N1), and A/Hongkong/8/68 (H3N2) were purchased from ATCC and propagated in 10-day-old embryonated chicken eggs at 37°C. Virus was harvested 48h after inoculation as pooled allantoic fluid. After a brief centrifugation (3,000 rpm at room temperature for 20 min) and virus titer measurement by a hemagglutination test, virus was aliquoted and stored at a -80°C freezer. Viral cytopathic effect (CPE) assay: To measure anti-influenza activity of compounds,
MDCK cells were seeded into 96-well plates at a density of 5,000 cells per well. Next day, compounds were serially half-log diluted with Gibco SFM containing trypsin. Compounds and 50 pfu of virus were added into corresponding wells to make m.o.i at 0.01 and a final trypsin concentration of 2.5 μ /ηι1. The testing plates also contained medium control, cell control, virus control, and compound toxicity control. After a 3 -day treatment, cell viability was measured with a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method. Briefly, 20 μΐ of MTT diluted in culture medium was added into each wells and incubated at 37°C for 4 hours. Reduced MTT (formazan) was extracted with acidic isopropanol and absorbance at wavelengths of 570 nm and 630 nm (OD570 and OD63o) was read on a microtiter plate reader. After subtraction of background OD values, dose response curves of half-log concentration vs. percent protection were generated, on which half maximal effective concentration (EC50) and half maximal toxic concentration (CC50) were calculated. Example VI
Results of HINI CPE EC50 (μ ) assay and Cytotoxicy IC50 (μ ) are given in Table 1.
Example A
A compound of formula (I) can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:
Per tablet
Active ingredient 200 mg
Microcrystalline cellulose 155 mg
Corn starch 25 mg
Talc 25 mg
Hydroxypropylmethylcellulose 20 mg
425 mg
Example B
A compound of formula (I) can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:
Per capsule
Active ingredient 100.0 mg
Corn starch 20.0 mg
Lactose 95.0 mg
Talc 4.5 mg
Magnesium stearate 0.5 mg
220.0 mg

Claims

Claims
A compound of formula (I)
Figure imgf000087_0001
R1 is hydrogen, C1-6 alkyl, or trifluoromethyl;
R2/R3 are hydrogen, halogen, OR10, or R1 lR hydrogen, C1-6 alkyl, or trifluoromethyl; -CH2-, or carbonyl;
Ar is selected from
Figure imgf000087_0002
Wherein
R5/R9 is hydrogen, halogen, trifluoromethyl, or C1-6 alkyl;
R6/R8 is hydrogen, halogen, trifluoromethyl, trifluoromethoxy, C1-6 alkoxy, cyano, C1-6 alkyl, -C(0)- H2, -S(0)2- H2, or -S(0)2- d-e alkyl;
R7 is hydrogen, halogen, C1-6 alkyl, cyano, C1-6 alkoxy, or -S(0)2- H2
R10 is hydrogen, C1-6 alkyl, carbonyl- C1-6 alkyl, or trifluoromethyl;
R11 or R12 is hydrogen, C1-6 alkyl, carbonyl- C1-6 alkyl, or sulfonyl; provided that R1, R2, R3, R4, R5, R6, R7, R8 and R9 are not hydrogen simultaneously; and pharmaceutically acceptable salt and stereoisomers thereof.
2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen or C1-6 alkyl; R2/R3 are hydrogen, halogen, OR10, or R1 lRn R4 is hydrogen or C1-6 alkyl;
X is -CH2-, or carbonyl;
Ar is selected from
Figure imgf000088_0001
, , , , , Wherein
R5/R9 is hydrogen, halogen, trifluoromethyl, or C1-6 alkyl;
R6/R8 is hydrogen, halogen, trifluoromethyl, trifluoromethoxy, C1-6 alkoxy, cyano, C1-6 alkyl, -C(0)- H2, -S(0)2- H2, or -S(0)2- d-e alkyl;
R7 is hydrogen, halogen, C1-6 alkyl, cyano, C1-6 alkoxy, or -S(0)2- H2 R10 is hydrogen, C1-6 alkyl, carbonyl-Ci-6 alkyl, or trifluoromethyl;
R11 or R12 is hydrogen, C1-6 alkyl, carbonyl- C1-6 alkyl, or sulfonyl; provided that R1, R2, R3, R4, R5, R6, R7, R8 and R9 are not hydrogen simultaneously and compound with two chiral center is in cis configuration.
3. A compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof , wherein R1 is C1-6 alkyl. .
4. A compound according to claim 3 or a pharmaceutically acceptable salt thereof , wherein R1 is methyl.
5. A compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein R2 or R3 is OR10.
6. A compound according to claim 5 or a pharmaceutically acceptable salt thereof , wherein R2 or R3 is hydroxy.
7. A compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof , wherein R4 is hydrogen.
8. A compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein or R3 is hydroxyl.
9. A compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof ,
wherein Ar is selected from
Figure imgf000089_0001
, or wherein R5/R9 is hydrogen or halogen;
R6/R8 is halogen, trifluoromethyl, trifluoromethoxy, cyano, -S(0)2- H2, or -S(0)2-Ci- ealkyl;
R7 is hydrogen, cyano, or halogen.
10. A compound according to claim 9 or a pharmaceutically acceptable salt thereof, wherein R2 or R3 is hydroxyl and R4 is hydrogen.
11. A compound according to claim 10 or a pharmaceutically acceptable salt thereof , wherein Ar is
Figure imgf000089_0002
R5/R9 is hydrogen, chloro, or fluoro;
R6/R8 is halogen, trifluoromethyl, cyano, -S(0)2- H2, or -S(0)2-methyl;
R7 is hydrogen, chloro, or fluoro.
12. A compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof , wherein X is -CH2-.
13. A compound according to claim 12 or a pharmaceutically acceptable salt thereof, wherein wherein
R2 or R3 is hydroxyl;
R4 is hydrogen;
Figure imgf000090_0001
wherein R5/R9 is hydrc
R6/R8 is halogen, trifluoromethyl, trifluoromethoxy, cyano, -S(0)2-NH2, or -S(0)2-Ci_ ealkyl;
R7 is hydrogen, cyano, or halogen.
14. A compound according to claim 13 or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000090_0002
R5/R9 is hydrogen, chloro, or fluoro;
R6/R8 is halogen, trifluoromethyl, cyano, -S(0)2- H2, or -S(0)2-methyl; R7 is hydrogen, chloro, or fluoro.
15. A compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, which is: c/. '-y.J -S^^-Trimethyl-S-phenylaminomethyl-cyclohexanol, (cis-1, 3) -3 -[(2-Chloro-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol, (cis-1, 3)-3-[(3 -Chloro-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol, (cis-1, 3) -3 -[(4-Chloro-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol, (¾/5-7,5 -3,3,5-Trimethyl-5-[(2-trifluoromethyl-phenylamino)-methyl]-cyclohexanol, (cis-1, 5) -3,3,5-Trimethyl-5-[(3-trifluoromethyl-phenylamino)-methyl]-cyclohexanol, (cis-1, 5) -3 , 3 , 5 -Trimethyl-5 -(p-tolylamino-methyl)-cyclohexanol, (¾/5-7,3)-3-[(3-Methoxy-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol,
3- [((¾/5-7,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile,
4- [((¾/5-7,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile, (cis-1, 3) -3 -[(3 -Isopropoxy-phenylamino)-methyl] -3,5 , 5-trimethyl-cyclohexanol, (¾/5-7,3)-3-[(3-Isopropyl-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol,
3- [((¾/5-7,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzamide, c/5-7,3)-3-[(3-Methanesulfonyl-phenylamino)-methyl]-3, 5, 5-trimethyl-cyclohexanol,
3 -[{(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -benzenesulfonamide,
(cis-1, 3)-3-[(3 -Chloro-5 -fluoro-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(¾/5-7,3)-3-[(3-Fluoro-5-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- yclohexanol,
(cis-1, 3) -3 -[(3 -Chloro-5 -methyl-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(cis-1, 3)-3-[(3 , 5-Dichloro-phenylamino)-methyl]-3 , 5, 5-trimethyl-cyclohexanol,
(¾/5-7,3)-3-[(3-Chloro-5-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- yclohexanol,
(¾/5-7,3)-3-[(3-Bromo-5-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- yclohexanol,
3-Fluoro-5- [((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile, 3-Chloro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile, 3 -[{(cis-1, 5) -5-Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -5 -trifluoromethyl- benzonitrile,
(cis-1, 3) -3 -[(3 , 5-Bis-trifluoromethyl-phenylamino)-methyl] -3 , 5 , 5 -trimethyl-cyclohexanol,
(cis-1, 3) -3 -[(2, 3 -Dichloro-phenylamino)-methyl] -3 , 5 , 5 -trimethyl-cyclohexanol,
(¾/5-7,3)-3-[(3,4-Dichloro-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol,
2-Fluoro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile,
2-Chloro-4-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile,
2-Chloro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile,
4-[((¾/5-7,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-phthalonitrile,
(¾/5-7,3 -3-[(4-Chloro-3-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol,
4- [((¾z's-7,5 -5-Hydroxy-l,3,3-trimethyl-c^
benzonitrile,
2- Chloro-5-[((¾/5-7,5)-5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide,
3- Chloro-5-[((¾/5-7,5)-5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide,
3 -[{(cis-1, 5) -5-Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -5 -trifluoromethyl- benzenesulfonamide,
3- Fluoro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide,
5- [((¾/5-7,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-2-methyl- benzenesulfonamide,
5-[((¾/5-7,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-2-methoxy- benzenesulfonamide,
4- [((cis-l, 5) -5-Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -2-trifluoromethoxy- benzenesulfonamide, (cis-1, 3) -3 -{[(3 -Chloro-phenyl)-methyl-amino] -methyl } -3 , 5 , 5 -trimethyl-cyclohexanol, (3 -Fluoro-5-trifluoromethyl-phenyl)-( 1,3,3 -trimethyl-cyclohexylmethyl)-amine, Acetic acid (^/^-/.J -S^^-trimethyl-S-phenylaminomethyl-cyclohexyl ester, (3 , 3 -Difluoro- 1,5,5 -trimethyl-cyclohexylmethyl)-(3 -fluoro-5 -trifluoromethyl-phenyl)- amine,
(3 -Bromo-5 -trifluoromethyl-phenyl)-(3 , 3 -difluoro- 1 , 5 , 5-trimethyl-cyclohexylmethyl)- amine,
(3-Fluoro-5-trifluoromethyl-phenyl)-( (¾z ,5 -5-methoxy-l,3,3-trimethyl- cyclohexylmethyl)-amine,
(¾/5-7,3 -3-[(3-Fluoro-5-trifluoromethyl-phenylamino)-methyl]-l,3,5,5-tetram
cyclohexanol,
((¾/5-7,5 -5-Dimethylamino-l,3,3-trimethyl-cyclohexylmethyl)-(3-fl^
trifluoromethyl-phenyl)-amine,
(cis-1, 5) -5-[(3-Fluoro-5-trifluoromethyl-phenylamino)-methyl]-3,3-dimethyl- cyclohexanol,
(^ra«s-/,5 -5-[(3-fluoro-5-trifluoromethyl-ph^
cyclohexanol,
(cis-1, 5^-3,3,5 -Trimethyl-5 -(pyridin-2-ylaminomethyl)-cyclohexanol, c/5-7,3)-3-[(5-Bromo-pyridin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol,
(cis-1, 5^-3,3,5 -Trimethyl-5 - [(6-trifluoromethyl-pyridin-2-ylamino)-methyl] -cyclohexanol, c/5-7,3)-3-[(4-Chloro-pyridin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol,
(cis-1, 5^-3,3,5 -Trimethyl-5 - [(3 -trifluoromethyl-pyridin-2-ylamino)-methyl] -cyclohexanol,
(cis-1, 5^-3,3,5 -Trimethyl-5 - [(5 -trifluoromethyl-pyridin-2-ylamino)-methyl] -cyclohexanol,
6-[((¾/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-pyridine-2-sulfonic acid amide,
2-[((¾/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-pyridine-4-sulfonic acid amide, (cis-1, 5) -3, 3, 5 -Trimethyl-5 - [(4-methyl-pyrimidin-2-ylamino)-methyl] -cyclohexanol,
(cis-1, 5) -3, 3, 5 -Trimethyl-5 - [(4-trifluoromethyl-pyrimidin-2-ylamino)-methyl] - yclohexanol,
(¾/5-7,3)-3-[(4-Methoxy-pyrimidin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol,
(cis-1, 3) -3 -[(4, 6-Dimethoxy-pyrimidin-2-ylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(cis-1, 3) -3 -[(4, 6-Dimethyl-pyrimidin-2-ylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(¾/5-7,3)-3-[(4-Chloro-5-methoxy-pyrimidin-2-ylamino)-methyl]-3,5,5-trimethyl- yclohexanol, c/5-7,3)-3-[(6-Chloro-pyrazin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol, (cis-1, 5) -3, 3, 5 -Trimethyl-5 - [(6-methyl-pyrazin-2-ylamino)-methyl] -cyclohexanol, (¾/5-7,3)-3-[(6-Methoxy-pyrazin-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol, c/5-7,3)-3-(Benzoxazol-2-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol, Benzoxazol-2-yl-(3,3-difluoro-l,5,5-trimethyl-cyclohexylmethyl)-amine, Benzoxazol-2-yl-( c/5-7,5)-5-methoxy-l,3,3-trimethyl-cyclohexylmethyl)-amine, c/5-7,3)-3-(Benzothiazol-2-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol, c/5-7,3)-3-[(6-Fluoro-benzothiazol-2-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol, c/5-7,3)-3-(Benzo[d]isoxazol-3-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol, c/5-7,3)-3-[(lH-Indazol-3-ylamino)-methyl]-3,5,5-trimethyl-cyclohexanol, (cis-1, 5) -3, 3, 5 -Trimethyl-5 -(quinazolin-2-ylaminomethyl)-cyclohexanol, (cis-1, 3) -3 -(Isoquinolin- 1 -ylaminomethyl)-3 ,5,5 -trimethyl-cyclohexanol, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid phenylamide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (4-fluoro-phenyl)-amide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-chloro-phenyl)-amide, (^/^-/.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-trifluoromethyl- phenyl)-amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-isopropyl-phenyl)- amide, c/^-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-tert-butyl-phenyl)- amide, c/^-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-ethoxy-phenyl)-amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-trifluoromethoxy- phenyl)-amide, c/^-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-methanesulfonyl- phenyl)-amide, c/^-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-sulfamoyl-phenyl)- amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 , 5 -difluoro-phenyl)- amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-chloro-5-fluoro- phenyl)amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -fluoro-5 - trifluoromethyl-phenyl)-amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-chloro-5- trifluoromethyl-phenyl)-amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -bromo-5 - trifluoromethyl-phenyl)-amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -methoxy-5 - trifluoromethyl-phenyl)-amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 , 5 -dichloro-phenyl)- amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3, 5-dimethoxy-phenyl)- amide, (cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (4-chloro-3 -fluoro- phenyl)amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3,4-dichloro-phenyl)- amide, c/^-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (4-fluoro-3- trifluoromethyl-phenyl)-amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (4-chloro-3- trifluoromethyl-phenyl)-amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (4-methoxy-3- trifluoromethyl-phenyl)-amide, c/^-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (4-cyano-3- trifluoromethyl-phenyl)-amide, c/^-y.J -S-Amino-l^^-trimethyl-cyclohexanecarboxylic acid (3-chloro-phenyl)-amide,
(cis-1, 5) -5 - Acetylamino- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -chloro-phenyl)- amide,
(cis-1, 5) -Diacetylamino- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -chloro-phenyl)- amide, and
(¾/5-7,5 -5-Methanesulfonylamino-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-chloro- phenyl)-amide.
16. A compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, which is c/. '-y.J -S^^-Trimethyl-S-phenylaminomethyl-cyclohexanol,
(cis-1, 3) -3 - [(2-Chloro-phenylamino)-methyl] -3 , 5 , 5-trimethyl-cyclohexanol,
(cis-1, 3) -3 - [(3 -Chloro-phenylamino)-methyl] -3 , 5 , 5-trimethyl-cyclohexanol,
(cis-1, 3) -3 - [(4-Chloro-phenylamino)-methyl] -3 , 5 , 5-trimethyl-cyclohexanol,
(¾/5-7,5)-3,3,5-Trimethyl-5-[(2-trifluoromethyl-phenylamino)-methyl]-cyclohexanol, (¾/5-7,5 -3,3,5-Trimethyl-5-[(3-trifluoromethyl-phenylamino)-methyl]-cyclohe (cis-1, 3)-3-[(3 -Methoxy-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol, 3-[((¾z ,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexy
(cis-1, 3) -3 - [(3 -Isopropyl-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(cis-1, 3)-3-[(3 -Methanesulfonyl-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
3 -[{(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -benzenesulfonamide,
(cis-1, 3) -3 - [(3 -Chloro-5-fluoro-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(¾/5-7,3)-3-[(3-Fluoro-5-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol, c/5-7,3)-3-[(3-Chloro-5-methyl-phenylamino)-methyl]-3,5,5-trimethyl-cyclohexanol,
(cis-1, 3) -3 - [(3 , 5 -Dichloro-phenylamino)-methyl] -3 , 5 , 5 -trimethyl-cyclohexanol,
(¾/5-7,3)-3-[(3-Chloro-5-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol,
(¾/5-7,3)-3-[(3-Bromo-5-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimethyl- cyclohexanol,
3-Fluoro-5- [((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile,
3-Chloro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile,
3 -[{(cis-1, 5) -5-Hydroxy- 1,3,3 -trimethyl-cyclohexylmethyl)-amino] -5 -trifluoromethyl- benzonitrile,
(cis-1, 3) -3 - [(3 , 5 -Bis-trifluoromethyl-phenylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol, (cis-1, 3) -3 - [(3 ,4-Dichloro-phenylamino)-methyl] -3 , 5 , 5 -trimethyl-cyclohexanol, 2-Fluoro-5- [((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile, 2-Chloro-4-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile, 2-Chloro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-benzonitrile, (¾/5-7,3 -3-[(4-Chloro-3-trifluoromethyl-phenylamino)-methyl]-3,5,5-trimeth^ cyclohexanol,
4-[((¾z ,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexy
benzonitrile,
2- Chloro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide,
3- Chloro-5-[((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide,
3-Fluoro-5- [((¾/5-7,5 -5-hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]- benzenesulfonamide,
(cis-1, 3)-3-{ [(3 -Chloro-phenyl)-methyl-amino] -methyl } -3 , 5 , 5 -trimethyl-cyclohexanol,
(3-Fluoro-5-trifluoromethyl-phenyl)-(l,3,3-trimethyl-cyclohexylmethyl)-amine,
Acetic acid (¾/5-7,5)-3,3,5-trimethyl-5-phenylaminomethyl-cyclohexyl ester,
(3 , 3 -Difluoro- 1 , 5 , 5-trimethyl-cyclohexylmethyl)-(3 -fluoro-5 -trifluoromethyl-phenyl)- amine,
(3 -Fluoro-5 -trifluoromethyl-phenyl)-( (cis-1, 5) -5 -methoxy- 1,3,3 -trimethyl- cyclohexylmethyl)-amine,
(¾z ,3 -3-[(3-fluoro-5-trifluorometh^
cyclohexanol,
{(cis-1, 5) -5 -Dimethylamino- 1,3,3 -trimethyl-cyclohexylmethyl)-(3 -fluoro-5 - trifluoromethyl-phenyl)-amine,
(¾/5-7,5 -5-[(3-fluoro-5-trifluoromethyl-phenylamino)-methyl]-3,3-dimethyl-cyclohexan
(^ra«5-7,5 -5-[(3-fluoro-5-trifluoromethyl-phenylamino)-methyl]-3,3-dimethyl- cyclohexanol,
(¾z ,5 -3,3,5-trimethyl-5-[(6-trifluorom
(cis-1, 5) -3 , 3 , 5-trimethyl-5 - [(3 -trifluoromethyl-pyridin-2-ylamino)-methyl] -cyclohexanol, 2-[((¾/5-7,5 -5-Hydroxy-l,3,3-trimethyl-cyclohexylmethyl)-amino]-pyridine-4-sul^^ acid amide,
(¾/s-/,5 -3,3,5-trimethyl-5-[(4-triflu
cyclohexanol,
(¾/5-7,3 -3-[(4-methoxy-pyrimidin-2-ylamino)-methyl]-3,5,5-trimethyl-cycloh^
(cis-1, 3) -3 - [(4, 6-dimethyl-pyrimidin-2-ylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol,
(cis-1, 3) -3 - [(6-chloro-pyrazin-2-ylamino)-methyl] -3 , 5 , 5 -trimethyl-cyclohexanol, c/5-7,3)-3-(benzooxazol-2-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol,
Benzooxazol-2-yl-(3 , 3 -difluoro- 1,5,5 -trimethyl-cy clohexylmethyl)-amine,
Benzooxazol-2-yl-( c/5-7,5)-5-methoxy-l,3,3-trimethyl-cyclohexylmethyl)-amine, c/5-7,3)-3-(benzothiazol-2-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol,
(cis-1, 3) -3 - [(6-fluoro-benzothiazol-2-ylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol, c/5-7,3)-3-(benzo[d]isoxazol-3-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol,
(cis-1, 3) -3 - [( 1 H-indazol-3 -ylamino)-methyl] -3 ,5,5 -trimethyl-cyclohexanol, c/5-7,5)-3,3,5-trimethyl-5-(quinazolin-2-ylaminomethyl)-cyclohexanol, c/5-7,3)-3-(Isoquinolin-l-ylaminomethyl)-3,5,5-trimethyl-cyclohexanol, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-chloro-phenyl)-amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -trifluoromethyl- phenyl)-amide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-isopropyl-phenyl)- amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -trifluoromethoxy- phenyl)-amide, c/5-7,5)-5-Hydroxy-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-sulfamoyl-phenyl)- amide, (cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 , 5 -difluoro-phenyl)- amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-chloro-5-fluoro- phenyl)amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -fluoro-5 - trifluoromethyl-phenyl)-amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3-chloro-5- trifluoromethyl-phenyl)-amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -bromo-5 - trifluoromethyl-phenyl)-amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -methoxy-5 - trifluoromethyl-phenyl)-amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 , 5 -dichloro-phenyl)- amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (4-chloro-3 -fluoro- phenyl)amide, c/. '-y.J -S-Hydroxy-l^^-trimethyl-cyclohexanecarboxylic acid (3,4-dichloro-phenyl)- amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (4-fluoro-3 - trifluoromethyl-phenyl)-amide,
(cis-1, 5) -5 -Hydroxy- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (4-chloro-3 - trifluoromethyl-phenyl)-amide,
(cis-1, 5) -5 - Acetylamino- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -chloro-phenyl)- amide,
(cis-1, 5) -Diacetylamino- 1,3,3 -trimethyl-cyclohexanecarboxylic acid (3 -chloro-phenyl)- amide, and
(¾/5-7,5 -5-Methanesulfonylamino-l,3,3-trimethyl-cyclohexanecarboxylic acid (3-chloro- phenyl)-amide.
17. A compound according to any one of claims 1 to 16 for use as a medicament..
18. Use of a compound according to any one of claims 1 to 16 for the manufacture of a medicament for treatment or prophylaxis of influenza.
19. A pharmaceutical composition comprising a compound in accordance with any one claim 1 to 16 and a therapeutically inert carrier.
20. The invention as hereinbefore described.
PCT/CN2010/070562 2010-02-08 2010-02-08 Compounds for the treatment and prevention of influenza WO2011094953A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/CN2010/070562 WO2011094953A1 (en) 2010-02-08 2010-02-08 Compounds for the treatment and prevention of influenza
PCT/EP2011/051626 WO2011095576A1 (en) 2010-02-08 2011-02-04 Compounds for the treatment and prevention of influenza
US13/021,793 US20110195979A1 (en) 2010-02-08 2011-02-07 Compounds for the treatment and prevention of influenza

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/070562 WO2011094953A1 (en) 2010-02-08 2010-02-08 Compounds for the treatment and prevention of influenza

Publications (1)

Publication Number Publication Date
WO2011094953A1 true WO2011094953A1 (en) 2011-08-11

Family

ID=43858443

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2010/070562 WO2011094953A1 (en) 2010-02-08 2010-02-08 Compounds for the treatment and prevention of influenza
PCT/EP2011/051626 WO2011095576A1 (en) 2010-02-08 2011-02-04 Compounds for the treatment and prevention of influenza

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/051626 WO2011095576A1 (en) 2010-02-08 2011-02-04 Compounds for the treatment and prevention of influenza

Country Status (2)

Country Link
US (1) US20110195979A1 (en)
WO (2) WO2011094953A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014135414A1 (en) 2013-03-04 2014-09-12 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN104387279A (en) * 2014-10-29 2015-03-04 河南师范大学 Method for simply synthesizing 3, 3-difluorocyclohexylmethylamine
EP3162790A1 (en) 2015-10-30 2017-05-03 Evonik Degussa GmbH Method for producing isophorone amino alcohol (ipaa)
EP3162791A1 (en) 2015-10-30 2017-05-03 Evonik Degussa GmbH Improved process for the preparation of isophorone amino alcohol (ipaa)
CN108276401A (en) * 2017-01-05 2018-07-13 广东东阳光药业有限公司 Inhibitors of influenza viruses replication and application thereof
EP3363781A1 (en) 2017-02-15 2018-08-22 Evonik Degussa GmbH Method for producing isophoronaminoalcohol (ipaa)
WO2021048365A1 (en) * 2019-09-11 2021-03-18 Solvay Sa Process for manufacturing an alkyl substituted cyclohexanecarbonitrile

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040749B2 (en) 2011-12-01 2018-08-07 Bikam Pharmaceuticals Inc. Opsin-binding ligands, compositions and methods of use
CN113966217A (en) * 2019-06-14 2022-01-21 达萨玛治疗公司 SARM1 inhibitors
CN116867764A (en) 2021-02-16 2023-10-10 巴斯夫欧洲公司 Method for producing isophorone diamine
EP4056553A1 (en) 2021-03-08 2022-09-14 Solvay SA Alkyl substituted cyclohexanecarbonitriles
US20230159929A1 (en) 2021-09-08 2023-05-25 Aligos Therapeutics, Inc. MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022561A1 (en) * 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
WO2008130570A1 (en) * 2007-04-20 2008-10-30 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022561A1 (en) * 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
WO2008130570A1 (en) * 2007-04-20 2008-10-30 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014135414A1 (en) 2013-03-04 2014-09-12 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN104387279A (en) * 2014-10-29 2015-03-04 河南师范大学 Method for simply synthesizing 3, 3-difluorocyclohexylmethylamine
EP3162790A1 (en) 2015-10-30 2017-05-03 Evonik Degussa GmbH Method for producing isophorone amino alcohol (ipaa)
EP3162791A1 (en) 2015-10-30 2017-05-03 Evonik Degussa GmbH Improved process for the preparation of isophorone amino alcohol (ipaa)
CN108276401A (en) * 2017-01-05 2018-07-13 广东东阳光药业有限公司 Inhibitors of influenza viruses replication and application thereof
EP3363781A1 (en) 2017-02-15 2018-08-22 Evonik Degussa GmbH Method for producing isophoronaminoalcohol (ipaa)
WO2021048365A1 (en) * 2019-09-11 2021-03-18 Solvay Sa Process for manufacturing an alkyl substituted cyclohexanecarbonitrile

Also Published As

Publication number Publication date
US20110195979A1 (en) 2011-08-11
WO2011095576A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
WO2011094953A1 (en) Compounds for the treatment and prevention of influenza
RU2695133C1 (en) Oxadiazolamine derivatives as histone deacetylase 6 inhibitor and pharmaceutical composition containing them
US5552419A (en) Arylsulfonamido-substituted hydroxamic acids
CA2584502A1 (en) 2-methylpropanamides and their use as pharmaceuticals
KR20020092348A (en) Npyy5 antagonists
CA2817211A1 (en) Hydroxamic acid derivatives and their use in the treatment of bacterial infections
NO344305B1 (en) Process for the preparation of piperazinyl and diazepanylbenzamide derivatives
NO312239B1 (en) Benzamidine derivatives, use and pharmaceutical preparations thereof, and process for preparation
WO2010121382A1 (en) Process for making indole cyclopropyl amide derivatives
CA3052353A1 (en) Piperazine derivatives for influenza virus inhibition
AU2001269895B2 (en) Hiv integrase inhibitors
JP4393376B2 (en) Phenylcyclohexylpropanolamine derivative, process for its preparation and therapeutic application thereof
US6689785B2 (en) Epoxysuccinamide derivatives
KR20040093123A (en) NK1 Antagonists
JP5815542B2 (en) Alkynyl derivatives useful as DPP-1 inhibitors
US20230303497A1 (en) Benzylamine or benzyl alcohol derivative and uses thereof
RU2228330C2 (en) N-arylsulfonyl amino acid omega-amides
KR101902567B1 (en) Fluorosubstituted (3R,4R,5S)-5-guanidino-4-acetamido-3-(pentan-3-yloxy)cyclohexene-1- carboxylic acids, their esters and use thereof
CN112771048B (en) Inhibitors of influenza virus replication and intermediates and uses thereof
WO2014082592A1 (en) Neuraminidase inhibitor prodrug and composition and use thereof
US20060135785A1 (en) Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof
HU206194B (en) Process for producing cyclomethylene-1,2-dicarboxylic acid derivatives and pharmaceutical compositions comprising same
JPWO2002057216A1 (en) Terphenyl compounds having substituted amino groups
CN108101804B (en) Carboxyl modified oseltamivir derivative and medical application thereof
CA3092749A1 (en) Deuterated compounds as rock inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10845038

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10845038

Country of ref document: EP

Kind code of ref document: A1